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Abstract 
Background. Liver cancer is the 3rd commonest cause of cancer death 
worldwide. Understanding the mechanisms of hepatocarcinogenesis is vital for 
developing more effective treatments.  Chronic liver disease is a predisposing 
factor for development of hepatocellular carcinoma (HCC) and increased 
translocation of gut bacteria is believed to exacerbate this inflammatory 
condition. Toll-like receptors (TLRs) play a crucial role in immunity against 
microbial pathogens and recent evidence suggests they may be important in 
pathogenesis of chronic liver disease. The aim of this thesis was to explore the 
role of TLRs in the pathogenesis of HCC. 
Materials & Methods: Tissue microarrays obtained from patients with cirrhosis, 
viral hepatitis and HCC were stained with for TLR4, TLR7 and TLR9 and the 
data were validated in actual patient samples. The role of gut translocation was 
explored in an animal model of HCC using diethylnitrosamine (DEN) and 
nitrosomorpholine (NMOR) after treatment with Norfloxacin. Proliferation of 
HCC cell lines were studied after stimulation (Imiquimod and CpG-ODN) and 
inhibition of TLR7 and TLR9 (IRS 954) and chloroquine. The effect of these 
interventions was confirmed in the DEN and NMOR and, a xenograft model. 
The studies were extended to determine their effect in cholangiocarcinoma. 
Results: TLR7 and TLR9 but not TLR4 were up regulated in HCC tissue and 
gut decontamination with Norfloxacin did not prevent HCC development but 
reduced liver fibrosis. TLR7 stimulation increased cell proliferation of HuH7 cells 
significantly and inhibition of TLR7 and TLR9 using IRS or chloroquine resulted 
in significant inhibition. TLR7 and TLR9 inhibition using IRS 954 and 
chloroquine reduced tumour growth in xenograft models and, chloroquine also 
decreased liver fibrosis and tumour growth in the DEN and NMOR model. 
These beneficial effects were also observed in cholangiocarcinoma.  
Conclusion: In conclusion, these data suggest that inhibiting TLR7 and TLR9 
and, using chloroquine could be potential novel therapeutic strategies for the 
prevention and the progression of primary liver cancers in susceptible patients.  
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1. Introduction 
1.1   Epidemiology and global distribution of HCC 
Liver cancer is the fifth most common cancer in the world and the third 
commonest cause of cancer death (Parkin et al., 2001 and Chen et al., 2006).  
About 85-90% of all primary liver cancer cases are diagnosed as hepatocellular 
carcinoma (HCC) (El Serag, 2011).  Nearly one million new cases of HCC are 
diagnosed annually accounting for approximately 500,000-600,000 deaths 
(Sherman, 2008, Feo et al., 2009 and Schutte et al., 2009).  The prognosis of 
HCC is poor with a median survival of less than one year (El Serag and 
Rudolph, 2007) and an actual 1-year survival rate of 3-5% (Schutte et al., 
2009).  
 
HCC is more common in men than women (Sherman, 2008), the mean male to 
female ratio being 2-4:1. HCC is the fifth most common cancer in men and 
seventh in women (El Serag, 2011).  It has also been noted that the peak HCC 
incidence in female patients occurs around 5 years later than in males (Schutte 
et al., 2009).  The high incidence of HCC in the male population is probably due 
to the higher exposure to risk factors such as sex hormones (Schutte et al., 
2009).  It has been shown that orchidectomy reduces the effect of chemical 
carcinogens in male rats (Leong and Leong, 2005). 
 
In the high incidence areas, HCC is common in younger patients, whereas in 
the low incidence areas it is predominantly a disease of the elderly (Leong and 
Leong, 2005).  The age-specific patterns are related to the differences in the 
distribution of dominant hepatitis virus in the population, the age at which viral 
infection occurs, and co-existence of other risk factors.  Of note, most Hepatitis 
C virus (HCV) carriers become infected in adulthood while most Hepatitis B 
virus (HBV) carriers acquire infection at a very young age (El Serag and 
Rudolph, 2007). 
 
There is a geographic variability in the distribution of HCC cases, highest 
incidence reported in south-east Asia and sub-Saharan Africa (Leong and 
Leong, 2005 and El Serag and Rudolph, 2007).  China alone accounts for more 
than 50% of the cases (El Serag and Rudolph, 2007).  European countries, 
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historically, have a low incidence of HCC, but over the past 20-years the 
incidence rate in Europe has been on the rise.  Similarly, although North and 
South America have a lower incidence of HCC (El Serag and Rudolph, 2007), 
the incidence of HCC has more than tripled in the United States of America in 
the last two decades (El Serag, 2011). 
 
 
Figure 1: Incidence of HCC worldwide. 
 
 
Figure 2: Regional variations in the mortality rates of HCC.  The rates are 
reported per 100, 000 persons (Adapted from El Serag and Rudolph, 2007). 
HCC incidence 
Eastern Asia and Sub-
Sahran Africa
Rest of the world
America and Northern 
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1.2 Risk factors for development of HCC 
The aetio-pathogenesis of HCC involves a process characterised by an 
increased hepatocyte turnover following chronic liver injury and regeneration, 
triggered by a variety of insults (Fung et al., 2009).  Around 70%-90% of HCC 
cases are observed in patients with liver cirrhosis and long standing hepatic 
inflammation (Schutte et al., 2009).  The risk factors (described below) induce 
tumour formation and proliferation through a number of distinct and complex 
biochemical pathways. However, nearly all of them seem to have an 
inflammatory basis. 
 
1.2.1 Viral hepatitis 
One of the most important risk factors for HCC development is chronic hepatitis 
B and C (Dragani, 2010).  HBV, and less commonly HCV, can cause HCC due 
to the oncogenic properties of the viruses themselves (Fung et al., 2009).  HCV 
and HBV increase the risk of developing HCC by 20- fold (Schutte et al., 2009), 
and are responsible for more than 80% of all cases of HCC globally.  
 
HBV can cause HCC directly by increasing inflammation and regeneration.  
This process leads to accumulation of potential mutations in the hepatocyte 
genome resulting in HCC (Fung et al., 2009).  HCC can also be induced directly 
through integration of HBV DNA into the host genome (Rocken and Carl-
McGrath, 2001).  This direct pathway does not occur in HCC induced by HCV 
because this is an RNA virus and does not contain the reverse transcriptase 
enzyme.  Therefore HCV can only cause HCC through indirect pathways (Fung 
et al., 2009).  In hepatitis C, the structural proteins (Core, E1, E2 and p7) and 
the non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) are the 
main carcinogenic agents and host- viral protein interactions the main pathway 
behind hepatocarcinogenesis (Kim et al., 2007).  For example, the NS5B affects 
the cell cycle and leads to arrest at the G2 Phase (Baek et al., 2006).  NS5A 
alters intracellular calcium levels, reactive oxygen species (Gong et al., 2001) 
and inhibits apoptosis (Baek et al., 2006).  
 
Since the discovery of the HBV vaccine, there has been a decline in the HBV-
related HCC (Schutte et al., 2009).  On the other hand, the incidence of HCV- 
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related HCC has continued to increase due to higher rates of intravenous drug 
abuse and contaminated blood supply (Armstrong et al., 2000).  Hepatitis A and 
E have no carcinogenic effects as neither virus leads to chronic hepatitis.  
Hepatitis D virus infects the liver only in patients with hepatitis B thus making it 
difficult to evaluate its direct role in hepatocarcinogensis.  It has been suggested 
however that hepatitis D places additional load on the damaged liver 
contributing to the risk of HCC (Leong and Leong, 2005).  
 
1.2.2 Life style; Alcohol, Obesity and Non-Alcoholic steatohepatitis  
a) Alcohol 
Heavy alcohol consumption is a major risk factor for HCC in developed 
countries (Schutte et al., 2009).  Heavy alcohol intake is defined as long-term 
ingestion of more than 50-70g/day for an average of 10 years (El Serag and 
Rudolph, 2007). 
Chronic alcohol consumption is associated with a variety of liver diseases 
ranging from steatosis, steatohepatitis, cirrhosis, and finally to HCC (Mandrekar 
and Szabo, 2009).  There is evidence of a direct carcinogenic effect of alcohol 
on the liver; however, there are several mechanisms implicated in the initiation 
of HCC (Schutte et al., 2009). 
 
Ethanol is primarily metabolised in the hepatocytes through alcohol 
dehydrogenase (ADH) in the cytosol, microsomal ethanol oxidizing system 
(MEOS) in endoplasmic reticulum which also contain inducible cytochrome 
P450 2E1, and catalase which is located in the peroxisomes (McKillop and 
Schrum, 2005). ADH dependent ethanol metabolism induces nicotinamide 
adenine dinucleotide (NADH) which results in an increase in the synthesis of 
reactive oxygen species (ROS).  These substances cause peroxidation damage 
to DNA (McKillop et al., 2006).  In alcohol induced liver injury, the innate 
immune response is activated in the liver, macrophages and the Kupffer cells 
playing a crucial role in the early stages of pathogenesis (Hines and Wheeler, 
2004). 
 
The effect of alcohol on the liver is evident in many cells including the innate 
immune cells, liver parenchymal cells and the hepatocytes. Innate immune 
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cells, including the macrophages (Kupffer cells), recognise the 
endotoxin/lipopolysaccharide in the portal circulation during the early stages of 
alcohol-induced liver injury.  Alcohol induces oxidative stress with production of 
inflammatory cytokines such as tumour necrosis factor-α (TNF-α) in the 
macrophages resulting in alcoholic liver disease (ALD).  Furthermore, alcohol 
also sensitises hepatocytes to apoptosis through TNF-α (Mandrekar and Szabo, 
2009).  
 
b) Obesity and Diabetes  
In a prospective cohort study conducted in the United States, it was reported 
that liver cancer mortality rates were 5 times higher amongst men with high 
baseline body mass (Calle and Rodriguez, 2003).  The risk of developing HCC 
is higher in patients whose body mass index (BMI) exceeds 30kg/m2 (Chen et 
al., 2008 and Polesel et al., 2009).  Obesity, especially central obesity, is 
associated with hepatic steatosis (Ratziu et al., 2000 and Ratziu et al., 2004).  
The effect of obesity on liver is called the non- alcoholic fatty liver disease 
(NAFLD) the features of which ranges from fatty liver (steatosis), steatohepatitis 
to cirrhosis.  Increased hepatic steatosis is often associated with severe necro-
inflammatory activity and fibrosis (El Serag and Rudolph, 2007). 
 
Several studies found a significant association between diabetes and HCC (El 
Serag and Rudolph, 2007).  Insulin resistance is another such factor associated 
with hepatic steatosis (Ratziu et al., 2000 and Ratziu et al., 2004).  Diabetes 
has been reported to be a risk factor for NAFLD and NASH, the latter shown to 
have a causative link with HCC (Schutte et al., 2009).  
 
1.2.3 Other factors  
a) Toxins  
A potent hepatocarcinogenic toxin is the mycotoxin aflatoxin B1, which has been 
classified as a carcinogen by the International Agency for Research on Cancer 
(Schutte et al., 2009).  It is produced by fungi of the Aspergillus family such as 
Aspergillus Flavis and Aspergillus Parasitans.  They grow mainly on cereal 
grains stored in humid regions (Leong and Leong, 2005).  The role of Aflatoxin 
in hepatocarcinogensis is due to its ability to induce a high degree of 
Introduction 
25 
 
chromosomal instability (Pineau et al., 2008). Simultaneous infection by viral 
hepatitis B potentiates the carcinogenic effects of these toxins (Schutte et al., 
2009).  Aflatoxin is also one of the most potent genotoxic agents.  It induces 
multiple chromosomal alterations and unscheduled DNA synthesis (Wang and 
Groopman, 1999).  
 
b) Haemochromatosis  
Haemochromatosis results from the excessive accumulation of iron in the liver 
due to hereditary or acquired causes.  It leads to chronic inflammation with 
subsequent fibrosis and can lead to cirrhosis (Schutte et al., 2009).  HCC in 
haemochromatosis patients with or without cirrhosis suggests a direct 
hepatocarcinogenic effect of iron (Kowdley, 2004 and Kew, 2009).  A Swedish 
study has reported that hereditary haemochromatosis increases the risk of HCC 
by 1.7 fold (El Serag and Rudolph, 2007). 
 
c) Autoimmune hepatitis 
Autoimmune hepatitis is a chronic and progressive autoimmune disease 
associated with inflammation and hepatocellular necrosis.  It is more common in 
females and around 70% of all cases are detected in women between the ages 
of 15 and 40 years. Diagnosis is based on clinical (jaundice, fever and right 
upper quadrant pain), laboratory (increase ALT and AST, serum gamma 
globulin concentrations more than twice the normal levels, and sometimes the 
presence of antinuclear antibodies and/or anti-smooth muscle antibodies 
(Krawitt, 1996) and histological features.  Autoimmune hepatitis can progress to 
cirrhosis, often leading to HCC with an annual incidence rate of 1.1% (Yeoman 
et al., 2008). 
 
d) α1- Antitrypsin deficiency (α1-ATD) 
α1- Antitrypsin deficiency is an inherited metabolic disorder which prevents α1- 
Antitrypsin being exported from hepatocytes as a consequence of mutations in 
the coding sequence of the serine protease inhibitor.  The abnormal 
accumulation of glycoprotein α1- Antitrypsin in the hepatocytes results in 
apoptosis, hepatitis, fibrosis and cirrhosis (Fairbanks and Tavill, 2008).  
Homozygous patients become symptomatic about 15 years earlier than those 
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who are heterozygous (Schutte et al., 2009).  In α-1 antitrypsin deficiency, older 
cells with accumulated mutant glycoprotein stimulate newly formed cells to 
proliferate (Rudnick and Perlmutter, 2005).  As a result of accumulation of 
genetic mutations, hepatocellular adenoma and carcinoma develop on a 
background of chronic inflammation (Fairbanks and Tavill, 2008).  
 
e) Glycogen storage disease type 1 (Von Gierke’s disease, GSD1) 
Von Gierke’s disease is caused by a deficiency of glucose-6-phosphatase 
(G6Pase), which leads to accumulation of glycogen in the liver (Dragani, 2010).  
There are two distinct types of this disease, the type 1a (complete absence of 
G6Pase) and type 1b (deficiency of glucose-6-phosphate translocase at the 
endoplasmic reticulum membrane) (Janecke et al., 2001). Most cases of GSD1 
present with hepatocellular adenoma in the second and third decades of life.  
HCC may develop as an adenoma-carcinoma sequence (Franco et al., 2005). 
 
f) Miscellaneous  
Several other factors are implicated as potential risk factors for HCC. These risk 
factors include biological conditions such as hepatic porphyrias, Tyrosinemia 
type 1 and hypothyroidism (Dragani, 2010), chemical factors such as nitrites, 
hydrocarbons, solvents, pesticides and processed food (Leong and Leong, 
2005) and radiation. Both internal α and β radiation are carcinogenic (Leong 
and Leong, 2005). 
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1.3 Histopathological changes from normal to HCC 
 As a result of chronic hepatic injury, hepatic necrosis results and this is 
followed by proliferation.  Chronic hepatitis is characterized by infiltration of 
inflammatory cells, mainly lymphocytic infiltration, with much less lobular 
involvement.  Piecemeal necrosis and fibrosis may also be present.  Depending 
on the presence or absence of piecemeal necrosis; chronic hepatitis may be 
divided into chronic active hepatitis and chronic persistent hepatitis (Chadwick 
et al., 1979). 
 
Repeated cycles of destruction and regeneration in chronic liver disease lead to 
liver cirrhosis.  Histologically, cirrhosis is characterised by the presence of 
abnormal liver nodules surrounded by collagen deposition.  Within these 
nodules, hyperplastic nodules may be formed which develop into dysplasia 
leading subsequently to HCC (Farazi and DePinho, 2006).  
Severity of fibrosis can be staged according to Ishak scoring criteria: 
 
Table 1: Ishak criteria for fibrosis scoring (Ishak et al., 1995 and table 
adopted from Standish et al., 2006). 
 
Ishak Score Ishak description 
0 No fibrosis (normal) 
1 Fibrous expansion of some portal areas± short fibrous septa 
2 Fibrous expansion of most portal areas± short fibrous septa 
3 Fibrous expansion of most portal areas with occasional portal to 
portal bridging 
4 Fibrous expansion of portal areas with marked bridging portal to 
portal as well as portal to central 
5 Marked bridging with occasional nodules (incomplete cirrhosis) 
6 Cirrhosis  
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Dysplastic nodules are pre-cancerous, also known as adenomatous 
hyperplasia, hepatocellular pseudotumour, adenomatous regeneration and 
borderline nodule (Leong and Leong, 2005 and Wong and Ng, 2008). 
 
Classification is divided into high and low dysplastic nodule based on cytological 
features and the degree of histologic abnormality (Wong and Ng, 2008).  With 
increasing grade of dysplasia, hepatocytes become preneoplastic, which find a 
suitable environment for growth and proliferation to progress into malignant 
cells (Hussain et al., 2007).  Malignant foci may be found in some of these 
nodules.  This is known as nodule-in-nodule (Teoh, 2009).  Hepatocytes 
progress from being benign to preneoplastic and then malignant.  This takes 
place on a background of inflammatory conditions, which lead to cirrhosis.   
 
Hepatocellular carcinoma: The gross picture (macroscopically) of HCC may 
constitute single or multicentric nodules, which may be well demarcated from 
surrounding liver tissue or have infiltrative growth (Kalinski and Roessner, 
2009).  The cross-section of these nodules may show areas of haemorrhage 
and necrosis.  The most important criteria of current tumour classification of 
Union Internationale contre Le Cancer (UICC) is vascular invasion of portal or 
hepatic veins.   
 
Microscopically, depending on the degree of differentiation, HCCs can resemble 
normal hepatic tissue.  HCC cells may take on different patterns, trabecular 
pattern enclosing sinusoid-like blood spaces, pseudoglandular or acinar pattern 
and compact or scirrhous pattern (Kalinski and Roessner, 2009).  The 
hepatocytes show high nucleo-cytoplasmic ratio, abundant finely granular 
eosinophilic cytoplasm, and prominent nucleoli.  There are cytologic variations 
in the form of clear cell type, pleomorphic type with giant cells and the 
sarcomatoid type (Drebber and Dienes, 2006).   
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1.4 Molecular pathogenesis of Hepatocellular carcinoma  
Carcinogenesis is the end result of accumulation of chromosomal abnormalities 
which can lead to cellular dysfunction.  These abnormalities may be genetic or 
epigenetic (Wong and Ng, 2008).  Accumulation of genetic alterations causes 
abnormal growth, malignant transformation followed by vascular invasion and 
metastasis (Teoh, 2009).   
 
For instance, genetic alterations include chromosomal deletions, gene 
amplifications, aneuploidy, rearrangement, mutations and epigenetic alterations 
including modulation of DNA methylation (Tada and Omata, 2009).  Both 
genetic and epigenetic alterations activate mediators that enhance cellular 
proliferation (such as cellular proto-oncogenes) and inactivate mediators that 
inhibit cell proliferation (tumour suppressor genes) (Pang et al., 2006).  
Mutations in human cancer have been found in many genes such as p53, 
adenomatous polyposis coli (APC), cancer breast 1(BRAC1) and (BRAC2), 
retinoblastoma (RB), Ras and β-catenin.  These genes are responsible for cell 
proliferation, cell cycle progression, apoptosis and metastasis.  In HCC, it was 
found that p53 and β-catenin are the most frequently mutated genes (Wong and 
Figure 3: Microscopic picture of HCC showing polygonal 
cells with increased nucleocytoplasmic ratio and 
prominent nuclei. 
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Ng, 2008).  As an example of the most frequent chromosomal deletions in HCC; 
deletions on chromosomal arms 17p, 8p, 16q, 16p, 13q, 1p, 4q, and 9p, and 
addition onto chromosomal arms 1q, 6p, 8q, 17q and 20q (Leong and Leong, 
2005 and Pang et al., 2006).   
 
Genetic alterations may be inherited mutations or acquired.  Acquired genetic 
alterations are due to a combination of chemical, physical or biological 
carcinogens attacking cells (Leong and Leong, 2005).  Carcinogenesis occurs 
due to either direct DNA damage followed by abnormal regeneration or 
secondary to chronic inflammation followed by cirrhosis.  It is important to note 
that, 90% of HCC cases have a background of chronic inflammation and fibrosis 
(or cirrhosis) irrespective of the cause of liver disease (Elsharkawy and Mann, 
2007).  Free radicals resulting from inflammation can damage DNA and proteins 
directly (Hussain et al., 2007).  As detailed above, the high incidence of 
developing HCC on a background of chronic inflammation makes the 
inflammation–cancer relationship a target for further study and investigation.
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1.5 Inflammation- cancer relationship in liver diseases 
Rudolf Virchow in 1863 noticed that cancer often occurred at sites of chronic 
inflammation suggesting that inflammation may play a pivotal role in 
tumourigenesis (Balkwill and Mantovani, 2001).  
 
The important role of inflammation and infection have also been shown to be 
integral in the pathogenesis of liver, colon, oesophagus, stomach, cervical, and 
nasopharyngeal cancer by causing cell damage and creating a 
microenvironment rich in cytokines that can enhance cell replication, 
angiogenesis and tissue repair (Palapattu et al., 2009).  In addition to these 
cancer types, a previous study highlighted that hepatocarcinogensis is strongly 
linked to chronic liver damage as it rarely exists in non diseased livers (El Serag 
and Rudolph, 2007).  The pathway from chronic liver inflammation to HCC is a 
multi-stage process involving progression from mild to severe liver inflammation 
followed by hepatic fibrosis, cirrhosis and finally hepato-carcinogenesis.  Liver 
inflammation is initiated by inflammatory cells either resident or recruited to the 
liver in response to signals released from damaged hepatocytes as a result.of 
exposure to toxins, infection or auto-immune causes. These inflammatory cells 
produce pro-inflammatory cytokines such as Interleukin 1B, Interferon-Gamma 
and Tumour necrosis factor α, which contribute to the creation of a pro-
inflammatory microenvironment leading to further hepatocellular damage. 
This ultimately leads to hepatocellular regeneration and restoration of liver 
integrity (Ramadori et al., 2008). The inflammation and cell proliferation subside 
after the noxious agent is removed and the repair is complete. However, when 
the assaulting agent is unable to be removed, the persistent infiltration of 
inflammatory cells and continuous damage to the parenchyma leads to 
activation of a wound-healing response characterized by the appearance of 
myfibroblast-like cells. Activated myofibroblasts are responsible for hepatic 
fibrosis.  These activated myofibroblasts may either be derived from quiescent  
hepatic stellate cell, bone marrow precursor or by epithelial to mesenchymal 
transition (EMT) (Brenner, 2009).   Oxidative stress resulting from increased 
production of free radicals (ROS and reactive nitrogen species (RNS)) and 
peroxides is another important factor contributing to tissue damage and 
fibrogenesis. According to Parola and Pinzani (2009) these three events; (1) 
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chronic activation of the wound-healing reaction; (2) oxidative stress and 
reactive intermediates and; (3) derangement of epithelial-mesenchymal 
interactions are the key mechanisms underlying the initiation and maintenance 
of liver fibrogenesis (Parola and Pinzani, 2009).  . 
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Figure 4: Mechanism of liver inflammation and fibrosis. The process of 
inflammation initiated with inflammatory cells, which produce pro-inflammatory 
cytokines which in turn lead to damage of stressed cells. This is followed 
by elimination of cellular debris and regeneration of hepatocytes. However 
with persistent of these stressfull conditions, there is absence of 
hepatocytes regeneration and an activation of wound healing proceeds and 
lead to fibrosis. 
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Cirrhosis is the most advanced stage of liver fibrosis and is characterized by 
irreversible changes in the normal tissue architecture whereby hepatocytes lose 
their normal two-cell plate-like arrangement and regenerative nodules are 
formed surrounded and separated by fibrotic septae. Distortion of the liver 
parenchyma leads to a reduction in the blood flow to parts of the liver resulting 
in tissue hypoxia, portal hypertension and increased risk of liver failure.  At the 
same time the cirrhotic environment promotes the accumulation of genetic and 
epigentic mutations in pre-neoplastic hepatocytes or liver stem cells.  These 
genetic alterations activate positive signals of cellular proliferation (including 
proto-oncogenes) and inactivate inhibitory signals of cell proliferation (including 
tumour suppressor genes) resulting in cells with autonomous growth potential. 
The altered cells develop into dysplastic foci and form nodules which finally 
undergo malignant transformation to HCC  
 
Chronic inflammation also leads to stimulation of apoptosis and increase of 
oxidative stress which may lead to DNA damage (Schutte et al., 2009).  This is 
due to the toxic metabolites such as acetaldehyde which have the capability to 
bind to DNA (Inoue et al., 2001) leading to genomic alterations.  The alterations 
become severe with inhibition of DNA-repair enzymes (Homann et al., 2006) 
and therefore lead to accumulation of abnormal DNA and end up with 
neoplastic transformation of the cells.   
 
Up regulation of toll like receptors (TLRs) signalling pathway has been reported 
in chronic liver diseases previously.  LPS, the potent TLR4 stimulant is elevated 
in the systemic circulation and the portal vein of cirrhotic patients (Pradere et 
al., 2010).  Moreover, TLR4 was identified as one of seven genes associated 
with development of cirrhosis in patients with chronic hepatitis C (Huang et al., 
2007).  There is evidence suggesting the implication of TLRs in chronic liver 
disease and cirrhosis, which can serve as a background for HCC.  Thus, in 
order to understand the mechanism of liver inflammation, we were interested in 
the role of TLRs. 
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1.6 Toll like receptors 
The Toll protein was discovered in Drosophila.  It was shown to be essential 
during embryogenesis for determining the dorsal–ventral patterning (Anderson 
et al., 1985 and Morisato et al., 1995).  It also has a role in the early formation 
of the innate immune system (Lemaitre et al., 1996 and Cherry and Silverman, 
2006) and it was also found that mutation of TLR in Drosophila increases 
susceptibility to fungal infection (Kawai and Akira, 2006).  TLRs are well known 
to play an important role in innate immune responses (Kawai and Akira, 2006). 
 
To date, 13 subtypes of TLRs have been discovered (Park et al., 2009).  The 
human TLR family includes 10 members (Kawai and Akira, 2006 and Mencin et 
al., 2009).  These TLRs are stimulated by pathogen-associated molecular 
patterns (PAMPs).  PAMPs are structural motifs expressed by bacteria, viruses 
and fungi (Janeway and Medzhitov 2002, Akira et al., 2006).  Recently, danger-
associated molecular patterns (DAMPs) have been reported to be a potent 
stimulant of TLRs and are derived from injured host and necrotic cancer cells 
(Sato et al., 2009).  TLRs are divided into different families according to the 
phylogenetic properties (Roach et al., 2005).  Each family is made up of TLR 
members, which respond to a general class of PAMPs.  A specific ligand 
(DAMPs or PAMPs) has the ability to stimulate one particular member of the 
TLR family (table 2). 
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Table 2: TLRs and their corresponding PAMPs 
 
Members of TLRs family  Corresponding stimulators (PAMPs) 
 
TLR2, TLR1, TLR6 and 
TLR10 
bacterial (lipopeptides, lipoteichoic acid, and 
peptidoglycan), fungal (Zymosan) and Viral (viral 
core proteins) 
TLR3 recognizes the double-strand RNA and synthetic 
RNA derivatives (polyinosilic-polycytidylic acid) 
TLR4 Lipopolysaccharide (LPS) 
TLR5 Bacterial flagella 
TLR7, TLR8 and TaLR9 TLR7 and TLR8 respond to nucleic acid structures 
such as guanosine- or uridinerich single-stranded 
RNA (ssRNA), from viruses TLR9 recognizes 
unmethylated CpG DNA motifs from DNA bacteria 
 
The TLR2 family includes TLR2 with TLR1, TLR6 and TLR10.  They respond to 
molecular patterns which include bacterial (lipopeptides, lipoteichoic acid, and 
peptidoglycan), fungal (Zymosan) and viral (viral core proteins) pathogens 
(Takeuchi and Akira, 2001 and Takeuchi et al., 2002).  TLR3 recognizes the 
double-strand RNA and synthetic RNA derivatives (polyinosilic-polycytidylic 
acid) (Alexopoulo et al., 2001 and Matsukura et al., 2006). 
 
TLR4 has receptors for lipopolysaccharide (LPS) (Yang et al., 2002) which 
forms a complex with LPS-binding protein (LBP), the membrane CD14 molecule 
and the MD-2 glycoprotein.  These attach to the extracellular domain of TLR4 
(Rallabhandi et al., 2006).  TLR5 recognizes bacterial flagella through its 
monomeric constituent (Hayashi et al., 2001).   
 
 TLR7, TLR8 and TLR9 are in one family.  TLR7 and TLR8 respond to nucleic 
acid structures such as guanosine- or uridine-rich single-stranded RNA (ssRNA) 
from viruses (Heil et al., 2004).  TLR9 recognizes unmethylated CpG DNA 
motifs from DNA bacteria (Hemmi et al., 2000) and also unmethylated CpG in 
viral genome which is not common in vertebrate genome and if present, this 
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CpG dinucleotide is highly methylated (Krieg, 2007).  However, recently it was 
found that TLR9 can be stimulated by either host or pathogen derived DNA 
(Basith et al., 2012).  TLR1, TLR2, TLR4, TLR5 and TLR6 are expressed on the 
cell surface while TLR3, TLR7, TLR8 and TLR9 are present on the endosome 
lysosome membrane (Seki and Brenner, 2008). 
  
 
Figure 5: TLRs Receptors and their ligands (Adapted from Akira, 2004). 
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1.6.1 TLR pathway 
 There are two pathways for TLR members to be stimulated, MyD88- dependent 
(all TLRs except TLR3) and MyD88 independent (TLR3 and TLR4) pathways.  
MyD88-dependent pathways play a role in the activation of p38, c-jun N-
terminal kinase (JNK) and inhibition of NF-κB kinase (IKK)/NF-κB (Seki and 
Brenner, 2008).  Once stimulated, MyD88 activates IRAK through 
phosphorylation, the cascade leading to activation of TRAF6, which then 
activates JNK and NF-κB (Takeda and Akira, 2004).  There are four members 
of IRAK that stimulate or inhibit TLR pathways.  IRAK1 and IRAK4 interact with 
MyD88 through its N-terminal, which possesses an aspartate residue in the 
kinase domain leading to a stimulatory cascade.  IRAK-2 and IRAK-M do not 
have this residue, and are therefore inactive catalytically (inhibitory stimulus) 
(Janssens and Beyaert, 2003).   
 
Upon stimulation, IRAK4 and IRAK1 activate tumour necrosis factor receptor-
associated factor 6 (TRAF6). TRAF6 activates transforming growth factor–β-
activated protein kinase1 (TAK1) which activates the inhibitor of kappa β kinase 
(IKK) complex (Kawai and Akira, 2006).   
 
 TLR3 and TLR4 use the TIR-domain containing the adapter-inducing 
interferon-β (TRIF) or TRIF-dependant pathway (the MyD88-independent 
pathway), which utilizes TRAM for its activation. TRAM is an adapter protein, 
which links TLR4 and TLR3 to TRIF (Kawai and Akira, 2006).  TRIF stimulation 
leads to the activation of the transcription factor IRF-3 inducing INF-β (Takeda 
and Akira, 2004).   The end result of the MyD88 dependent and non dependent 
TLR activation is the stimulation of the transcription factor nuclear factor-kappa 
B (NF-κB).   
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Figure 6: MyD88-dependent and independent pathways. (A) MyD88-
dependent: MyD88 stimulation leads to activation of IRAK by 
phosphorylation which in turn leads to activation of TRAF6 and NF-κB. 
(B)MyD88- independent pathway; stimulation of TRIF leads to activation of 
the transcription factor IRF-3 followed by INF-B (adapted from Kawai & 
Akira, 2006). 
 
1.6.2 Role of Toll like receptors in liver inflammation-cancer progression  
Due to the anatomical relationship between the liver and the intestine, and 
increased gut permeability associated with chronic liver disease, the liver is 
exposed to gut-derived pathogens and pathogenic molecules. This stimulates 
TLRs, releasing multiple cytokines and inflammatory mediators including 
activation of NF-κB, which is one of the most potent inflammatory mediators.  
NF-κB activation produces an inflammatory state in the liver through up 
regulation in the expression of cytokines, chemokines, growths factors, 
adhesion molecules, matrix metalloproteinase and anti-apoptotic proteins 
(Shishodia and Agarwal, 2002 and Pikarsky et al., 2004),  thus inducing 
chemoresistance in cancer cells (Nakanishi and Toi, 2005) and  hepatocyte 
death (Elsharkawy and Mann, 2007).  In addition to NF-κB pathway, TLRs also 
act as potent activators of gene transcription and translation (Wolska et al., 
2009), causing chemoresistance and cancer progression (Chen et al., 2008).  
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Not only TLR4 is linked to liver disease but also elevated bacterial DNA levels in 
blood and ascites of liver cirrhosis patients (Guarner et al., 2006 and Frances et 
al., 2008) suggesting a strong causative link between infection and liver 
inflammation. The bacterial unmethylated CpG-containing DNA stimulates TLR9 
(Yang and Seki, 2012), leading to further inflammation, liver fibrosis, and 
malignancy. Indeed, an increased expression of TLR9 is observed in many 
malignant human cell lines such as lung cancer cells (Droemann et al., 2005), 
human gastric carcinoma cells (Schmausser et al., 2005) and human prostate 
cancer (Ilvesaro et al., 2007).  Moreover, TLR9 modulates cytotoxicity by 
enhancing the NK cell cytokine response to antibody-coated tumour cells 
(Wysocka et al., 2004, Roda et al., 2005 and Ren et al., 2008).  
  
1.6.3 TLR effects in cancers 
The idea that TLRs are restricted to immune cells has changed, with a number 
of recent studies confirming expression of functional TLRs in cancer cells as 
well (Basith et al., 2012). 
 
a) TLRs in cancer immunology, cytotoxicity 
In any immune response, regulatory T cells (Treg) mediate antigen-specific 
immune attenuation and therefore can assist the tumour progression.  The 
function of Tregs is to inhibit exaggerated immunological reactions (Coussens 
and Werb, 2002, Fisson et al., 2003 and Sakaguchi, 2004) including 
autoimmune, antimicrobial and antitumour immune responses by inhibiting T 
cell, B cells and NK cells (Yang et al., 2009).   
 
It was found that Treg cells produce mRNA for TLR4, TLR 5, TLR 7 and TLR 8 
and TLR4 stimulation with LPS activates the suppressive function of Treg on 
cytotoxic T lymphocytes (Caramalho et al., 2003) which inhibit antitumour 
immune response and lead to tumour progression.  On the other side, 
stimulation of TLR9 modulates cytotoxicity of tumour cells by enhancing the NK 
cell cytokine response to antibody-coated tumour cells (Wysocka et al., 2004, 
Roda et al., 2005 and Ren et al., 2008).   
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Although TLRs recruit more immune cells to the tumour microenvironment, the 
tumour cells secrete pro-angiogenetic and growth factors, which make the 
tumour more resistant and can escape the cytotoxic lymphocytes. 
 
Recently, some TLR agonists have been used as a vaccine for induction of anti-
tumour immunity and the use of TLR agonists have shown promising results as 
anticancer agents.  Therefore Basith and colleagues described the role of TLRs 
in cancer as double edged sword (Basith et al., 2012). 
 
b) TLR effect on proliferation 
Cancer develops as a result of increase of the cell proliferation to cell-death 
ratio (Hanahan and Weinberg, 2000).  NF-κB has been reported to have a role 
as a hepatocyte survival factor (Elsharkawy and Mann, 2007).  NF-κB signalling 
produces more cytokines, chemokines and antiapoptotic proteins, which 
contribute to increase in tumour proliferation (Basith et al., 2012).  It was found 
that TLR stimulation leads to the activation of  phosphoinositide3-kinase (PI3K) 
and Akt which may have a role in regulation of glycogen synthase kinase 3 
(GSK3) (Monick et al., 2001 and Martin et al., 2005) and β-catenin (Monick et 
al., 2001 and Thiele et al., 2001).  It also activates MAP kinase, JNK, p38 and 
ERK (Rakoff-Nahom and Medzhitov, 2008). 
 
Previous studies reported that TLR ligands augment tumour growth (Harmey et 
al., 2002, Luo et al., 2004, Sfondrini et al., 2006 and Huang et al., 2007).  It has 
been reported that TLR4 with TLR3 play a role in tumour proliferation (Jego et 
al., 2006, Chochi et al., 2008, Kundu et al., 2008 and Pries et al., 2008).   
 
c) TLR effect on Apoptosis  
NF-κB which is produced from stimulation of TLRs activates pro-apoptotic 
factors.  In addition, NF-κB up regulates TNF-α which inhibits apoptosis (Salaun 
et al., 2006).  TLR4 was found in the human lung cancer cell line and thought to 
play a role in protecting lung cancer cells through the induction of 
immunosuppressive cytokines and resistance to apoptosis (He et al., 2007).  In 
some studies, TLR9, TLR3, TLR4 and TLR7 trigger apoptosis (Jahrsdorfer et 
al., 2002, Jahrsdorfer et al., 2005, Smits et al., 2007, Lehner et al., 2007 and 
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Paone et al., 2008).  However, Jego and colleagues found that in myeloma cells 
triggering TLR7 and TLR9 prevents chemotherapy-induced apoptosis and 
induces cell growth (Jego et al., 2006).  Another study suggested that the anti-
apoptotic effect of TLR9 was through involvement of HSP90β.  Lim et al., 
suggested the mechanism of anti-apoptotic effect mediated by stimulation of 
TLR9 depended on the Akt-FoxO3a signaling pathway (Lim et al., 2010). 
 
d) TLR effect on Angiogenesis 
 It has been demonstrated that both TLR2 and TLR9 act as pro-angiogenic 
factors (Chang et al., 2005).  TLR4 also enhances chemoresistance (Kelly et 
al., 2006).  Although TLR9 is a pro-angiogenic factor it can also act as an anti-
angiogenic factor together with TLR7 (Li et al., 2005, Majewski et al., 2005 and 
Damiano et al., 2006).  NF-κB was also found to promote angiogenesis 
(Muccioli et al., 2012). 
 
e) TLR effect on Metastasis 
TLR-derived signals regulate the function of cyclooxygenases, chemokines, 
VEGF and matrix metalloproteinase (Rakoff-Nahoum et al., 2004, Pull et al., 
2005 and Fukata et al., 2006).  They have been known activate mesenchymal 
stem cells (Pevsner- Fisher et al., 2007).  It was noticed that injecting 4T1 
murine mammary carcinoma cells into the tail vein of mice resulted in increased 
lung metastasis after LPS (TLR4 agonist) injection (Harmey et al., 2002).  In two 
different studies, stimulation of TLR9 was associated with increased cancer 
invasion and this was attributable to the activity of matrix metallopeptidase-13 
(MMP13) (Ilvesaro et al., 2007 and Ilvesaro et al., 2008). 
 
f) TLR effect on autophagy  
Autophagy is a process of intracellular compartment degradation in stressful 
conditions and this process is thought to be related to cell survival, cell death 
and antigen presentation (Munz, 2009, Dalby et al., 2010 and Levine et al., 
2011).  Autophagy is primarily a cell survival mechanism.  However, excessive 
autophagy can cause programmed cell death, which can be through apoptotic 
or non-apoptotic pathways (Gozuacik and Kimchi, 2004).  In addition to this, 
autophagy enhances the process of presentation of tumour antigen via MHC 
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class II (Dengjel et al., 2005, Schmid and Munz, 2007 and Bertin and Pierrefite-
carle, 2008).  This suggests that autophagy can have an anti-tumoural effect by 
increasing immune surveillance (Bertin and Pierrefite-carle, 2008).  However, in 
solid tumours which express MHC class II the tumour antigen presentation 
could enhance tumour growth as a result of induction of tolerance (Dengjel et 
al., 2006 and Bertin and Pierrefite-carle, 2008). 
 
TLR signaling was suggested to link the autophagy pathway to phagocytosis 
(Sanjuan et al., 2007).  Two subsequent studies demonstrated that TLR ligands 
have the ability to stimulate autophagy (Xu et al., 2007 and Delgado et al., 
2008).  A previous study showed that CpG (TLR9 ligand)  not only induced 
autophagy in different tumour cell lines such as colon, breast and prostate 
cancer, but also that TLR9 itself  was required for autophagy (Bertin and 
Pierrefite-carle, 2008).  Light chain B (LC3B) is continuously degraded during 
the process of autophagy and more LC3B is needed to replenish the LC3B pool 
(Mammucari et al., 2008).  For autophagy, the fusion of autophagosome with 
lysosomes is a mandatory step.  Chloroquine has been reported to inhibit the 
fusion of autophagosome, thereby inhibits autophagy (Boya et al., 2005 and 
Ramser et al., 2009). 
 
g) TLR effect on cytotoxicity and tumour management  
Interestingly, it was noted that chemotherapy can induce initial inhibition of 
tumour growth, which is then followed by recurrence of more aggressive tumour 
phenotypes.  This may be explained by the stimulation of TLRs by partial 
induction of cell death after chemotherapy, which stimulates inflammatory cells 
in a process known as sterile inflammatory response (Chen et al., 2008).   
 
Inhibition of endosomal TLRs has a potential therapeutic in autoimmune 
diseases treatment.  Chloroquine, the antimalrial drug has been used to treat 
immune-mediated inflammatory disorders such as SLE, rheumatoid arthritis and 
Sjogren’s syndrome (Sun et al., 2007).  It also inhibits CpG DNA-driven cellular 
activation (Macfarlane and Manzel, 1998) and this inhibition occurs as a 
consequence of alkalinisation as acidification of endosome is essential for TLR 
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activation (Macfarlane and Manzel, 1998, Hacker et al., 1998 and Yi and Krieg, 
1998). 
 
1.6.4 Clinical application of TLRs agonist and antagonist  
a) Clinical application of TLRs agonist  
 TLR2 agonist SMP-105 consists of mycolic acids and peptidoglycan 
derived from Mycobacterium Bovis.  It has been used to treat bladder cancer 
(Simons et al., 2008). 
 TLR3 was found to be a promising candidate for cancer treatment and 
clinical trials have reported that darn (TLR3 agonist) is linked to survival in 
cancer patient particularly breast cancer, primary and metastatic clear cell renal 
cancer (Salaam et al., 2006). 
 TLR4 agonist, monophosphoryl lipid A (MPLA) is less toxic than the well-
known agonist LPS.  This has been approved as a part of the improved 
hepatitis B vaccine (Basith et al., 2012). 
 TLR5 agonist (Flagellin) is under investigation with another component 
for the treatment of viral infection and as a vaccine against influenza (Huleatt et 
al., 2008). 
 TLR7 agonist (imiquimod) has been approved as a topical treatment of 
cancer skin and cutaneous metastasis (Schon and Schon, 2008). 
 TLR9 agonist unmethylated CpG (cytosine-phosphate-guanine) has 
been studied in targeting many cancers (Basith et al., 2012).  However, 
immunomodulatory oligonuclutides (IMOs), which are also TLR9 stimulants are 
in clinical development for chronic HCV treatment.   IMO-2055 has an 
anticancer effect and it is under clinical trial for the treatment of non-small lung 
cancer and in colorectal cancer (Krieg, 2008). 
 
b)  Clinical application of TLRs antagonist 
TLRs antagonists have also been used in the treatment of different diseases. 
 TLR2 inhibitor is being investigated for the treatment of inflammatory 
diseases including cardiac and kidney ischemia/reperfusion injuries and sepsis 
(Arslan et al., 2008). 
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 TLR4 antagonist, Chaperon 10 had been tested in patients with multiple 
sclerosis, for the treatment of sepsis and septic shock, rheumatoid arthritis and 
psoriasis (Vanags et al., 2006 and Broadley and Hartl, 2009). 
 TLR7 and TLR9 antagonists, IMO-3100 have been developed for the 
treatment of autoimmune diseases.  Dynavax produced an oligonucleotide-
based compound, which inhibits endosomal TLRs, called immunoregulatory 
sequences (IRS 954).  IRS 954 inhibits both TLR7 and TLR9 and has been 
tested in animal models for the treatment of systemic lupus erythematosis and 
also under investigation for the treatment of HIV infection (Pawar et al., 2007).   
Another inhibitor of TLR7 and TLR9 is the antimalarial drug, chloroquine.  It has 
been used as an endosomal TLR inhibitor.  It is a weak base and it incorporates 
into the acidic vesicle within the endosome and interferes with its acidification 
as the acidic pH is mandatory for the endosomal TLR activation (Macfarlane 
and Manzel, 1998, Yi and Krieg, 1998 and Kuznik et al., 2011).  It has been 
reported also that chloroquine inhibit the CpG-TLR9 interaction and can be 
used as TLR9 antagonist and endosomal acidification inhibitor at the same time 
(Rutz et al., 2004).   
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2. Aims of the study 
This thesis was designed to explore the role of toll like receptors in the 
pathogenesis of HCC and evaluate their role as a potential therapeutic target.  
Specifically I aimed to  
1. Establish 2 animal models of primary liver cancer; a chemically-induced 
and a xenograft model.   
2. Determine whether gut decontamination with Norfloxacin could prevent 
HCC.   
3. Determine whether the expressions of TLR4, TLR7and TLR9 were 
increased in primary liver cancer in patient. 
4. Evaluate the expression of these TLRs in primary liver cancer cell-lines 
and the effect of stimulation or inhibition on cell proliferation. 
5. Determine the effect of inhibiting TLR7 and 9 using specific antagonists 
or non-specific inhibitor (chloroquine) in animal models. 
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3 Materials & Methods 
 Animal models are explained in details in chapter (4.1). 
 All the reagents that had been used in this research are reported in the 
appendix section. 
 
3.1  Animal tissues collection 
Rats and mice were anaesthetized in an induction chamber supplied with 
isoflurane from a vaporizer (5% and O2 1L/min) until the rodent was 
anaesthetised then anaesthesia was maintained using isoflurane (2%).  The 
liver was surgically removed and pictures of each liver were taken.  In the case 
of rats the dimensions of the whole rat liver and any obvious tumour(s) was 
measured using a ruler.  Half of the liver was then placed in 10% formalin and 
the other half was snap frozen in liquid nitrogen.  The formalin-fixed tissue 
contained representative areas of tumour and tumour-free tissue.  The snap-
frozen liver samples were divided into liver tissue macroscopically free from 
tumour and tumour nodules. 
 
In the case of mice only the tumours were measured.  The tumour was excised 
and snap-frozen in liquid nitrogen.  A corresponding tumour free area of liver 
tissue was also snap-frozen in a separate tube.  In other cases the whole of the 
mouse liver was fixed in formalin. Blood was collected in heparinised tubes 
which were placed directly on ice and then centrifuged for 10 minutes, 13000 
rpm, 4°C. 
 
3.2 Processing of tissue for histological examination 
Freshly harvested livers from rats and mice were cut into thin slices using a 
scalpel and placed in an embedding cassette for processing in a Benchtop 
Tissue Processor (Leica TP1020).  The processor automatically fixes the tissue 
in formalin, dehydrates it in alcohol and infiltrates it with paraffin wax (Ficher 
Scientific, UK).  Once the tissue processing was complete, 4 μm sections were 
cut from the paraffin embedded tissue blocks using a microtone (Leica, UK).  
The sections were then mounted from warm water (40C) onto adhesive poly- L-
Lysine coated glass slides ready for immunohistochemical staining and 
analysis.
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3.3 Haematoxylin and Eosin (H&E) staining  
Paraffin-embedded tissue sections were stained with H&E using conventional 
methods.  The sections were first de-paraffinised by immersing in two tanks of 
xylene, 2 x 5 minutes each and rehydrated by submerging in descending 
grades of ethanol; 100%, 95% and 75% ethanol, 5 minutes each.  The sections 
were then washed in distilled water for 5 mins, stained with Mayer/s 
Haematoxylin (Dako, UK), 3 mins, rinsed in tap water for 15 minutes, stained 
with Eosin (Sigma, UK) for 1 min and washed in a few changes of distilled water 
before dehydrating with ascending grades of ethanol;  75%, 95% and 100% 
ethanol, 3 minutes each.  Finally, the slides were cleared in 2 separate tanks of 
xylene, 5 minutes each, and mounted as follows: a drop of DPX mounting 
medium (Sigma, UK) was placed in the middle of a coverslip making sure to 
avoid any air bubbles.  The slide to be mounted was tapped to remove excess 
xylene and gently lowered on top of the coverslip so that the tissue section was 
sandwiched between the slide and coverslip.  The slide was then turned over 
and the DPX allowed to fully spreading under the coverslip.  The slides were left 
to harden in a fume hood overnight before being examined under microscope. 
 
3.4 Reticulin staining 
The silver stain has the ability to bind to collagen and fibrous tissue. 
 Methods 
The sections were first de-paraffinised by immersing in two tanks of xylene, 2 x 
5 minutes each and rehydrated by submerging in descending grades of ethanol; 
100%, 95% and 75% ethanol, 5 minutes each.  The sections were washed in 
distilled water.  The slides were treated with acidified potassium permanganate 
for 10 minutes then washed well with distilled water.  Oxalic acid was added to 
cover the slides for 1 minute until the colour acquired by potassium 
permanganate disappeared; the slides were then washed with water.  
Ammonium sulphate was added to slides for 10 minutes then washed with 
water.  The slides were treated with ammonical sliver solution for 5-20 seconds 
then washed and 10% formalin was added for 1 minute.  Then the slides were 
washed in water and dehydrated with ascending grades of ethanol; 75%, 95% 
and 100% ethanol, 3 minutes each.  Finally, the slides were cleaned in 2 
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separate tanks of xylene, 5 minutes each, and mounted as described in in the 
previous section (3.3). 
 
3.5  Picro-Sirius red staining 
This stains the collagen and fibrous tissue with red colour. 
 Method 
The sections were first de-paraffiinised by immersing in two tanks of xylene, 2 x 
5 minutes each and rehydrated by submerging in descending grades of ethanol; 
100%, 95% and 75% ethanol, 5 minutes each.  The sections were washed in 
distilled water.  Then sections were treated with picro-Sirius mixture for 15 
minutes then 100% ethanol for 5 minutes.  The slides were dehydrated with 
ascending grades of ethanol; 75%, 95% and 100% ethanol, 3 minutes each.  
Finally the slides were cleared in 2 separate tanks of xylene, 5 minutes each, 
and mounted as described in section (3.3). 
 
3.6 Measuring Liver enzymes and bilirubin 
Plasma samples were analyzed for ALT, AST and bilirubin (Cobas Integra 400, 
Roche Diagnostics, Burgess Hill, West Sussex, UK).   
Using a specific tube for Cobas (Roche Diagnostics Ltd, UK), 200μl of rat’s 
plasma was added.  The corresponding cartridges for the enzymes and bilirubin 
were placed in the Cobas machine.  The machine was run according to 
manufacturer’s instructions.   
 
3.7 Endotoxin kinetic LAL assay measurement  
 Method  
1. The samples (rat’s plasma) were diluted 1:10 LAL reagent water to 
prevent protein interference (50μL sample + 450μL LAL) then heated in a 
boiling water bath for 10 minutes. 
2. The Standard Reconstituted Endotoxin was diluted to obtain a 50EU/ml 
concentration (220µL for the standard curve plus 20uL/sample). 
3. Plate reader was switched on, Endotoxin test was selected, and 
temperature adjusted to 37ºC. 
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4.  5-point standard curve (50EU to 0.005EU) was made, in duplicate with 
the following dilutions :  
a) 111µL of the 50EU standard in the first well A of the 1st 2 rows 
b) 100µL of LAL water in the wells B, C, D, E, F  first 2 rows 
c) 11µL from the well A into the well B, from B to C and so on.  Down to 
E, 11µL was discarded from well E.  Well F was the blank sample. 
5. 100μL of each sample was transferred aseptically in quadruplicate (4 
wells in the plate).  In the last two wells, 10µL of 50EU standard endotoxin was 
added as spike well.   
6. The plate was then placed in plate reader for 5 minutes to warm up. 
7. The LAL reagent was prepared as the following (each bottle was diluted 
with 3.2ml of LAL reagent water) then vortexed for 20 seconds.  100µL of LAL 
regent was added to each well to start the reaction.  Then the plate was read at 
350 – 650nm (on scan mode). 
 
3.8 Western blot 
3.8.1 Protein extraction from liver tissue 
The liver tissue was disrupted using a pre-cleaned, autoclaved pestle and 
mortar which had been pre-cooled by placing in a -20ºC freezer for an hour or 
more.  A small piece of liver tissue, 100 mg, was dissected from the frozen 
tissue stock, and weighed by placing it inside an eppendorf safe-lock tube 
(Eppendorf UK Limited) on ice.  After weighing, the tissue was then placed in 
the cold mortar and 300μl of lysis buffer added per 100 mg of tissue.  The pestle 
was used to macerate the tissue to a pulp and the grinding continued until a 
homogenous liquid was produced.  The tissue extract was poured into a sterile 
1.5ml eppendorf safe-lock tube and then centrifuged for 5 minutes, 13000 rpm, 
4°C.  The supernatant was then aliquoted into a fresh eppendorf tube and the 
protein concentration in the liver tissue lysate determined using a biuret assay. 
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3.8.2 Determination of Protein Concentration  
 Biuret Protein Assay 
The protein concentration in the liver tissue extract was determined using the 
biuret protein assay.  This is a colorimetric assay used to determine the the 
protein concentration.  It is used for detecting the presence of peptide bonds.  It 
depends on the reduction of copper (II) ions to copper (I), the latter forms a 
complex with the nitrogen of the peptide bonds in an alkaline solution.  A violet 
colour indicates the presence of proteins. 
 
 Preparation of albumin standard curve 
A set of protein standards was prepared from a 2 mg/ml albumin (Zenalb) stock 
solution with the following concentration: 40μg/ml, 20μg/ml, 10μg/ml, 5μg/ml 
and 2.5μg/ml. 
 
 Biuret assay 
200μl of Biuret solution was added per well in 96 wells.  Standard serial dilution 
of albumin was prepared from albumin.  10μl from each standard and from each 
sample was placed into the biuret solution in the 96-well plate in duplicate for 2 
hours at 37°C then read in a plate reader for 562nm wave length.  After the 
reading, the amount of protein in each well was calculated.   
 
3.8.3 Addition of loading buffer to protein extract  
The loading buffer (LB) (Life technologies, UK) contains SDS which is a 
detergent that denatures the proteins and applies a negative charge which 
allows the proteins to migrate through a gel based on their length.  The LB also 
contains a dye, bromophenol blue, which helps to track the movement of 
proteins through the gel and glycerol, which adds viscosity to the mix making it 
easier to load the samples on a gel.  The samples were prepared by mixing 20 
ug of protein in given volume, made up to 15µl in de-ionised water, with 1/4th  
volume of 4 x LB and 1/10th volume of reducing agent (Life technologies, UK).  
The samples were then heated to 95-100°C for 5 minutes to denature the 
proteins and help SDS to bind.  The samples were then spun briefly for a few 
seconds in microcentrifuge to bring all the droplets to the bottom of the tube.  
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The samples were then ready to load onto an SDS polyacrylamide gel for 
electrophoresis. 
 
3.8.4 Gel electrophoresis  
Electrophoresis of proteins was carried out using pre-cast 4-12% Bis-Tris 
Nupage gels (Life Technologies, UK).  The gel cassette was removed from its 
casing and placed inside a Nupage gel tank according to the manufacturer’s 
instructions.  The gel tank was then filled with 1 x SDS running buffer (Life 
Technologies, UK).  The gel comb was gently removed and a Pasteur pipette 
was used to gently wash the wells.  The protein samples were then loaded onto 
the gel along with a protein molecular weight marker (See Blue ladder, Life 
technologies) loaded onto one of the wells.  The lid was then put in place on the 
gel tank, which was then connected to an electrical power supply.  
Electrophoresis was then carried out at 200V for 45 minutes or until the blue 
dye was around 1cm from the bottom of the gel. 
 
3.8.5 Western blot transfer 
a) Transfer buffer 
25ml of 20X transfer buffer (Life Technologies, UK) was added to 375 ml 
deionised water then 100 ml of methanol was added.  Prior to transfer Four 
sponges and 2 filter papers were soaked in the transfer buffer for around 30 
min.  The PVDF was first activated by soaking it in ice cold methanol for 15 
seconds followed by ice cold transfer buffer for 5 minutes.   
 
b) Transfer of proteins from gel to membrane 
When gel electrophoresis of proteins was complete, the proteins were 
transferred from the gel onto a membrane made of polyvinylidene difluoride 
(PVDF, Life technologies, UK) by electroblotting.  During this process, the 
proteins move from within the gel onto the membrane whilst maintaining the 
organization they had within the gel.  As a result of this blotting process, the 
proteins are exposed on a thin surface layer for detection.  The transfer 
sandwich was then assembled as seen in (Fig. 7) in a transfer cassette XCell 
II™ Blot Module CE Mark (Life Technologies, UK).   
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Figure 7: Transfer process.  The diagram showing the arrangement of the 
sponge, paper, membrane and gel in the transfer cassette.  The current 
flow runs from cathode to anode. 
 
Any air bubbles were removed from between the layers by using a designated 
roller which was rolled over the different layers after they were put in place.  Once 
the stack was complete, the sandwich unit was closed and placed in the blotting 
apparatus following manufacturer’s instructions.  Ice cold transfer buffer was then 
poured on top of the sandwich until its contents were entirely immersed.  The 
compartment outside the sandwich unit was filled with distilled water.  The lid was 
then placed on the blotting apparatus which was then connected to an electrical 
power supply.  Protein transfer was carried out at 30 V for 1 hour.   
 
c) Checking protein transfer 
After western blotting was complete, protein transfer to the PVDF membrane was 
checked by staining with Ponceau S solution (Sigma, UK).  The membrane was 
removed from the blotting sandwich and immediately immersed in a sufficient 
volume of Ponceau S to cover the membrane.  Five minutes later the Ponceau S 
(Sigma , UK) was poured off and the membrane was rinsed in several changes of 
deionised water until the background membrane staining disappeared and the 
pink protein bands were clearly visible.  Once protein transfer was verified, the 
stain was completely removed from the proteins by continued washing with Tris-
Buffered Saline and Tween 20 (TBST) buffer for 20 minutes.  The membrane 
was then blocked and probed with antibody as described in the next section. 
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3.8.6 Probing membrane with antibody 
Probing of Western blot membranes with antibody involves several steps.  
SNAP i.d.  Protein Detection System (Millipore, UK) was used.  It is a device 
that has place to accommodate particular cassettes; the cassettes are opened 
and the membrane inside was hydrated with de-ionised water then the 
Polyvinylidene difluoride (PVDF) membrane after which was put in specific 
order, the membrane face which was contact with gel during the transfer was 
put directly to face the cassette’s membrane then the cassette closed and put in 
the device.  The nonspecific binding was blocked with block solution (Millipore, 
UK).  This block reduces the background and eliminates false positives for an 
hour.  Following the blocking step, the blocking solution was removed by 
suction and the membrane was incubated with the following primary antibodies: 
mouse monoclonal NF-κB (1/500, Millipore, UK), rabbit polyclonal Akt (1:1000, 
cell signalling, UK), rabbit monoclonal pAkt (Ser473) (1:1000, cell signalling, 
UK), rabbit polyclonal LC3B (1:1000, cell signalling, UK) and rabbit polyclonal 
VEGF (1:500, Abcam, UK).  For checking the loading, protein amount, rabbit 
polyclonal β-actin (1:500, Abcam, UK) and mouse monoclonal α-tubulin 
(1:1000, Millipore, UK) the antibodies were diluted in blocking solution for 10 
minutes.  Then the antibody was removed by suction and after three washes 
with TBST 5 ml each and suction was turned on to remove the washing buffer.  
The membrane in the cassette was incubated with the secondary antibody 
diluted in blocking buffer for 10 minutes.  The secondary antibody is directed at 
a species-specific portion of the primary antibody (hence it is referred to as anti-
mouse (1:5000, Abcam, UK), anti-rabbit (1:5000 cell signalling).  The secondary 
antibodies were horseradish peroxidase-conjugated.  The secondary antibody 
was removed by suction and the 5ml of TBST was put in the cassette to wash 
the membrane 3 times then the wash buffer was removed by suction and the 
cassettes removed from the snap id device.   
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3.8.7 Visualizing antibodies on Western Blots by ECL 
The enhanced chemiluminescence (ECL) Western Blotting substrate for 
visualizing bound antibodies on membrane blots was used as recommended by 
the manufacturer (GE healthcare life sciences, UK).  One ml of each of the 
detection reagents, Reagents 1 and 2, was mixed and added to the membrane.  
After 1 minute the membrane was drained, covered in cling film and exposed to 
photographic film (Thermoscientific, UK) up to 2 minutes inside an intensifying 
film cassette.  The exposed film was then removed and placed in a film 
developer to visualize the antibody signals.  If necessary, a second sheet of 
photographic film was exposed to the membrane for a longer or shorter period 
of time (from a few seconds to 10 minutes) in order to get a stronger or weaker 
signal.   
 
3.9 TNF-α measurement by ELISA 
Measuring rat TNF-α was performed by ELISA (BD Bioscences, UK) on liver 
tissue lysate.  Liver tissue was homogenised and protein was measured as in 
section 3.8.1 and 3.8.2.  96-well plate was used and the plate was read on 
wave length 650nm as specified in the protocol and the results presented as the 
amount of TNF-α per amount of protein added (known from protein 
measurement). 
 
 Method 
a) 96-well plate was coated with the capture antibody.  Capture antibody 
was diluted 1 in 250 in coating buffer and then 100μl was added per well.  
The plate was sealed and incubated overnight in 4°C.   
b) On the second day the plate was washed with 300μL per well (5 times).  
This was blocked by adding 250μL of assay diluents to each well and 
incubated for 1 hour.  Then this was washed 5 times as described 
before. 
c) Sample or standard was added per well (in duplicate) as follow.  50μL of 
assay diluent in each well, then 50μL of sample or standard.  The 
samples used were tissue lysates.   
d) A seven point standard curve was achieved using serial dilutions.  Then 
the plate was covered and incubated for 2 hours.  After 2 hours the plate 
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was washed 5 times as before with washing buffer.  Then, the detection 
antibody was added.   
e) The detection antibody was diluted 1 in 250 in assay diluents and 100μL 
of the diluted detection antibody was added to each well.  The plate was 
covered and incubated for 1 hour then washed as before.  100μL of 
Streptavidin-HRP was added to each well after dilution (1 in 250 with 
assay diluents) and plate covered and incubated for 30 minutes.  The 
plate was then washed 7 times with 300μl per well each time.  100μL 
substrate solution was added per well and incubated for 20 minutes at 
room temperature in a dark place.   
f) After 20 minutes, 50μl of stop solution was added per well.  The plate 
was taped to mix gently and the plate was placed in the plate reader and 
read at a wavelength of 450nm. 
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3.10  Immunohistochemistry  
3.10.1 Materials  
a) Human Tissue Microarrays 
Human tissue microarrays (TMA) were purchased from Vbiolabs, Cambridge 
(UK).  Custom made slides were prepared containing 4μm parallel sections 
from 111 paraffin embedded human liver tissues of different histologies.  The 
samples were originally derived from 78 males and 33 females of a similar age 
group.  96 of cases were associated with hepatitis virus infection; 53 with HBV 
and 33 with HCV.  Details of the tissue samples along with the relevant clinical 
data are given in (Table 3). 
 
Table 3: Details of the Tissue Microarrays 
 
Histology Total 
No. 
Males 
No. 
Females  
 
No. 
Median Age 
(range) 
No. with 
hepatitis 
virus 
Males Females B C 
Normal 9 6 3 42 (34-58) 41 (30-41) 0 0 
Hepatitis 26 19 7 55 (26-68) 57 (52-72) 18 8 
Cirrhosis 24 23 1 55 (33-69) 47 (47) 16 8 
Hepatocellular 
carcinoma  
41 24 17 54.5 (29-68) 53 (41-72) 19 18 
Cholangio 
carcinoma 
9 2 7 54.5 (34-63) 61 (27-69) 0 0 
 
b) Archival Liver Tissue (Validation Set) 
Paraffin embedded liver tissue samples from patients who were admitted to the 
Royal Free Hospital between 1993 & 2004 were retrieved from the hospital 
pathology department.  The histology of these samples and other relevant data 
are given in Table 2.  All the cases of HCC were on a background of cirrhotic 
liver.  4 micron sections were cut from each paraffin-embedded tissue block 
using a microtome.  The sections were placed on poly-L Lysine coated slides 
(VWR, UK).
Materials and Methods 
59 
 
Table 4:  Details of the archival liver tissue samples (Validation Set) 
 
 Histology Total  
No. 
  
 Males 
No. 
 Females 
No. 
 Age Range  No. with 
Hepatitis 
virus  
 Males  Females  B  C 
 Normal  2  -  -  -  -  -  - 
 cirrhosis  5  -  -  -  -  -  - 
 HCC 19  16  3  43 - 68  31 - 51  3  9 
 
3.10.2 Immunohistochemistry procedure 
Immunohistochemistry was carried out on the human tissue specimens (TMA 
and validation set).   Paraffin was removed (from the sections) by heating at 
60˚C for 20 minutes before processing.  Tissue section on glass slides were first 
de-paraffiinised by immersing in 3 changes of xylene, 5 mins  each and 
rehydrated by submerging in descending grades of ethanol; 100%, 90%, 80 %, 
and 70% ethanol, 5 mins each.  Following a 5 minute wash in phosphate 
buffered saline (PBS) the slides were immersed in target retrieval solution, 
citrate pH 6 (Dako UK Ltd) and placed in a microwave oven for 10 minutes at 
700 watt power.  The slides were allowed to cool for approximately 30 mins 
approximately and then washed in PBS, 3 x 2 mins.  The excess liquid was 
removed by gently tapping the slides on a piece of tissue before applying 10% 
hydrogen peroxide for 30 mins to block the endogenous peroxidase activity.  
This was followed by another wash in PBS, 3 x 2 min.  The PBS was carefully 
removed again before incubating the slides with serum blocking reagent (Life 
Technologies, UK) for 30 mins.  The blocking reagent was tapped off the slides 
and the excess liquid was wiped away from around the tissue.  Each tissue 
section was then covered with diluted primary antibody or negative control 
(without primary antibody) and left to incubate overnight at 4 C in a closed 
chamber.  The slides were removed from the incubation chamber and washed 
in PBST, 3x2 minutes.  The excess liquid was then wiped away and each 
section was covered with secondary antibody for 45 minutes.  The slides were 
next washed in PBST, 3x2 mins and covered in freshly prepared 
Diaminobenzidine (DAB) chromogenic/substrate solution for 2-3 minutes 
Materials and Methods 
60 
 
(Envision Kit, Dako UK Ltd).  Following by a 5 min rinse in tap water the slides 
were counterstained with Haematoxylin (Dako UK Ltd), 3 mins, followed by 
another wash in tap water for 20 mins.  Finally, the coverslips mounted with 
aqueous mounting medium (Life Technologies, UK).  The slides then placed in 
an oven for 30 min to harden.   
 
3.10.3 Scoring of the immunohistochemistry data 
The immunohistochemically stained slides were examined by two independent 
pathologists.  Smooth muscle actin staining was scored by the presence or 
absence of the stain.  For TLR4, TLR7 and TLR9 the scoring system was 
depend on the intensity and extent.  The total score was calculated as the 
following. 
 
 The staining intensity was scored as follows: 
(0) No staining   
(+) Faint staining    
(++)  Moderate staining  
(+++)  Intense staining  
 
 The staining  extent was scored as follows: 
   < 1/3 of the cells stained  
    > 1/3 and <2/3 of cells stained 
    > 2/3 of the cells stained. 
 
 Then total score was calculated as the following: 
 
Table 5: Scoring system of immunohistochemistry 
 
staining Score description 
0  Negative or + staining in less than 1/3 of the cells 
1  (+) intensity  in more than 1/3 of the cells or ++ in less than 
1/3  
2  (++) or (+++) intensity of staining in more than2/3 of the cells  
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Ki-67 index:  A proliferation index was calculated by counting 1000 tumour cells 
and using a cell counter to count the number of Ki-67-positive nuclei among the 
1000 nuclei in highly expressed selected fields (el-Sader et al., 1996) and the 
index was presented as percentage.   
 
3.11  Cell cultures 
3.11.1 Cell Lines 
Human hepatocellular carcinoma cell line HepG2 was purchased from the 
American Type Culture Collection (ATCC) (as frozen vial).  The human 
hepatocellular carcinoma cell line HuH7 was purchased from SIGMA (as a 
growing cells).  HuCCT1 cell line was provided by another Laboratory (Riken 
BioResource centre, Japan).   
 
3.11.2 Cell Culture Medium 
Cells were grown in T75 culture flasks angled neck filter sterile (VWR) 
containing 15 ml of Dulbecco’s minimal essential medium (DMEM) for HepG2 
and HuH7 or Roswell Park Memorial Institute (RPMI) for HUCCT1 both media 
supplied with 2mM glutamine purchased from (Gibco) supplemented 10% fetal 
bovine serum (FBS) heated inactivated, from (Gibco), and 10000 U penicillin 
streptomycin (Life Technologies, UK).  The culture flasks were placed at 37°C in 
a 5% CO2 incubator.  The culture medium was changed twice a week until the 
cells were 70-80% confluent after which the cultures were subdivided by 
trypsinization. 
 
3.11.3 Trypsinization of cell cultures 
Cell lines were subcultured by trypsinization.  The culture medium was 
discarded from the flask and the cells were rinsed with 10 ml PBS (Life 
Technologies, UK).  The PBS was poured off and 1ml of 0.25% Trypsin-EDTA 
(Life Technologies, UK) was added to the flask.  The flask was then incubated 
at 37C for 2-3 minutes to allow the cells to detach from the flask.  The trypsin 
was then neutralized by adding 5 ml of DMEM containing 10% FBS.  The 
trypsinised cells where divided equally between five T75 flasks each containing 
10ml of DMEM supplemented with 10% FBS, 2mM glutamine and 10 000 U of 
penicillin/ streptomycin. 
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3.11.4 Cell Counting by Trypan Blue Staining 
Freshly trypsinised cells were counted using a haemocytometer as follows: 10μl 
of Trypan blue (Sigma, UK) were mixed with an equal volume of a well-mixed 
cell suspension.  The haemocytometer was cleaned by rinsing in distilled water 
followed by 70% ethanol.  The haemocytometer coverslip was cleaned in the 
same way then carefully placed in position on the counting chamber.  10 µl of 
the typan blue cell suspension were applied to the edge of the coverslip using a 
Gilson pipette and allowed to run under the coverslip.  When the counting 
chamber was completely filled with sample the cell numbers were determined 
by direct counting under a light microscopy at 20 X objective.  Live cells appear 
colourless whilst dead cells stain blue. 
The number of live cells in one of the large corner squares was counted in each 
of the 4 large corner squares and an average was taken.  The average was 
then multiplied by the dilution factor (in this case 2) and by 104, i.e. the average 
was multiplied by 20 000.   
 
3.11.5 Cell Viability  and proliferation Assay  
 Principle of the assay 
The assay is composed of tetrazolium compound [3-(4, 5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS].  
MTS is reduced by living cells into coloured product that is soluble in tissue 
culture medium.  The assay was performed by adding the reagent directly to the 
culture wells and it was incubated for 2 hours and then recording the 
absorbance at 490nm with a 96-well plate reader (Data sheet of the MTS assay, 
Promega). 
The cells were grown in 96-well plate (Nunc) 104 cells were seeded separately 
into 3 wells each and the number of cells was estimated after  24, 48, 72 and 98 
hours to detect the growth behaviour of the cells.  Before the reading, the media 
which was added to the cells was discarded and 100μl of fresh media added to 
each well.  Then 20μl of the proliferation assay solution was added to the media 
(as described by the manufacture protocol).  The plate was incubated (37ºC 
and 5% CO2) for 2 hours.  The plate was placed in the plate reader and read at 
a wavelength of 490 nm. 
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 Cell response to treatment 
104 HuH7 or HuCCT1 cells per well were plated in a 96-well plate.  A time-
course (24, 48 and 72-hours) of the proliferation of the cells was determined 
following treatment with CpG-ODN 5μM (TLR9 agonist, Invivogen, UK), 
Imiquimod 5ug/ml (TLR7 agonist, Invivogen, UK), chloroquine 15uM (Invivogen, 
UK) and IRS- 954 (Dynavax, USA) 20ug/ml [IRS-954 is an immunoregulatory 
DNA sequence which is a specific TLR7 and TLR9 antagonist and is being 
developed as a potential treatment of systemic lupus erythematosis (Barrat el 
al., 2005).  The proliferation assay was performed to detect any effect of 
treatment on proliferation. 
 
3.11.6 Neutral red uptake test 
 Principle of the test 
This test is based on the ability of viable cells to uptake the supravital dye 
Neutral Red (NR).  NR is weak cation which, through non-inionic passive 
diffusion penetrates cell membrane and accumulates in the lysosomes (Repetto 
et al., 2008).   
 
 NR dye preparation 
Under sterile conditions, neutral red stock solution was prepared by dissolving 
40 mg neutral red dye (Sigma, UK) in 10ml PBS in a falcon tube then protected 
the tube from light by foil.  The neutral red stock solution was diluted 1:100 in 
DMEM media and kept overnight in the incubator. 
HuH7 cells were trypsinised and seeded 104 cells per well for 48 hours and 
treated with the dosage as in cell response to treatment section.  DMEM media 
was discarded and 100μl of the diluted NR solution was added per well.  The 
plate was incubated for 2 hours.  Then the plate was examined under light 
microscopy to observe the red stain inside the cells. 
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3.11.7 Immunofluorescence staining 
HuH7 cells and HuCCT1 cells were stained using the immunofluorescence 
technique.  From each cell line, 5x103 cells were grown on 13mm glass 
coverslips (treated with 1 molar HCL then rinsed in 70% ethanol and finally 
washed with PBS).  Coverslips with cells were placed in 24-well plate for 24 
hours incubation to allow the cells to settle down.   
Then coverslips with cells were treated in duplicate with one of the following 
treatments: Imiqumoid (IMQ), CpG, chloroquine and IRS and one group without 
any treatment as a control.  The dosage of treatment mentioned in cell 
response to treatment section.  After 24 hours the media was discarded and 
cells fixed with methanol as describe before (Minogue et al., 2006).  Then the 
cells were washed with PBS and 70% cold methanol was added to each well.  
Then the plate was placed in -20ºC freezer  for no longer than 3 minutes this 
was then washed with PBS tree times then blocked with 3% bovine serum 
albumin (BSA)(Sigma, UK) for 20 minutes.  After blocking the following 
antibodies were added after dilution in 0.3% BSA as an antibody diluent.  
Mouse monoclonal TLR9 (1/50, Abcam, UK), mouse monoclonal lamp-1 
(1/100Abcam, UK), rabbit polyclonal TLR7 (1/100, Abcam, UK) and Rabbit 
polyclonal calnexin (1/100, cell signaling).  The matching secondary antibody 
was diluted in the same antibody diluents, antimouse Alex fluor 543 (1/500, Life 
Technologies, UK) and anti rabbit Alex fluor 488 (1/500, Life Technologies, UK) 
with hoechst 33342 (1/5000, Life Technologies, UK) for nuclear counterstaining.  
Cells were mounted using prolong gold antifade reagent (Life Technologies, 
UK) and observed under an LSM 510 Meta laser-scanning confocal 
microscope, (Carl Zeiss Ltd).  All images were obtained with a Zeiss 63× 1.4 NA 
oil-immersion objective with pinholes set to one Airey unit.  12-bit fluorescence 
images were collected to peak. 
 
3.11.8 Western Blot Analysis for cells  
The expression of specific proteins in the cell cultures was examined by 
Western blot analysis.  The method involves the following steps which are 
described in more in sections 3.8 
1. Extraction of proteins from cells  
2. Measurement of protein concentration in the cell.   
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3. Separation of proteins by electrophoresis on a nupage gel. 
4. Transfer of proteins from the gel to membrane  
5. Staining of the protein with antibodies 
6. Visualization of antibody signal by ECL reagent (steps 3, 4, 5 and 6 were 
described before in section 3.8 
 
 Protein extraction from cell cultures 
Cells were grown in T75 flasks until they were about 80% confluent.  The 
culture medium was then discarded and the cells were rinsed in 10 ml of PBS.  
The PBS was discarded and 500μl of mammalian protein extraction reagent M-
PER (Thermo Fisher Scientific, UK) was added to the flask.  The cells were 
then scraped off the flask using a cell scraper (Fischer scientific, UK) and 
collected in a 1.5 ml eppendorf tube then placed on ice and sonicated for 1 min.  
The tube was spun for 5 min, 13000 rmp, 4°C to pellet the debris.  The 
supernatant was collected and then aliquoted into a fresh tube and the protein 
concentration determined using a Bicinchoninic Acid (BCA) Protein Assay Kit 
(Thermo Fischer Scientific, UK). 
 
 Protein estimation by micro BCA Assay Kit 
The Bicinchoninic acid (BCA) assay was used to determine protein 
concentration in the cell culture lysates.  The principle of the assay is the 
reduction of Cu II to Cu I by proteins in an alkaline medium then detection of the 
Cu I ions by BCA reagent.  BCA is a chromogenic reagent that reacts with Cu I 
ions producing a purple complex with strong absorbance at 562nm.  The 
intensity of the colour produced is directly proportional to the concentration of 
protein in the sample.  The protein concentration is determined by measuring 
the colour intensity in the sample against a protein standard curve.  The 
standard curve is prepared using a series of bovine serum albumin (BSA) 
dilutions, at known concentration, which are assayed alongside the unknown(s) 
(Data sheet of the assay).   
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 Method 
A serial dilution of the protein extracted from cells, 1/75, 1/100 and 1/150 had 
been prepared in distilled water and had been put in triplicates and standard 
serial dilution of albumin 40mg/ml, 20mg/ml, 10mg/ml, 5mg/ml and 2.5mg/ml 
was prepared.  In 96-well plate the dilution of standard was put in total volume 
150µl in descending order in duplicate with one with only water  then the 
reagents had been mixed as a kit instruction and incubated with the proteins 
from the cells for 2 hours in 37°C then read in a plate reader for 562nm wave 
length. After the reading, the amount of protein in each well was determined 
after the linear regression correction and the accuracy of standard was 
calculated.   
 
 Albumin Standard 
BSA (2mg/ml) in 0.9% saline a set of protein standards was prepared from a 2 
mg/ml BSA stock solution with the following concentration: 40μg/ml, 20μg/ml, 
10μg/ml, 5μg/ml and 2.5μg/ml. 
 
3.12 Statistical analysis 
Continuous variables were analysed with t-test or ANOVA.  For inter-group 
comparison, Mann-Whitney-U-test or Kruskal-Walllis test were used for the 
nonparametric analyses.  For correlation spearman test was used.  Statistical 
significance was taken as P< 0.05.  All statistical analyses were performed 
using Prism software Version 4 (GraphPad).   
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4.1 Establishment of HCC animal models 
4.1.1 Introduction 
Animal models of HCC were established to determine the role of TLRs in HCC.  
Types of HCC animal models that have been used are as follows: 
 
a) Chemical-induced models of HCC 
Many chemical carcinogens have been used to develop HCC models including: 
Carbon tetrachloride, diethynitrosamine, acetylaminoflurane and 
nitrosomorpholine.  Natural substances such as aflatoxin, pyrrolizide and safrole 
have also been used (Heindryckx et al., 2009).  These substances have been 
administered orally by mixing with food or drinking water or via intraperitoneal 
injection. 
 
b) Viral-induced Models of HCC 
Previous studies have used HBV, HCV and Woodchuck hepatitis virus to 
produce HCC related to viral infection.  The viral models have been used to test 
chemoprevention of HCC and evaluation of gene therapy.  However, these 
models take more than 2 years to develop and are associated with considerable 
expense.  Both factors ruled out the possibility of these models for our study 
(Wu et al., 2009). 
 
c) Transplantable models of HCC & Cholangiocarcinoma 
There are two common transplantable models of HCC, syngeneic models and 
xenograft models.  Syngeneic models are created by implantation of rodent 
cancer cell lines into inbred animal to produce tumours.  In these models the 
immune system is intact.  The xenograft models are created by implanting 
human cancer cells taken directly from a patient (or cultured cell line) into 
immunodeficient mice (mainly nude mice).  The xenograft models have the 
advantage of perhaps making the model mimic the human tumour behaviour 
more closely, but the major disadvantage is the absence of the immunologic 
interaction, which occurs normally between the host and the tumour (Wu et al., 
2009). 
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d) Genetically engineered models of HCC  
Genetically engineered models of HCC are highly sophisticated using 
transgenic mouse technology.  These models use immunocompetent animals 
and have been shown to demonstrate similar pathophysiological features to 
human cancers.  However, they are expensive and substantial time is required 
for successful tumour development (Heindryckx et al., 2009). 
 
4.1.2 Choice of animal models for exploring our aim 
From the above models we decided to develop 
a)  chemically induced model of HCC for the following reasons: 
i. A relatively short period of time is required for tumour induction: typically 
three months. 
ii. Technically simple requiring oral or intraperitoneal administration of an 
agent. 
iii. Relatively inexpensive. 
b) Xenograft model 
Human cells can be used in this model and therefore the behaviour of any 
resulting tumours is more likely to be representative of the situation in humans. 
 
Two different models of HCC were established in an attempt to ensure the 
results obtained from our studies were not model specific.  For our purposes, a 
small animal (such as rats and mice) model was preferable for ease of handling.  
All experiments were conducted in accordance with local ethical approval and 
subjected to the complied with the UK’s animals’ (Scientific Procedures) Act 
1986. 
 
4.1.3 DEN & NMOR- induced rat model of HCC 
a) Method of establishment 
Fischer rats were chosen as the first model as they are well-known for their 
ability to develop HCC (Yoshino et al., 2005).  Thirteen, 5-weeks old male rats 
were divided into two groups: 1) the carcinogen group (n=7) and 2) the naive 
group (n=6).  All rats were acclimatised for one week before beginning the 
experiment (standard housing conditions 29-32°C, humidity 60%-65%).  From 
the start of the study, animals were health checked on alternate days including 
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body weight and drinking water intake to ensure that the carcinogen treated rats 
were not unduly affected by the administration of the substances.   
 
Rats were injected with diethylnitrosamine (DEN) (100mg/kg) intraperitoneal 
(IP) on day zero and given nitrosomorpholine (NMOR) 80 PPM in drinking water 
for a period of 14 weeks.  All rats (from carcinogen treated group) underwent an 
MRI scan at week 10 and week 14.  For the MRI, rats were transported to the 
UCL animal radiology unit and anesthetised with isoflurane.  They were then 
allowed to recover, and after a period of observation they were then returned to 
their ordinary cages.  MRI scanning was conducted using a 9.4 Tesla scanner 
with a horizontal bore system (Agilent, Varian).  MRI settings used were: fast, 
multi-slice, spin echo with a 1mm slice thickness.  Thirty slices were obtained 
per rat in the coronal orientation.  Images were analysed using Amira software 
5.3.1.  Total liver volume and volume of each nodule were calculated. 
 
One carcinogen group rat was culled at week 10 and the other rats were culled 
at week 16.  Animals were terminated under terminal anaesthesia by isoflurane 
(inhalation).  Livers were collected and fixed in 10%formalin.  Four μm liver 
sections were cut and stained with H&E, reticulin and Sirius red for 
histopathological evaluation.  Smooth muscle actin immunohistochemistry 
staining was also carried out.  (Further details of histology technique are 
provided in section materials and methods). 
 
b) Results of DEN & NMOR rat model 
At the beginning of the experiment, the average weight of the rats was 
229.3±10.5 g for carcinogen group and 221-249g in the naive group.  At the end 
of experiment the carcinogenic group weighted 328-353g and the control group 
430-478g (P <0.01).  In both groups there was an increase body weight, 
although this was reduced in the carcinogen treated group. 
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Figure 8: Graph showing increase in the body weight of rats in both 
groups treated or untreated with DEN and NMOR.  The weight of rats 
treated with DEN and NMOR was lower compared to the naïve untreated 
rats.  
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I. Rat liver MRI scans 
At week 10, there were small pinhead sized lesions that could not be 
conclusively classified as tumours.  At week 14 multiple nodules of variable 
sizes (Fig. 9), suggestive of tumour, were identified in all rats in the carcinogen 
group.   
 
 
 
Figure 9: MRI scanning showing liver lesion after 14 weeks treatment with 
DEN and NMOR.  The arrows point to the lesions. 
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By using Amira software, the total liver volume and total nodule volume were 
calculated and the percentage of nodule volume relative to total liver volume 
was estimated as listed in the table (6).    
 
Table 6: Liver lesion volume in rats treated with DEN and NMOR.  MRI 
scan results of DEN and NMOR treated rats showing the total volume of 
lesion compared to liver volume per rat. 
 
   Liver 
volume/pixels  
Lesion 
volume/pixels 
% 
Rat 1 15462.36133 2616.24585 16.92009 
Rat 2 12224.68652 1799.691772 14.72178 
Rat 3 14481.61719 1471.139038 10.15867 
Rat 4 14390.74316 820.014832 5.69821 
Rat 5 12694.27246 1324.208862 10.43155 
Rat 6 13924.06055 2082.059082 14.95296 
 
II. Histopathology of DEN & NMOR rat livers 
Macroscopic appearance rat livers 
 The livers of rats in carcinogen group were found to be pale in colour and 
larger in volume (average of 5x4x3 cm), compared to the control group 
(average of 3.5x3x2 cm).  The livers in the carcinogen group were nodular with 
an irregular surface, and on cut sections showed multiple pale nodules (Fig.  
10).  In the control group, all the animals had normal livers; a bright red glossy 
colour with a smooth outer surface, cut section shows homogenous liver tissue 
without any nodules (Fig. 10). 
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Figure 10: Macroscopic picture of livers obtained from DEN and NMOR 
treated and untreated rats.  Livers of treated rats demonstrate 
multinodular irregular outer surface and pale colour, while livers from 
naive group demonstrate bright red smooth outer surface. 
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Microscopic appearance of rat livers 
 Haematoxylin & Eosin staining  
Two independent pathologists assessed and graded slides from the livers of all 
rats.  Liver from one animal that was culled at week ten demonstrated high-
grade dysplasia (atypical polygonal large cells with large nucleus and prominent 
nucleoli).  The non-tumourous background showed an inflammatory cell 
infiltrate, with bridging necrosis and fibrosis.  In addition, there were small foci 
indicative of HCC showing small compact cells with hyperchromatic nuclei (Fig.  
11). 
 
  
 
Figure 11: Histopathologic changes in rat liver treated with DEN and 
NMOR for 10 weeks showing dysplasia and inflammation.  Areas of severe 
inflammation (black arrows) and high-grade dysplasia (yellow arrows) 
with foci suspicious of HCC (white arrow). 
 
After 16 weeks, all the livers of rats treated with DEN and NMOR developed 
severe inflammation, necro-inflammatory foci, bridging necrosis (moderate to 
severe) and multiple scattered dysplastic nodules, which together formed the 
background for multiple foci of HCC.  The hepatocytes inside these foci showed 
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frequent abnormal mitosis, increased nucleo-cytoplasmic ratio and irregular 
nuclear membranes which provided further support that these represented HCC 
foci.  The tumour grade ranged from well differentiated to poorly differentiated 
HCC.  Five out of six developed moderate to poorly differentiated HCC and 
severe inflammation.  One animal developed well-differentiated HCC.  All the 
animals developed fibrosis, which was confirmed with reticulin staining.   
 
 
 
Figure 12: Microscopic picture of normal rat liver showing the central vein 
and hepatocytes radiating around with no inflammation or atypical cells. 
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Figure 13: Microscopic picture of liver section derived from DEN and 
NMOR treated rats for 14 weeks: 10x magnification showed nodules of 
atypical cells, the black arrows point to the nodules.  40x magnification 
showed atypical cells within the nodules.  There was small cell dysplasia 
(white arrow), pleomorphism of the cells with prominent nucleoli and 
other cells had two nucleoli (yellow arrow).  There were also abnormal 
mitoses (black arrow) suggesting that this is a malignant nodule (HCC).    
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40x
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 Smooth muscle actin staining  (SMA) 
Immunohistochemical analysis of liver sections stained with SMA antibody 
(shown in brown colour) in all blood vessel walls.  It was also found also within 
the foci identified as  HCC providing additional confirmation of tumourigenesis 
as it stained the newly formed blood vessles within the tumour (Fig. 14). 
 
  
 
Figure 14: immunohistochemistry of smooth muscle actin (SMA) 10x 
magnification showed brown staining in the smooth muscle in the wall of 
blood vessels and the smooth muscle in the new blood vessels in the 
tumour mass.  20x showing the SMA staining in the tumour. 
 
10x
20x
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 Reticulin & Sirius red staining 
The DEN and NMOR treated rats developed liver fibrosis which was detected 
by silver stain (black colour) with reticulin or Sirius red.  The fibrosis varied from 
3/6-5/6 grade depending on Ishak criteria listed page (28).  The fibrosis in the 
carcinogen treated group varied from bridging fibrosis, portal to portal and in 
some cases it was found to be portal to central.  Bridging fibrosis reached the 
level of incomplete cirrhosis where the fibrous bands formed incomplete 
nodules (Fig.  15).  However, the livers in the control group did not show any 
evidence of fibrosis. 
 
  
  
Figure 15: Reticulin staining of liver section obtained from naïve (normal) 
and DEN & NMOR treated rat showing silver staining around blood 
vessels and fibrous band of pre-cirrhotic stage of liver with incomplete 
nodules and in normal liver the silver staining is around the blood vessels 
only.
DEN&NMOR
Normal
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Sirius red staining also confirmed fibrosis.  Livers obtained from the carcinogen 
group showed evidence of severe fibrosis (Fig. 16). 
  
 
 
Figure 16: Sirius red staining of liver section obtained from Naive (normal) 
and DEN & NMOR treated rats.  It stained the collagen in the wall of blood 
vessels and fibrous tissue red.  Liver section obtained from normal and 
DEN&NMOR treated rats showed multiple red stained fibrous septa, which 
tended to form nodules with DEN&NMOR treatment and only red staining 
around blood vessels in normal liver.   
 
DEN&NMOR
Normal
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4.1.4 Xenograft mouse model of HCC 
a) Method of Establishment 
Scatton and colleagues established the xenograft model in seven to eight week 
old male NOD-SCID mice (Scatton et al., 2008). The value of choosing this type 
of mouse is that they have severe combined immunodeficiency and therefore 
the injected cells in the liver are not exposed to repeat cycles of inflammation 
which can lead to cell rejection.  The human cell lines used (HuH7, HepG2 and 
HuCCT1) were injected intrahepatically following visualisation via a small 
laparotomy with five million cells in 100μl of saline of either HuH7 or HepG2 
(hepatocellular carcinoma cell lines) HuCCT1 (cholangiocarcinoma cell-line) 
underneath the Glisson's capsule. The procedure was performed under general 
anaesthesia using sterile conditions, with the laparotomy closed using 
absorbable suture (Vicryl, Johnsosn and Johnson). The animals were allowed 
to recover, before being returned to the housing rooms in independently 
ventilated cages for the duration of the study.  Blood and tissue samples were 
collected under terminal anaesthesia.  
 
Mice were injected intrahepatically with either HuH7 (n=7) or HepG2 (n=5) or 
HuCCT1 (n=7).  For HepG2 and HuCCT1 cells it took about approximately 60 
days (study protocol duration) to develop a tumour nodule, while  proliferation 
with HuH7 was noticeably faster and at 60 days these animals often developed 
a massive tumour that would lead to  the animal  having impairment in its 
movement with some mice dying before the protocol study period was 
complete. In consideration of this the end-point for the HuH7 injected mice was 
revised to 35 days.  With the HCC cell lines, it was found that there was a 
tumour in the liver and another mass was usually found outside the liver 
attached to the muscle wall over the site of cell injection, which could be 
explained as leakage from the injection site. With HuCCT1 cells, even though 
the cells were injected intrahepatically, there was no tumour found inside the 
liver but instead the tumour nodule found was outside the liver attached to the 
muscle of the abdominal wall. The tumour size was calculated by multiplying the 
three dimensions of the mass. 
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b) Results of mouse xenograft models  
I. HuH7 derived tumour characteristics  
The HuH7 cells derived tumour characterised by its rapid proliferation and the 
masses formed inside and outside the liver. The masses developed inside the 
liver were lobulated outer surface and the cut sections showed areas of 
necrosis and haemorrhage, which increased proportionally with the tumour 
volume. The average volume of these tumours varied from 0.2 cm3 to 3 cm3 
(Table 3). However, there were two cases in which the tumour developed 
outside the liver and there was no lesion within the liver. These masses were 
similar macroscopically and microscopically to the tumour cells inside the liver 
(Fig. 17). The volume of these tumours varied from  a mean of 2.3±0.5 cm3 and 
only one animal developed tumour within the liver only without any extra-hepatic 
masses. 
  
Table 7: 3 HuH7 derived tumour volumes in NOD-SCID mice 
 
HuH7 derived tumour volume (cm3) 
Intra-hepatic mass  Extra-hepatic mass  Total mass volume  
0.62  0.6  1.22  
0.5  3.6  4.1  
0.26  1.26  1.52  
0  0.5  0.5  
3  0.05  3.05  
2.4  0  2.4  
0  3.38  3.38  
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Figure 17: Macroscopic and microscopic picture of HuH7 derived tumour.  
The tumour was formed inside and outside the liver.  The microscopic 
picture 5x shows the tumour (blue lesion).  10x shows areas of 
haemorrhage (black arrows) and areas of necrosis (yellow arrows).  40x 
shows HCC cells and areas of necrosis (black arrows). 
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II. HepG2 derived tumour characteristics 
HepG2 cells derived tumours also formed inside and outside the liver.  It was 
characterised by its slower rate in progression compared to HuH7.  The masses 
that developed inside the liver were distinct from the surrounding tissue and the 
cut sections showed areas of necrosis and haemorrhage.  The tumour volume 
of these tumours varied from a mean of 2.0±0.7 cm3 (Table 4).  The extra-
hepatic masses were similar macroscopically and microscopically to the tumour 
cells inside the liver (Fig. 18) and they attached to the muscle of the anterior 
abdominal wall.  The volume of these tumours varied from 0.1 cm3 to 2.4 cm3. 
 
Table 8: HepG2 derived tumour volumes in NOD-SCID mice 
 
HepG2 derived tumour volume (cm3) 
Intra-hepatic masses Extra-hepatic masses  total  masses volume 
0.69  0.675  1.365  
1.4  0.18  1.58  
0.125  0.375  0.5  
1.152  2.4  3.552  
1.575  2.4  3.975  
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Figure 18:  Macroscopic and microscopic picture of HepG2 derived 
tumour.  The mass was formed inside the liver and compressed the 
surrounding liver tissue.  The microscopic picture 5x magnification 
revealed dark blue cells surrounded by normal liver.  10x showed area 
of haemorrhage (yellow arrows) and areas of necrosis (white arrows).  
40x showed malignant cells with prominent nuclei and frequent 
abnormal mitosis (black arrows). 
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III. HuCCT1 derived tumour characteristics 
The main aim of developing this type of tumour was to study 
cholangiocarcinoma, which is a primary liver cancer.   This tumour was different 
from the previous type of HCC cells induced tumour. All the tumour masses 
were formed outside the liver and nothing was found within the liver tissue.  This 
tumour had different phenotype macroscopically to the other models.  This 
tumour was white in colour, rounded and had a smooth outer surface.  The cut 
section did not show any haemorrhage or necrosis (Fig.  19).  HuCCT1 derived 
tumour was attached to the anterior abdominal wall muscle as well.  The 
volume of this tumour varied from 1 cm3 to 1.95 cm3 (Table 9). 
 
Table 9: HuCCT1 derived tumour volumes in NOD-SCID mice 
 
 
 
 
 
 
 
 
 
 
  
 HuCCT1 derived tumour 
volume (cm3) 
1.44 
1.95 
1.10 
1.44 
1.44 
1.00 
1.10 
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Figure 19: Macroscopic and microscopic picture of HuCCT1 cell derived 
tumour.  The tumours found outside the liver, the red box surrounded the 
mass.  5x showed the invasion of the tumour to the abdominal muscle 
wall.10x magnification showed the acinar pattern formation by the cells.  
40x magnification revealed malignant epithelial cells with nuclear 
pleomorphism and prominent nuclei surrounded by stroma consistent 
with cholangiocarcinoma.   
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4.1.5 Discussion  
There are different types of HCC models, chemical-induced, transplantable, 
viral and genetically engineered models.  The last two types are more 
expensive and time consuming to develop.  In this study, the chemical and 
transplantable-induced models were established, as they are relatively easy, 
cheap and quick to develop – approximately 2 to 3 months.  In our chemical-
induced model, DEN and NMOR treatment was used to induce HCC on a 
background of fibrosis and inflammation in Fischer rats.  Yoshino and 
colleagues originally developed the use of DEN and NMOR to induce HCC in 
rats (Yoshino et al., 2005). Following treatment with these drugs the animals 
were weighed twice weekly for 16 weeks as a means of checking their 
development and relative health.  Their weight was found to increase over time 
although the rate of weight gain was less than in the control untreated rats.  
Other than this, the rats appeared normal with no obvious abnormalities.  This 
was taken as an indication that the chemical-induced HCC model was a stable 
and suitable model for our study. 
 
After 10 weeks of DEN and NMOR treatment the rats were scanned by MRI to 
look for any tumours in their livers.  At this time point only a few pinhead size 
lesions could be seen in some of the rat livers.  After 14 weeks of treatment 
multiple masses were detectable in all the treated rat livers.  The size of these 
lesions was measured using the Amira software program.  The average size of 
these masses varied from 5 to 16% of the total liver volume.  The treatment with 
DEN and NMOR was stopped after 14 weeks and the rats were culled two 
weeks later.  The livers were harvested from the DEN and NMOR treated rats 
as well as the control group.  The livers of the treated rats were noticeably paler 
in colour with multiple nodules visible on the outer surface as well as the inner 
surfaces of the cut liver.  There were also areas of haemorrhage within some of 
the nodules suggesting that these were malignant lesions. 
 
When the H&E stained liver sections from the carcinogen treated rats were 
examined under a microscope they revealed foci and nodules with cellular 
atypia, hyperchromatism, increased nucleo-cytoplasmic ratio, prominent 
nucleoli and abnormal mitotic figures suggestive of HCC.  Other changes in the 
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form of large and small cell dysplasia were also observed in the background 
liver of the treated animals.  In addition, the background liver was severely 
inflamed.   
 
Histological examination of the liver sections by reticulin and Sirius red staining 
(of the fibrous bands and collagen) revealed the livers from the treated rats 
were also fibrotic.  According to the Ishak criteria (Ishak et al., 1995) the stage 
of fibrosis varied from stage 3 (fibrous expansion of most portal areas with 
occasional portal to portal bridging) to stage 5 (incomplete cirrhosis).   
 
Immunohistochemical analysis of the liver sections with smooth muscle actin 
(SMA), which stains the blood vessel smooth muscle cells, was used to identify 
newly formed blood vessels within the liver nodules.  SMA staining was 
therefore useful for distinguishing malignant nodules from nodules formed as a 
result of incomplete cirrhosis and which contained dysplastic cells.   
 
Successful establishment of the chemically induced HCC model above provided 
the opportunity to examine the effects of liver inflammation on HCC growth and 
development.  The model was also useful for targeting various molecular 
pathways, which could play an important role in HCC pathogenesis. 
 
One obvious disadvantage of this chemically-induced HCC model is that it may 
not be representative of the way that HCC develops in humans.  For this reason 
a second tumour model using human liver cancer cell xenografts was 
established with the view that these may be more representative of primary liver 
cancer behaviour in humans.  In this case HCC (HuH7 or HepG2) or CC 
(HuCCT1) cells from established cultures were injected into the sub-capsular 
area of the right liver lobe of NOD-SCID mice.  These mice are immuno-
compromised thus reducing the possibility of rejection of the injected cells.  The 
xenografts were initially allowed to establish for 60 days.  However, by this time 
some of the animals injected with the HuH7 died and others developed 
abdominal masses, which were large enough to prevent the mice from walking.  
As a result, the experiment with the HuH7 cells was repeated using a fresh 
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group of NOD-SCID mice but in this case the xenografts were allowed to 
develop for only 35 days in total. 
 
At the end of the 60 day period the animals injected with HepG2 and HuCCT1 
were culled and their livers harvested.  In the case of the HuCCT1 injected 
animals no tumours were detected in the liver but instead tumours were 
observed attached to the anterior abdominal wall.  This unexpected result could 
be due to the fact that these cells derived from bile duct cancer cells, which may 
prefer to grow outside the liver.  Fava and colleagues developed a xenograft 
cholangiocarcinoma mice model outside the liver.  However, they used different 
types of cells such as SV40-transformed normal human cholangiocytes and Mz-
ChA-1cell lines (Fava et al., 2009).   
 
In the case of mice injected with HCC lines, Huh 7 or HepG2, the cancer cells 
formed intra-hepatic tumours and in some cases small nodules were found 
outside the liver attached to the muscle of the anterior abdominal wall.  Their 
exact location was in the midline with some shifting toward the right 
hypochondrium.  The extra-hepatic masses may have arisen as a result of 
leakage from the site of cell injection or as a result of tumour invasion.  The 
mean volume of the HuH7, HepG2 and HuCCT1 derived tumours was found to 
be 2.3 ± 0.5cm3, 2.0 ± 0.7 cm3 and 1.45 ±0.5 cm3 respectively.  H&E analysis of 
tumour sections derived from the HepG2 and HuH7 injected animals revealed 
the tumour histology had the criteria of HCC i.e. polygonal cells, hyperchromatic 
nuclei, prominent nucleoli and abnormal mitotic figures.  In addition, there were 
areas of haemorrhage and necrosis.  Histological analysis of the HuCCT1 
derived tumours had all the hallmarks of cholangiocarcinoma; sheets of 
cuboidal cells within a stromal background, the cuboidal cells showing 
increased nucleo-cytoplasmic ratio and nuclear hyperchromatism with lots of 
abnormal mitotic figures scattered within the tumour.   
 
As well as being more representative of the situation in humans, establishment 
of the tumour xenograft models enabled us to study the effects of inhibiting 
particular cell receptors, which were up regulated in primary human liver 
cancers.  
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One of the disadvantages of the xenograft model was the complicated surgical 
procedure needed to inject the cancer cells into the livers and the high rates of 
animal mortality incurred during or shortly after surgery.  Another disadvantage 
with this model is that the tumour environment in an immunocompromised 
animal is very different from that of a normal animal.  It is well established that 
tumourigenesis is an integrated process whereby the interactions between 
tumour and immune system can have a significant effect on tumour behaviour 
(Igney and Krammer, 2002).   
 
Challenges of establishing xenograft models and lessons learnt: 
One of the biggest hurdles in establishing the xenograft models was trying to 
avoid the high mortality rate associated with the NOD-SCID mice. These 
animals are extremely fragile and many died either during or shortly after the 
surgical interventions. Some expired in response to administration of 
anaesthetic only whilst others arrested a few seconds following intra-hepatic 
injection of cells. In order to reduce the number of deaths occurring during 
surgery the latter was carried out by one individual who was highly skilled with 
operating on mice.  The surgical procedures were conducted in a highly sterile 
environment,: The anaesthetic chamber and surgical table were all thoroughly 
cleaned by spraying with 70% ethanol and wiping with clean tissue prior to any 
surgery; the floor and walls in the area surrounding the surgical table were also 
cleaned with 70 % ethanol and all surgical instruments were cleaned and 
sterilized by autoclaving prior to use. The high mortality rate associated with the 
NOD-SCID mice often meant that the number of viable animals at the end of 
some experiments was smaller than initially planned.  As a precaution any 
experiment involving NOD-SCID mice should begin with a larger number of 
animals than is actually required in order to take such losses into account. 
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4.2 Effect of gut decontamination on HCC pathogenesis 
4.2.1 Introduction  
Several studies have suggested that increased gut permeability in the presence 
of chronic liver disease maintain a state of enhanced and continuous exposure 
of the liver to pathogen associated molecular patterns (PAMPs) (Mencin et al., 
2009).  This may form the basis for the persistent activation of TLR-MyD88-
TRAF6- NF-ĸB system, which in turn leads to chronic liver inflammation and 
development of HCC.  NF-ĸB was linked to inflammation-fibrosis-carcinoma 
sequence (ElSharkawy and Mann, 2007).  Particularly, TLR4 has been a target 
for therapy in chronic liver disease and fibrosis (Soares et al., 2010).  As 
inflammation and fibrosis was found to be a hallmark in the development of 
HCC and gut sterilization inhibited the development of liver fibrosis (Rakoff-
Nahoum et al., 2004 and Seki et al., 2007), I decided to study the effect of gut 
decontamination on chronic inflammation and development of HCC in 
DEN&NMOR rodent model of HCC.  The aims of this study were to reduce 
bacterial translocation using the antibiotic Norfloxacin and monitor the effect on 
HCC development. 
 
4.2.2 Gut decontamination using Norfloxacin in rat model of HCC 
I. Method 
Three groups of 6 rats each were used for this experiment: 
i. The first group of rats were treated with the carcinogens 
DEN&NMOR for 14 weeks in order to induce HCC as previously 
described in chapter 4.1.  
ii. A second group DEN & NMOR treated rats were also given 
Norfloxacin treatment by gavage at a dose of 20mg/kg/day in two divided 
doses for 14 weeks.  
iii. A third group of naïve rats were used as controls. 
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II. Results of Gut Decontamination  
Histopathology of livers from Norfloxacin treated rats 
a) Macroscopic appearance of rat livers 
The animals in each group were terminated at the end of experiment under 
terminal anaesthesia.  The livers of rats treated with DEN&NMOR were pale in 
colour, bigger in size (around 5x4x3 cm), and nodular in character with irregular 
surfaces, and on cut section showed multiple nodules, which were even paler 
than the surrounding tissue.  In the group treated with Norfloxacin in additon to 
DEN&NMOR the livers were much brighter and red in colour with smoother 
outer surfaces, and measured smaller (around 4x3.5x2 cm).  The cut section of 
the liver in both groups showed nodules, which were paler than the surrounding 
tissue.  In the naive group, all animals had normal bright red glossy livers with 
smooth outer surfaces and around 3.5x3x2 cm, cut section showing 
homogenous liver parenchyma devoid of nodules. 
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Figure 20: Macroscopic appearance of livers from DEN & NMOR rat 
models of HCC in the presence or absence of Norfloxacin treatment. The 
liver from the rat without Norfloxacin treatment is pale with an irregular 
outer surface and multiple nodules. The liver from the Norfloxacin-treated 
rat is brighter and less nodular in appearance. 
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b) Microscopic appearance of rat livers 
 Haematoxylin & Eosin staining 
Following Haematoxylin and Eosin staining, two independent pathologists 
examined the slides under light microscopy. 
All animals in the DEN&NMOR group; developed severe inflammation, 
apoptosis, bridging necrosis (moderate to severe) and multiple scattered 
dysplastic nodules with multiple foci of HCC.  The presence of HCC was 
confirmed by the presence in these foci of frequent abnormal mitosis, increase 
in the nucleo-cytoplasmic ratio and irregular nuclear membrane.  The tumour 
grade ranged from well differentiated to poorly differentiated HCC, and in 
addition, all the animals developed severe fibrotic changes, which were 
confirmed with reticulin staining. 
In the Norfloxacin, treated group the liver tissue showed less inflammation and 
only the severity of fibrosis was mild to moderate.  HCC in all the animals were 
well-differentiated except in one rat in this group where there was only evidence 
of a very early grade of HCC, considered high-grade dysplasia. 
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Figure 21: H&E stained liver sections from DEN&NMOR rat models of HCC 
in the presence or absence of Norfloxacin treatment. Yellow arrows point 
to areas of inflammation. Without Norfloxacin treatment, the liver 
inflammation is severe. With Norfloxacin treatment, the liver inflammation 
is minimal. 
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 Evaluation of liver inflammation & fibrosis with Norfloxacin treatment 
using reticulin staining 
In DEN and NMOR group all the rats developed inflammation and liver fibrosis 
ranging from grade 3/6 and 5/6 according to Ishak criteria, while in the 
Norfloxacin treated group there was minimal inflammation in the liver.  The 
degree of fibrosis varied from 0/6 to 2/6, and did not exceed 2, suggesting a 
significant reduction in the development of fibrosis with Norfloxacin treatment (P 
<0.04).   
 
Table 10: Pathological differences in fibrosis and tumour development 
between rats treated with DEN&NMOR±Norfloxacin 
 
 Rat 
No 
DEN&NMOR DEN&NMOR+Norfloxacin 
1 Incomplete cirrhosis, 5/6 fibrosis, 
multifocal poorly differentiated 
HCC 
Fibrosis grade 1/6, well 
differentiated HCC 
2 Fibrosis 4/6 , Foci of HCC Fibrosis 2/6, haemorrhagic HCC 
3 Fibrosis 5/6, 2 foci of HCC 
moderately differentiated 
Fibrosis 1-2/6, with some 
dysplastic Changes suggestive of 
early HCC 
4 Fibrosis 4/6, one focal HCC 
moderately differentiated, and 2 
foci well differentiated 
Fibrosis 0/6, moderately 
differentiated HCC   
5 Fibrosis 3/6 and moderately 
differentiated HCC 
Fibrosis 0/6, well differentiated 
HCC 
6 Fibrosis 4/6, well differentiated 
HCC 
Fibrosis 1/6, well differentiated 
HCC 
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Figure 22: Graph demonstrating degree of liver fibrosis in DEN & NMOR 
rat models of HCC in the presence or absence of Norfloxacin treatment 
and in naive rats. The degree of liver fibrosis is significantly lower in the 
Norfloxacin treated rats compared to that in the livers from the DEN & 
NMOR only treated rats. 
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Figure 23: Reticulin staining in livers from DEN&NMOR rat models of HCC 
in the presence or absence of Norfloxacin treatment. Multiple fibrous 
bands are visible in the liver of the DEN&NMOR only treated rat. The 
degree of fibrosis is minimal in the liver of the Norfloxacin treated rat. 
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4.2.3 Improvement of liver enzymes with Norfloxacin treatment 
Serum transaminases, AST and ALT, were measured in all animals (Cobas 
Integra 400, Roche Diagnostics, Burgess Hill, West Sussex, UK). 
ALT and AST (mean ±SE) levels were significantly lower the group treated with 
Norfloxacin (P <0.05, and P <0.01 respectively) 
 
Table 11: Reduced levels of ALT and AST with Norfloxacin treatment in 
DEN & NMOR rat models of HCC (P < 0.05 for ALT & P < 0.01 for AST). 
 
Test DEN&NMOR 
U/L 
DEN&NMOR+Norfloxacin 
U/L 
Control 
U/L 
ALT 143.4 ±5.1 120.2±4.0 68.4±4.8 
AST 142.3±3.17 118.0±1.3 77.1±9.4 
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4.2.4 Decreased endotoxin levels in response to Norfloxacin treatment 
 In order to prove a possible connection between the protective effect of 
Norfloxacin on liver inflammation through its effect on gut decontamination and 
subsequent reduction in endotoxin (LPS) production, an endotoxin assay was 
carried out.  The plasma levels of endotoxin were measured as (EU/ml).  There 
was a significant reduction in the endotoxin level (P =0.02) with Norfloxacin 
treatment.  No endotoxin was detected in the control group.   
 
  
 
Figure 24:  Graph showing endotoxin levels in the DEN & NMOR rat model 
of HCC in the presence or absence of Norfloxacin treatment. Gut 
decontamination using Norfloxacin treatment resulted in a significant 
reduction of endotoxin levels in the DEN&NMOR rat models. 
 
4.2.5 TLR4 expression decreased in rat livers with Norfloxacin treatment. 
To determine whether gut decontamination has an effect on the expression of 
TLR4, immunohistochemistry using TLR4 antibody was performed on liver 
tissue derived from DEN&NMOR treated rats with and without Norfloxacin 
treatment.  TLR4 was negative in the malignant hepatocytes and was only 
found positive in the background of HCC.  TLR4 expression was strongly 
positive (Score 2) in the cytoplasm of non-malignant hepatocytes which formed 
the background in the non-Norfloxacin treated group. In the Norfloxacin treated 
group, TLR4 expression varied from mild to moderate (Score 1) suggesting 
down-regulation of TLR4 in the liver following Norfloxacin treatment (Fig.  26). 
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Figure 25: Graph demonstrating reduced TLR4 expression with 
Norfloxacin treatment in livers from DEN&NMOR rat models of HCC. The 
TLR4 scores are from non-tumour regions of the liver. 
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Figure 26: Immunohistochemical analysis of TLR4 expression in livers 
from DEN & NMOR rat models of HCC in the presence and absence of 
Norfloxacin treatment. TLR4 is not expressed in malignant hepatocytes 
(white arrow) but highly expressed in the surrounding background tissue 
from the liver of the DEN & NMOR treated rat. Very weak expression of 
TLR4 is seen in the liver of the Norfloxacin treated rat.  
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4.2.6 NF-κB expression decreased in rat livers with Norfloxacin treatment  
Using western blot, an up regulation of NF-κB protein was observed in the liver 
tissue lysate obtained from the DEN&NMOR induced HCC group without 
Norfloxacin treatment, which was significantly reduced in the Norfloxacin treated 
group, (P <0.02).   
 
 
   
 
 
 
Figure 27:  Western blot analysis showing reduced expression of NF-κB 
with Norfloxacin treatment in livers of DEN & NMOR rat models of HCC. (a) 
The expression of NF-κB was up regulated in the liver of DEN & NMOR 
treated rats compared to normal untreated rat liver. However, the levels of 
NF-κB expression were significantly reduced in the livers of Norfloxacin 
treated rats compared to those without Norfloxacin treatment (P <0.02). (b) 
The graph shows the densitometry results from the Western blot 
expressed as the ratio of NF-κB relative to β-actin signal. 
 
 
 
 
 
 
DEN&NMOR CTRL
NF-κB
Β-actin
DEN&NMOR
+Norfolaxacin
a) 
b) 
45 kDa 
65 kDa 
 Results                                             Effect of gut decontamination on HCC 
105 
 
4.2.7 TNF-α expression is not significantly altered in rat livers with 
Norfloxacin treatment 
TNF-α level was measured using ELISA in liver tissue lysate obtained from rats 
treated with DEN&NMOR ± Norfloxacin. The results were divided by the amount 
of protein per sample. In DEN and NMOR animals TNF-α level was 193±149.3 
pg/1μg protein of liver tissue lysate, which showed slight, statistically non- 
significant, reduction with Norfloxacin co-treatment; 111.5±63.8 (P =0.783). 
TNF-α level in the liver of Naïve rat as control was 32.8±7.5. 
 
 
 
Figure 28: Graph showing levels of hepatic TNF-α in livers of DEN & 
NMOR rat models of HCC with and without Norfloxacin treatment. TNF-α 
levels were increased in the livers of DEN & NMOR-treated rats compared 
to the livers from naïve rats. There was no significant reduction in levels 
of TNF-α expression in response to Norfloxacin treatment. 
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4.2.8 Discussion 
The idea that a relationship exists between chronic inflammation and cancer 
was first suggested by Virchow in 1863.  Persistent inflammation in chronic liver 
disease is believed to be the predisposing factor in HCC development (Chen et 
al., 2008).  Persistent inflammation of the liver in these patients is thought to 
arise from an increased exposure of the liver to pathogens associated 
molecular patterns (PAMPs) derived from the gut.  The translocation of these 
pathogens from the gut to the liver is a consequence of the increased gut 
permeability frequently found in patients with chronic liver disease (Bauer et al., 
2002).  Particularly, the levels of circulating bacterial lipopolysaccharides (LPS) 
have been reported to be increased in patients with liver cirrhosis (Lin et al., 
1995, Chan et al., 1997 and Pinzone et al., 2012).  LPS is known to be a 
stimulator of TLR4 (Fitzgerald et al., 2003).  Toll like receptor 4 has been 
reported to play an important role in liver fibrosis (Seki et al., 2007) and 
promotion of HCC (Dapito et al., 2012).   
 
Several studies on patients with cirrhosis and in animal models of cirrhosis have 
shown that decontamination of the gut using antibiotics such as Norfloxacin can 
lead to a decrease in bacterial translocation from the gut to the liver (Gines et 
al., 1990, Llovet et al., 1996 and Rabiller et al., 2002).  Further studies in 
humans also demonstrated a reduction in bacterial translocation in response to 
Norfloxacin treatment (Francés et al., 2008).  In addition to these findings a 
reduction in liver inflammation was also reported with Norfloxacin treatment in 
rodent models of liver fibrosis (Zhang et al., 2010).  However, the effects that 
gut decontamination might have on HCC development had not been reported 
prior to our study.  I therefore set out to examine the effect of gut 
decontamination using antibiotics in rat model of HCC.  The HCC rat model 
used in this study had previously been developed in our laboratory (Chapter 
4.1).  For this particular experiment one group of rats was treated with the 
antibiotic Norfloxacin for 14 weeks in addition to treatment with the carcinogens 
DEN and NMOR.  A second group of rats was treated with DEN and NMOR 
only.  A third group of control rats which was not given either carcinogens or 
antibiotics was also included in the study. 
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The experiment was terminated 16 weeks later as previously described and the 
livers were immediately removed for examination.  There were some obvious 
differences in the macroscopic appearance of the livers in all 3 groups.  The 
livers from the Norfloxacin and carcinogen treated rats were paler and the 
surface of the liver was more irregular than livers from the control untreated 
group of rats.  The livers from the rats treated with DEN and NMOR were even 
paler and more irregular than those from either the control or Norfloxacin with 
carcinogen treated groups.  All rats treated with DEN and NMOR developed 
multiple tumours regardless Norfloxacin treatment.  There were no obvious 
differences in the number and size of tumours between the two groups 
macroscopically.  However, closer inspection of the tumours histologically 
revealed some differences in tumour grade between the two different groups.  
The tumours from the Norfloxacin treated rats were found to be mild to 
moderately differentiated whilst 5/6 livers from the rats treated with DEN and 
NMOR also included tumours with poor differentiation.  A similar study on the 
effect of gut sterilization on HCC development was recently reported by Dapito 
and colleagues.  A number of antibiotics (ampicillin, neomycin, metronidazole 
and vancomycin) were used for gut sterilization in a CCL4-induced mouse 
model of chronic liver injury and HCC (Dapito et al., 2012).  The outcome of this 
study was a reduction in the number and size of tumours, by 90% and 70% 
respectively, in the antibiotic treated group of mice.  Moreover, TLR4 mutant 
mice demonstrated less HCC number and size.  The authors concluded that the 
intestinal microbiota could promote HCC progression in chronically injured liver 
through stimulation of the TLR4 pathway by LPS derived from translocated 
bacteria.   
 
The results from our study on gut decontamination and development of HCC 
were not as dramatic as those of Dapito but the lack of poorly differentiated 
tumours in the Norfloxacin plus carcinogen treated rats in our study and their 
appearance in the group of rats without gut decontamination could lend support 
to the idea that gut bacterial translocation could influence tumour development 
and/or behaviour although the number of animals used in our study is too small 
to confirm this.  The differences in results between our study and that of Dapito 
et al. may in part be explained by the fact that only one type of antibiotic, 
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Norfloxacin, was used in our study whereas a combination of 4 different 
antibiotics which targeted a variety of pathogens other than gram negative 
bacteria were used for gut decontamination in the study by (Dapito et al., 2012) 
No data was given regarding liver fibrosis in their study.   
 
Although the effect of selective gut decontamination on HCC development was 
marginal in our study, the impact on liver fibrosis was more remarkable.  The 
degree of fibrosis in the rat livers was assessed histologically by staining the 
liver sections with reticulin and examining them microscopically.  The degree of 
liver fibrosis as scored by the Ishak criteria was found to be 3/6 - 5/6 for rats 
treated with carcinogens alone and 0/6 - 2/6 for rat livers treated with 
carcinogens plus Norfloxacin.  Selective gut decontamination with Norfloxacin, 
therefore, significantly reduced fibrosis in the livers of rats treated to gut 
decontamination compared to those without gut decontamination (P <0.04). 
 
In addition to reducing liver fibrosis, the treatment of rats with Norfloxacin also 
resulted in an improvement of the level of the liver enzymes ALT (P <0.05) and 
AST (P <0.01).  An improvement of liver function with Norloxacin treatment was 
previously demonstrated in two separate models of liver cirrhosis using CCL4 
and BDL treated rats (Zhang et al., 2010 and Shah et al., 2012).  These findings 
are all compatible with the hypothesis that bacterial translocation from the gut 
into the systemic circulation could play a role in liver inflammation and fibrosis. 
 
In order to confirm that gut decontamination by Norfloxacin treatment was 
successful in our experimental rats the levels of plasma endotoxin in these 
animals were measured using an endotoxin assay.  As expected, the levels of 
plasma endotoxin were significantly reduced in the Norfloxacin treated group of 
animals as compared with the Norfloxacin untreated group (P <0.02).  In the 
naïve control group of rats no endotoxin was detectable.  Since the endotoxin 
plasma levels are a reflection of the levels of circulating LPS the results from 
the assay confirmed that there was reduction with Norfloxacin treatment.  A 
reduction in plasma endotoxin levels and bacterial translocation from the gut in 
response to Norfloxacin treatment have also recently been reported (Zhang et 
al., 2010 and Corradi et al., 2012)  
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It is known that bacterial LPS acts as ligands and stimulators of TLR4 so I 
decided to examine the levels of TLR4 expression in the livers of our 
experimental rats to see if Norfloxacin treatment also had any effect on these.  
The levels of TLR4 expression, as measured by immunohistochemical analysis 
of the rat liver sections using a TLR4-specific antibody, were very low in the 
naïve group of animals but high in the rats treated with DEN and NMOR alone 
(Score 2) in the liver background and not in HCC.  In the group of rats treated 
with Norfloxacin with carcinogens TLR4 expression in liver background was 
higher (Score 1) than normal but significantly lower than in the non-Norfloxacin 
treated group (P <0.01).  This findings are compatible with TLR4 being 
stimulated by bacterial LPS and suggests that selective gut decontamination 
reduces inflammation and fibrosis via the TLR4 pathway.  Although Testro and 
colleagues reported that Norfloxacin increased the expression of TLR4 in 
cirrhosis, their study investigated the expression of TLR4 in mononuclear cells 
and not hepatocytes (Testro et al., 2010).  This suggests that different location 
of TLR4 could have several effects on the pathogenesis of liver disease.  
 
Since NF-κB and TNF-α are known to be stimulated by TLR4 (as well as other 
TLRs) I decided to also look at their expression in the rat livers.  The expression 
of NF-kB was measured by Western blot analysis and demonstrated low levels 
in the liver from the naïve rats but was highly expressed in both groups of 
carcinogen treated rats.  However, in the Norfloxacin treated animals the levels 
of NF-kB were significantly lower than in the untreated animals (P <0.02).  The 
levels of TNF-α were measured by ELISA assays on rat liver tissue lysates that 
were macroscopically free from any visible tumour.  The TNF-α levels were 
found to be low in the naïve rat livers but high in the livers of the all the 
carcinogen treated animals.  The levels of TNF-α expression were lower in the 
Norfloxacin treated rats as compared with the non-Norfloxacin treated rats but 
this difference was not significant ( P =0.7).  A similar study on the effects of gut 
decontamination using Norfloxacin in a cirrhosis model using BDL rats was 
previously carried out by Shah et al.  In this particular case. the effects of gut 
decontamination on the kidneys was studied.  The endotoxin levels were found 
to be reduced in the plasma of the Norfloxacin treated rats as compared with 
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the non-Norfloxacin treated rats.  Levels of TLR4, NF-kB b and TNF-α 
expression were also downregulated in the kidneys of the Norfloxacin treated 
rats compared with non-Norfloxacin treated rats (Shah et al., 2012).   
 
In summary my findings support the hypothesis that bacterial translocation from 
the gut to the systemic circulation may play a role in liver inflammation and 
fibrosis and this action may be brought about through induction of the TLR4 / 
NF-kB pathway.  Selective gut decontamination with Norfloxacin does not 
however, appear to have a dramatic effect on HCC development and / or 
progression despite that fact that Norfloxacin can bring about a reduction in 
TLR4 and NF-kB b expression.  Norfloxacin is a poorly absorbed antibiotic, 
which acts mainly on gram-negative bacteria so the possibility that other types 
of pathogens may still play a role in HCC development via translocation from 
the gut still exists.  The pathways used by these pathogens may circumvent the 
TNF-α pathway.  TNF-α is known to be stimulated by other TLRs and pathways.  
Many studies revealed that LPS and unmethylated CpG, which is derived from 
bacterial translocation, are involved in the pathogenesis of chronic liver disease 
(Takeuchi and Akira, 2010 and Frasinariu et al., 2012).  In addition, several 
lines of investigation in humans indicate that TLR9 is up regulated in chronic 
liver disease and promotes the development of non-alcoholic steatohepatitis 
and hepatic fibrosis (Gäbele et al., 2008, Stadlbauer et al., 2008 and Henao-
Mejia et al., 2012).  Increased bacterial DNA is a feature of cirrhosis due to 
bacterial translocation (Seki and Schnabl, 2012) and the unmethylated CpG 
sequences in bacterial DNA are potent stimulators of TLR9 (Yamamoto and 
Takeda, 2010).  An examination of TLR9 and TLR4 expression in human livers 
will be presented in the next chapter. 
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4.3 TLR Expression in human liver tissue 
As gut decontamination with Norfloxacin was not linked to great effect on HCC 
development, I decided to study the expression of the TLR4, TLR7 and TLR9 in 
HCC and a variety of human liver diseases.  These TLRs were correlated to 
chronic liver diseases in many studies (Gabele et al., 2008, Mencin et al., 2009, 
Starkel et al., 2010, Jing et al., 2012 and Xu et al., 2012).  Expression of TLR4, 
TLR7 and TLR9 in human liver was examined by immunohistochemistry on 
custom made tissue arrays containing a variety of human liver samples and a 
validation set as described in materials and methods. 
 
4.3.1 Results of TLR expression in tissue microarrays 
a) TLR4 expression in liver tissue microarrays 
 Normal Liver: TLR4 expression was negative in normal liver 
hepatocytes but strongly positive (Score 2) in the cytoplasm of all the bile duct 
epithelium in all 9 cases. 
 Hepatitis: TLR4 expression was negative in the hepatocytes but strongly 
positive in the bile duct epithelium and inflammatory cells in all 26 hepatitis 
cases. 
 Cirrhosis: Weak cytoplasmic staining (Score 1) of hepatocytes was 
observed in 3/24 cases of cirrhosis.  The remaining 21 cases were all negative 
for TLR4 expression in the hepatocytes.  However, the bile ducts, inflammatory 
cells and fibroblasts in all 24 cases were strongly positive for TLR4 expression.   
 HCC: TLR4 expression was negative in the hepatocytes but strongly 
positive in the bile ducts, inflammatory cells and fibroblasts in 41 cases of HCC. 
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Figure 29: TLR4 expression in liver tissue arrays (a) TLR4 expression is 
absent in the hepatocytes of normal liver. The hepatitis liver demonstrates 
TLR4 expression in the bile duct epithelium and inflammatory cells. In the 
cirrhotic liver TLR4 expression is absent in the hepatocytes but strongly 
expressed in the bile duct epithelium, inflammatory cells and fibrous 
tissue. In HCC, TLR4 expression is absent in the hepatocytes but visible 
in the inflammatory cells and bile ducts. b) The HCC and cirrhotic tissue 
shown at higher magnifications. 
 
a) TLR7 expression in liver tissue microarrays 
 Normal liver: TLR7 was detected as dark brown staining around 
hepatocyte nuclei in 2/9 normal livers.  However, the expression involved less 
than 1/3 of the hepatocyte in each case (Score 1).  Faint brown cytoplasmic 
staining was detected in 2 cases in less than 1/3 of the hepatocyte in each 
case.   
 Hepatitis: Perinuclear TLR7 was detected in 9/26 cases of hepatitis.  
However, less than 1/3 of the hepatocyte nuclei were stained in 8 cases (Score 
1).  One case showed perinuclear TLR7 in more than 1/3 of the hepatocytes 
(Score 2).  Cytoplasmic TLR7 was observed in 5 cases of hepatitis in less than 
1/3 of the hepatocytes and considered as (0). 
Normal Hepatitis Cirrhosis HCC
a)
b)
Cirrhosis
HCC zoom
zoom
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 Cirrhosis: TLR7 was expressed in 6/24 cases of cirrhosis.  In 3 cases 
less than one third of the hepatocyte nuclei stained positive for TLR7 (Score 1) 
and in 2 cases more than two thirds of the hepatocyte showed cytoplasmic 
TLR7 (Score 1) (Fig. 30).  Perinuclear TLR7 was detected in more than two 
third of the hepatocytes in one case (Score 2). 
 HCC: TLR7 was expressed in 37/41 HCCs.  The expression involved 
over two thirds of the hepatocyte nuclei (Score 2) in 27 cases (Fig. 30) and less 
than one third of the hepatocyte nuclei (Score 1) in 9 cases and one case 
showed cytoplasmic TLR7 in more than two third of the hepatocytes (Score 2).  
4 HCCs were negative for TLR7. 
 
 
 
Figure 30: TLR7 expression in liver tissue arrays. a) TLR7 is absent in 
the normal, hepatitis and cirrhosis tissues. Perinuclear expression of 
TLR7 is seen in the HCC section. b) Graph demonstrating the 
percentage of normal, hepatitis, cirrhosis and HCC cases in the liver 
tissue arrays expressing TLR7 at different levels; 0 = no expression, 1 = 
weak  and 2 = high expression. c) 40 x magnification of the cirrhosis 
and HCC tissue. The dark brown staining of TLR7 is seen more clearly 
in the nuclei of HCC cells. The zooming box shows some cytoplasmic 
staining of TLR7 in the cirrhosis tissue. 
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b) TLR9 expression in liver tissue microarrays 
 Normal liver: TLR9 expression was visible on the cell membranes in 2/9 
cases.  No cytoplasmic staining was detected in 8/9 cases of the normal livers 
and (Score1) TLR9 was found in 1/9 case. 
 Hepatitis: Membranous staining was detected in 12 cases of hepatitis.  
Cytoplasmic TLR9 was absent in 21/26 of hepatitis cases and faintly 
cytoplasmic in more than two third of hepatocytes (Score 1) in the other 5 
cases.   
  Cirrhosis: Membranous staining of TLR9 was observed in the 
hepatocytes of 13/24 of cirrhosis cases.  Cytoplasmic TLR9 was not detected in 
23/24 cases and was visible in 1 case (Score1). 
 HCC: Cytoplasmic staining of TLR9 was observed in 29/41 HCCs and 
absent in 12 cases.  TLR9 score was (Score 1) in 11 cases and high (Score 2) 
in the remaining 18.  No cytoplasmic staining was observed in 12 HCCs.   
Membranous staining of TLR9 was seen in 13/41 HCCs.  The membranous 
staining was associated with weak cytoplasmic staining of TLR9 in 9 cases 
(Score 1) and with high cytoplasmic staining (Score 2) in the remaining 4 cases. 
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Figure 31: TLR9 expression in the liver tissue arrays. (a) TLR9 is absent 
in normal and hepatitis tissue. Weak cytoplasmic expression of TLR9 is 
visible in the cirrhosis section.  In HCC, TLR9 is highly expressed in the 
cytoplasm of malignant hepatocytes. b) Graph demonstrating the 
percentage of normal, hepatitis, cirrhosis and HCC cases in the tissue 
array expressing cytoplasmic TLR9 at different levels; 0 =no expression, 
1 =weak expression or  2 =high expression. c) 40 x magnification of the 
cirrhosis and HCC sections with zooming boxes showing more clearly 
the membranous expression of TLR9 in the cirrhosis sample and its 
expression in the cytoplasm of malignant hepatocytes in the HCC 
section. 
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4.3.2 Results of TLR expression in human liver tissue validation set  
a) TLR4 expression in human liver tissue validation set 
TLR4 expression was absent in malignant hepatocytes but positive in the 
normal bile ducts, inflammatory cells and fibroblasts of the cirrhotic liver.  These 
findings are similar to those observed in the liver tissue arrays. 
 
 
 
Figure 32: TLR4 expression in HCC and cirrhotic background. The top left 
image shows absence of TLR4 expression in the malignant hepatocytes 
but high TLR4 expression in the bile duct epithelium (black arrows). Top 
right is a magnified image of the TLR4 negative hepatocytes. The lower 
left image shows high expression of TLR4 in the inflammatory cells of the 
cirrhotic background, seen more clearly in the magnified image to the 
lower right. 
 
b) TLR7 expression in human liver tissue validation set 
 Normal liver: TLR7 was not detected in the cytoplasm or the nuclei of 
2/2cases. 
 Cirrhosis: TLR7 was found in hepatocytes perinuclear in 1/5th of the cases.  
However the expression was found in less than 1/3 of the hepatocytes (Score 
1).  The other 4 cases were all negative. 
HCC 
Cirrhotic background
Zoom HCC 
Zoom
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 Cirrhotic background: 6/19 cases were positive for TLR7.  5 cases 
exhibited perinuclear TLR7 in less than 1/3 of the hepatocytes (Score 1) and 1 
exhibited cytoplasmic TLR7 in more than 2/3 of the hepatocytes (Score 1).  The 
remaining 13 were all negative for TLR7.   
 HCC: TLR7 was expressed in 16/19 cases.  The expression was found 
perinuclear in less than 1/3 of the malignant hepatocytes (Score 1) in 4 cases 
and perinuclear in more than 2/3 of the malignant hepatocytes (Score 2) in 12 
cases.  The remaining 3 cases were all negative for TLR7.   
 
 
 
Figure 33: TLR7 expression in the validation set confirms the findings in 
the tissue microarrays. Peri-nuclear expression of TLR7 is visible in more 
than two thirds of malignant hepatocytes in the HCC section (top left and 
top right images). TLR7 was weakly expressed in the cirrhotic background 
and cirrhotic tissue (lower left and lower right) 
zoom
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Figure 34: Graph showing distribution of TLR7 expression among normal, 
cirrhosis, cirrhotic background and HCC tissues from the validation set 
expressed as the percentage of cases demonstrating no (0), weak (1), or 
high (2) expression of TLR7. TLR7 was not expressed in normal liver but a 
large proportion of HCCs demonstrated high expression of TLR7. Its 
expression was largely weak or absent in the cirrhotic background and 
cirrhosis cases. 
 
 
c) TLR9 expression in human liver tissue validation set 
 Normal liver: The 2 normal livers were both negative for TLR9 expression. 
 Cirrhosis: 2/5 cases demonstrated weak (Score 1) cytoplasmic TLR9 
expression.  The other 3 were TLR9 negative. 
 Cirrhotic background: 7/19 cases expressed cytoplasmic TLR9.  The 
expression was low (Score 1) in 6 cases and high (Score 2) in 1 case.  The 
remaining 12 cases were TLR9 negative. 
 HCC: 14/19 cases were positive for TLR9.  The expression was weak 
(Score 1) in 8 cases, high (Score 2) in 6 cases.  The remaining 5 cases were all 
negative for TLR9 expression (Fig. 35). 
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Figure 35: TLR9 expression in the validation set of liver samples confirms 
the findings in the tissue microarrays. The top left image shows intense 
brown cytoplasmic staining of TLR9 in more than two thirds of the 
malignant hepatocytes - seen more clearly at higher magnification in the 
top right image. A magnified image of the cirrhotic background within the 
red zooming box can be seen to the lower left and demonstrates less 
intense cytoplasmic staining of TLR9. The image to the lower right 
demonstrates weak cytoplasmic expression of TLR9 in the liver cirrhosis 
section. 
 
 
 
 
HCC 
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Figure 36: Graph showing distribution of TLR9 expression among normal, 
cirrhosis, cirrhotic background and HCC tissue from the validation set 
expressed as the percentage of cases demonstrating no (0), weak (1), or 
high (2) expression of TLR9. TLR9 was not expressed in normal liver but 
high expression was demonstrated in HCCs and cirrhotic background. 
 
4.3.3 Increased TLR7 & TLR9 expression correlates with high Ki-67 
proliferation index.   
Ki-67 index was estimated as percentage of positivity of hepatocytes nuclei 
stained with Ki-67.  By examination all HCC cores in tissue microarray and 
validation set, It was found that cases showed high expression of TLR7 (Score 
2) had high Ki-67 index.  There were a significant correlation between increased 
TLR7 expression and increased the Ki-67 index r= 0.3 and (P <0.05).  By 
investigating the correlation between Ki-67 index and TLR9 staining, I found 
that the highest proliferation index was associated with high expression of TLR9 
in HCC.  There were also close correlation between increased TLR9 expression 
in HCC cases and proliferation index r=0.5 and (P <0.0001).   
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Figure 37: High Ki-67 index was associated with high TLR7 and TLR9 
expression of  a) Cores represented different cases from TMA stained with 
immunohistochemistry technique and Ki-67 antibody showing the 
difference in Ki-67 expression.  There were no Ki-67 expression in normal, 
hepatitis and cirrhosis whereas there was high expression of Ki-67 in HCC 
core.  b) HCC section from the validation set showing the high expression 
of Ki-67 index and zooming box showing the Ki-67 in the nuclei of 
malignant hepatocytes.  c) Graph demonstrates the correlation between 
the high expression of TLR7 and TLR9 with high proliferation index 
estimated with Ki-67.   
Normal hepatitis Cirrhosis HCC
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4.3.4 Summary of TLR & Ki-67 data in human liver tissue arrays & 
validation set 
 TLR4 is not expressed in HCC cells but highly expressed in inflammatory 
cells and fibroblasts. 
 TLR7 is highly expressed perinuclear in HCC cells.  The expression is 
weak in hepatitis and cirrhosis. 
 TLR9 is expressed on the hepatocyte cell membranes in hepatitis and 
cirrhosis.  There is a shift in expression from cell membranes to the cytoplasm 
in malignant hepatocytes where it is expressed at high levels. 
 There is a positive correlation between Ki-67 proliferation index and 
expression of TLR7 and TLR9.  This suggests there may be a link between 
over-expression of these TLRs and proliferation of the tumour cells in HCC.   
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4.3.5 Discussion 
There is much evidence in the literature to suggest that increased expression of 
TLR4 and TLR9 play important roles in development of chronic liver disease 
and fibrosis (Dolganiuc et al., 2006, Seki et al., 2007 Gäbele et al., 2008, 
Stadlbauer et al., 2008, Aoyama et al., 2010 and Henao-Mejia et al., 2012).  
However, prior to the beginning of our research little if anything was known 
about the roles of TLR4, TLR7 and TLR9 in HCC pathogenesis and 
progression.  I therefore set out to determine if any relationship existed between 
these TLRs and the development of HCC in human liver.  For this purpose two 
sets of liver tissue were examined by immunohistochemistry (1) a custom made 
liver tissue microarray containing formalin fixed paraffin embedded (FFPE) liver 
samples from normal, hepatitis, cirrhosis and HCC tissue and (2) a set of liver 
samples, dubbed the validation set, consisting of FFPE tissue samples from 
normal, cirrhosis and HCC on a background of cirrhosis obtained from the 
Pathology department of the Royal Free Hospital, London.   
 
The immunohistochemistry data from the TMA samples and validation set 
revealed a very similar pattern of TLR 4 expression; TLR4 was not expressed in 
the hepatocytes from normal livers, hepatitis or HCC cases.  Only weak staining 
of hepatocytes was observed in a few cases of cirrhosis (3/24 from the TMA).  In 
contrast, however strong expression of TLR4 was visible in the fibroblasts, 
inflammatory cells and bile duct epithelium in the different types of liver tissue 
from both the TMA and validation set.  Our findings are in agreement with those 
of Vespasiani-Gentilucci, et al., 2012 who reported that the parenchymal 
elements responsible for the highest level of TLR4 expression were the hepatic 
progenitor cells and biliary epithelial cells of interlobular bile ducts in HCV related 
liver disease.  Furthermore, they found a significant correlation between TLR4 
positivity and stage of liver disease and grade of inflammation.  It was concluded 
that TLR4 expression by hepatic progenitor cells and biliary epithelial cells 
contributes to the progression of liver damage in the course of chronic HCV-
related infection.   
 
Unlike our findings, however, Wei et al., 2008 demonstrated that TLR4 is 
expressed in the cytoplasm and cell membranes of hepatocytes in normal and 
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chronic hepatitis livers.  A similar finding was reported by Benias who showed 
increased TLR4 and TLR9 expression in hepatocytes of chronic Hepatitis C liver 
(Benias et al., 2012) TLR4 expression has also been reported in focal 
hepatocytes and inflammatory cells of paediatric hepatitis C (Mozer-Lisewska et 
al., 2005).  These findings suggest some role for TLR4 in the pathogenesis of 
chronic hepatitis both in adults and children. 
 
Only one other study has so far been reported on TLR4 expression in HCC.  
(Jing et al., 2012).  However, in contrast to our findings they found that TLR4 
was expressed in the vast majority (86%) of HCCs examined.  Furthermore, 
high expression of TLR4 in the primary HCCs was shown to significantly 
correlate with HCC metastasis and recurrence.  It was therefore suggested that 
TLR4 could potentially be used as a novel prognostic marker and therapeutic 
target for HCC.  The differences in TLR4 data from our study and that of Jing et 
al. may be partly explained by differences in the sample population or 
differences in HCC aetiology.  However, the lack of TLR4 expression in our 
HCCs and its presence in inflammatory cells within or surrounding the HCC 
tissue is a finding that I previously observed in our rat animal models of HCC 
(discussed in Chapter 4.2).  It may be the case in our HCC samples that 
expression of TLR4 is not necessary for HCC pathogenesis, but this doesn’t 
rule out the possibility that TLR4 expression in the surrounding tumour 
environment might still have an immunomodulatory influence on tumour 
behaviour since inflammatory cells are known to produce signals which promote 
vital processes in tumour development, such as angiogenesis, tumour growth 
and invasion (reviewed by Hanahan and Weinberg, 2011 and Oblak and Jerala, 
2011).   
 
TLR7 expression in the normal liver tissues was weakly detectable in only 2/11 
cases (9 cases TMA and 2 cases validation set).  The staining was perinuclear 
but occurred in less than 1/3 of hepatocytes.  In the cirrhotic liver TLR7 was 
weakly expressed in 20% of cases (6/24 from the TMA set and 1/5 from the 
validation set) only one case showed strong expression (from the TMA).  In the 
hepatitis tissues, the TLR7 expression was also weak and involved only 30% of 
cases (8/26 in the TMA).  Only one case of hepatitis tissue exhibited strong 
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expression of TLR7.  As in the case of normal livers the pattern of TLR7 
expression was also perinuclear in the cirrhotic and hepatitis tissues. 
Unlike TLR4, the expression of TLR7 was found to be up regulated in the 
majority (85%) of HCC samples (35/41 HCCs from the TMA and 16/19 HCCs 
from the validation set).  The level of TLR7 expression was strong in 61% of 
HCCs (37/60 HCCs) and weak to moderate in 23% of all positive cases (14/60 
HCCs).  The expression was also confined to the perinuclear region of 
hepatocytes in all of 51 positive cases of HCC.  The same pattern of perinuclear 
staining was previously reported in lung adenocarcinoma and bronchial 
epithelium (Cherfils-Vicini  et al., 2010). 
 
The up regulated expression of TLR7 in HCC suggests that TLR7 may play an 
important role in HCC development and/or progression.  This is supported by 
TLR7 expression studies in other cancers e.g. in oesophageal carcinoma TLR7 
expression was found to be high and a strong correlation was found between 
the levels TLR7 of expression and tumour grade (Sheyhidin et al., 2011).  
Similarly in cervical cancer a strong correlation was reported between levels 
TLR7 expression and tumour differentiation (Hasimu et al., 2011).  In another 
study using cell lines derived from lung cancer increased TLR7 expression was 
shown to promote cell survival and tumour progression (Cherfils-Vicini et al., 
2010).  In addition, TLR7 has also been reported to promote pancreatic cancer 
growth (Ochi et al., 2012).   
 
Although few investigations have been conducted on the expression of TLR7 
protein in human liver, there has been some mRNA expression studies reported 
on ALD and HCV (Starkel et al., 2010 and Tarantino et al., 2013).  However, in 
contrast to the TLR7 immunohistochemistry findings Lin and colleagues 
reported TLR7 mRNA was significantly down regulated in neoplastic 
hepatocytes (Lin et al., 2013).  It is difficult to make direct comparisons between 
these findings and our immunohistochemistry data.  Furthermore, little is known 
about the expression of TLR7 in the liver and other human tissues and these 
will need to be determined more precisely in future before any definitive 
conclusions can be reached. 
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An examination of TLR9 in the normal livers demonstrated expression in only 
18% of cases (2/9 TMA and 0/2 from the validation set).  The expression was 
confined to the membrane of the hepatocytes in both cases.  In the hepatitis 
tissues, expression of TLR9 was seen in a total of 46% of cases (17/26 TMA).  
The staining was membranous in 12/26 cases and low cytoplasmic expression 
(Score 1) was found in 5/26.  In the cirrhotic tissues, TLR9 was expressed in 
55% of cases (14/24 TMA and 2/5 validation set).  The expression was 
membranous in 54% of TMA cases and weak cytoplasmic (Score 1) in 10% of 
all cases (1/24 TMA and 2/5 of validation set cases).  In the HCC tissues TLR9 
expression was more widespread with 71% (29/41 TMA and 14/19) 
demonstrating positivity for TLR9.  The staining was strong in 40% of cases 
(18/41 TMA and 6/19 validation set cases) and weak in the remaining 31%.  
However, the expression was mainly cytoplasmic in the HCCs although some 
membranous co-staining of TLR9 was observed in 13 / 60 (21%) of cases (9 
were associated with weak cytoplasmic staining of TLR9 and 4 cases were 
associated with strong cytoplasmic expression).   
 
During the course of my investigation, another study on TLR9 expression in 
HCC was reported.  Similar to our findings, a high percentage of HCCs (87%) 
was shown to express TLR9 (87%)  (Tanaka et al., 2010).  However, unlike our 
findings the pattern of TLR9 expression was largely membranous.  The up 
regulated expression of TLR9 in our samples and those of Tanaka suggests 
that TLR9 might have a role to play in hepatocarcinogenesis.  This is supported 
by immunohistochemistry studies in other cancers, which have demonstrated 
high levels of TLR9 expression in oesophageal, prostatic and cervical cancer 
(Takala et al., 2011, Kauppila et al., 2011, González-Reyes et al., 2011 and 
Hasimu et al., 2011).  In addition, the up regulation of TLR9 was also found to 
be associated with poor differentiation in oesophageal adenocarcinoma 
(Kauppila et al., 2011) and lymph node metastasis in cervical carcinoma 
(Hasimu et al., 2011).  Furthermore, the addition of a TLR9 agonist to a HCC 
cell line was found to increase survival of the HCC cells when treated with the 
anti-cancer drug Adriamycin (Tanaka et al., 2010). 
In order to determine whether there was any relationship between the 
expression of TLR7 or TLR9 and proliferation of HCC I also looked at the 
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pattern of Ki-67 staining in all HCCs from the TMA and validation set.  I found a 
significant correlation between high proliferation index and high expression of 
TLR7 r=0.3 (P <0.05) and TLR9 r=0.5 (P <0.0001) in both sets of samples.  
These findings further strengthen the idea that TLR7 & and TLR9 are involved 
in HCC proliferation.  Further support is provided by the findings in other 
studies, For instance, Min et al., 2011 reported that high expression of TLR9 in 
human oral squamous cell carcinoma tissue was significantly associated with 
high ki-67 index.  A correlation between increased TLR7 expression and 
increased tumour proliferation has also been described in pancreatic cancer 
(Ochi et al., 2012).   
 
In conclusion, my immunohistochemistry data has demonstrated that 
expression of TLR7 and TLR9 is up regulated in human HCC.  In addition, there 
is a strong association between high expression of these TLRs and high 
proliferation index.  The results suggest TLR7 and TLR9 may have an important 
role to play in HCC pathogenesis.  A role for TLR4 cannot be ruled out at this 
stage.  However, additional studies are needed to more precisely determine the 
pattern of TLR4, TLR7 & TLR9 expression in normal liver as well as diseased 
liver and HCC before I can fully appreciate their role in these different 
conditions. 
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4.4 Expression of TLR7 & TLR9 in HuH7 human HCC cell line 
4.4.1 Introduction 
Over expression of TLR7 and TLR9 in human HCC has been described in the 
previous chapter.  A correlation between the high expression of these TLRs and 
high proliferation index was found suggesting that TLR7 and TLR9 may have a 
role in HCC pathogenesis.  It is well-known that both TLR7 and TLR9 localise to 
endosomal compartments in many cells (Ewald et al., 2008) and contribute to 
signal transduction in the nucleus (Platta and Stenmark, 2011).  The subcellular 
distribution of TLR9 has previously been shown to be linked to its activation 
status (Latz et al., 2004).  For example, in dendritic cells, TLR9 under resting 
conditions is located in the endoplasmic reticulum and upon stimulation, it 
translocates to the lysosomes (Latz et al., 2004).  Chloroquine is known to 
inhibit TLR7 and TLR9 signaling by altering the endosomal pH (Macfarlane and 
Manzel, 1998, Yi et al., 1998 and Kuznik et al., 2011) 
 
4.4.2 Aims 
1. Determine whether TLR7 and TLR9 expressed in HCC cell lines such as 
HuH7 and study their distribution. 
2. Determine whether TLR7 and TLR9 stimulation by using specific 
agonists such as imiquimod (IMQ) and CpG-ODN respectively or TLR7 and 
TLR9 inhibition using specific antagonists (IRS 954) or signalling inhibitor 
(chloroquine) is associated with change of their subcellular localisation.   
3. Determine whether TLR7 and TLR9 stimulation and inhibition influence 
the proliferation of HuH7 cell line.   
4.  Study the effect of TLR7 and TLR9 stimulation or inhibition on protein 
expression of some of the well-known pathways in HCC such as Akt and LC3B.  
These proteins expression were investigated for the following reasons: 
 Akt pathway has been implicated in HCC carcinogenesis and its role 
was linked to cell survival and proliferation in HCC in previous studies and 
(Chen et al., 2011 and Zhou et al., 2011) and chloroquine treatment has a 
potential effect on Akt and phosphorylated Akt (pAkt) (Loehberg, et al., 
2012). 
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  Chloroquine was known previously by its effect on autophagy which 
is a one of the pivotal pathways in tumourigenesis (Ding et al., 2011) and 
particularly HCC (Shimizu et al., 2012).   
 
4.4.3 Results of TLR7 & TLR9 Expression Studies in HuH7 Cells  
a) TLR7 & TLR9 distribution in untreated HuH7 cells 
Immunofluorescence staining with TLR7 or TLR9 antibodies demonstrated that 
TLR7 and TLR9 are both expressed in HCC.  TLR7 was localised mainly in the 
nucleus and for some extent in the cytoplasm of HuH7 cells whereas TLR9 was 
detected in the cytoplasm as shown in (Fig. 38).   
 
 
 
Figure 38: TLR7 and TLR9 expression in HuH7 cells and differences in 
their subcellular distribution. In HuH7 cells fixed with methanol, TLR7 was 
found mainly in the nucleus as shown in the TLR7 (white channel0. The 
merged channel shows the TLR7 in white and the nuclear Hoechst 33342 
stain in blue. TLR9 was highly expressed in the cytoplasm (white channel) 
and the location clearly appeared in merge channel with TLR9 staining 
and Hoechst 33342. 
 
This experiment confirmed the presence of TLR7 and TLR9 in HuH7 cells and 
raised an important question: does the localisation of TLR7 or TLR9 impact 
HCC progression?  
TLR9
TLR7Hoechst
Hoechst
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b) TLR7 subcellular localisation unchanged with IMQ, chloroquine or IRS 
treatment of HuH7 cells 
Having demonstrated that the intra-cellular distribution of TLR9 is altered upon 
stimulation in previous study, I investigated whether the localisation of TLR7 in 
HuH7 cells may also alter in response to treatment with IMQ (TLR7 stimulant), 
chloroquine and IRS (TLR7 inhibitors). However, no detectable changes in 
TLR7 distribution were found with any of the above treatments (Fig. 39).  
 
  
 
Figure 39: TLR7 localisation in HuH7 cells did not change with IMQ, CQ or 
IRS treatment. In methanol fixed HuH7, TLR7 was detected in the nucleus 
of HuH7 cells (white channel). The blue channel is Hoechst 33342.  The 
merge channel showed both TLR7 and Hoechst 33342. There were no 
changes observed in the localisation of TLR7 with IMQ (TLR7 agonist) or 
with chloroquine or IRS (TLR7 and TLR9 inhibitor) treatment (scale 
bar=10μm).  
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c) TLR9 expression shifts towards nucleus with CpG-ODN treatment 
of HuH7 Cells  
Subcellular distribution of TLR9 was affected by CpG-ODN treatment.  In 
untreated HuH7 cells, TLR9 was found homogenously distributed in the 
cytoplasm.  Upon treatment with CpG-ODN (TLR9 stimulant), TLR9 stained 
vesicles shifted from the cytoplasm to accumulate around the nucleus.  This 
phenomenon was not observed with chloroquine or IRS treatment (Fig.  40).  
  
 
 
Figure 40: Shifting of TLR9 stained vesicles from the cytoplasm to 
accumulate around the nucleus with CpG-ODN treatment.  Methanol fixed 
HuH7 cells and immunofluorescent staining with TLR9 antibody and 
Hoechst 33342 showed TLR9 in untreated HuH7 was found homogenously 
distributed in the cytoplasm whereas with CpG treatment there was more 
aggregation of TLR9 stained vesicles around the nucleus in the zooming 
box (yellow arrows).  With chloroquine, treatment or IRS, TLR9 was in the 
cytoplasm and there was no accumulation around the nucleus.  Scale bar 
=10μm).
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4.4.4 TLR9 does not localise to the endoplasmic reticulum in HuH7 cells   
TLR9 has previously been reported to translocate between the endoplasmic 
reticulum (ER) and endolysosomal system in response to stimulation and 
inhibition.  I therefore investigated whether the subcellular localisation of TLR9 
in HuH7 cells is altered upon treatment with CpG-ODN, chloroquine and IRS.  
Co-immunofluorescence staining of HuH7 cells with TLR9 and organelle 
markers in which TLR9 was predicted to co-localise, such as the ER marker 
calnexin and the lysosomal marker lamp-1, was performed.  In HuH7 cells 
either treated with CpG-ODN, chloroquine, IRS or untreated, there was no clear 
evidence supporting that TLR9 co-localised with the endoplasmic reticulum 
(ER) marker calnexin (Fig. 41). 
 
 
 
Figure 41:  Co-localisation between TLR9 and calnexin was not observed 
in untreated or treated HuH7 cells.  In the merge panel TLR9 green colour, 
calnexin (red colour) and (blue colour) Hoechst 33342 there was no co-
localisation observed in untreated HuH7 or with CpG, CQ and IRS 
treatment.  
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4.4.5 Limited co-localisation of TLR9 and lamp-1 in HuH7 cells   
In untreated HuH7 cells, limited co-localisation of TLR9 and the lysosomal 
marker lamp-1 was found.  This limited co-localisation did not change upon 
CpG-ODN, chloroquine or IRS treatment (Fig. 42).   
 
 
 
Figure 42: Limited co-localisation of TLR9 and lysosomal marker (lamp-1) 
found in HuH7 cells.  In methanol fixed HuH7 and double 
immunofluorescence staining with TLR9 and lamp-1 antibodies, limited 
co-localisation was found between TLR9 and lysosomal marker lamp-1 
(appeared yellow in colour in the merge channel).  There were no changes 
detected for the TLR9 and lamp-1 co-localisation associated with CpG, 
chloroquine, or IRS treatment the merge panel showing TLR9 (green 
colour), lamp-1 (red colour) and Hoechst 33342 in nucleus (blue colour). 
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4.4.6 Swelling of lysosomes in response to chloroquine treatment of 
HuH7 cells  
As it was expected from the known effect of chloroquine on lysosome, 
chloroquine treatment was associated with ballooning or swelling of the 
lysosome, which was detected with the lamp-1 staining (Fig.  43).  This effect 
was not observed with CpG-ODN, IRS treatment and control untreated cells.  
  
 
 
Figure 43: Lysosomal swelling associated with chloroquine treatment.  
Methanol fixed HuH7 stained with lamp-1 the late endosomal marker 
showing swelling of the lysosome with chloroquine treatment.  Zoom box 
showing clearly the difference between lysosome labelled with lamp-1 
with chloroquine treatment compared to the control, CpG and IRS 
treatment.
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4.4.7 Results of TLR7 & TLR9 proliferation studies in HuH7 cells 
Cell proliferation was assessed by seeding 10,000 cells per well (96-well plate) 
in triplicate for each condition.  Cell viability was measured by adding 3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulfophenyl)-2H-
tetrazolium MTS reagent (Promega) treatment details and dosages are reported 
in materials and methods section.   
   
a) TLR7 stimulation with IMQ increased proliferation of HuH7 cells 
Treatment of HuH7 cells with IMQ for 48 hours resulted in a significantly higher 
rate of cell proliferation when compared to that of untreated control cells (P 
<0.04) (t-test n=3).   
 
 
 
Figure 44: Increased HuH7 cell proliferation with IMQ treatment.  After 48 
hours incubation of 104 HuH7 cells in triplicate in 96-well plate, cell 
proliferation was measured using MTS proliferation assay.  There was a 
significant increase in absorbance reading in the wells treated with 5µg/ml 
IMQ treatment (TLR7 agonist)  compared to the untreated cells (P <0.04). 
 
b) HuH7 cell proliferation unchanged in response to TLR9 stimulation 
with CpG-ODN 
On the other hand, treatment of HuH7 cells with TLR9 ligand CpG for 48 hours 
did not show significant influence on HuH7 cell proliferation measured with the 
MTS assay.   
Effect of IMQ treatment on HuH7 cell proliferarion 
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Figure 45: Graph demonstrating CpG-ODN treatment does not increase 
proliferation of HuH7 cells.  The cells were incubated with 5 µM CpG (TLR9 
agonist) for 48 hours and their proliferation rate was then measured using 
the MTS assay. There was no significant increase of absorbance in the 
CpG-ODN treated cells compared to untreated HuH7 control cells (CTRL). 
The experiment was conducted in triplicate 
 
c) Reduction of HuH7 Cell proliferation in response to chloroquine or IRS 
treatment  
Chloroquine treatment for 48 hours inhibited the proliferation of HuH7 cells.  
The level of absorbance measured showed significant reduction with 
chloroquine treatment compared to untreated cells (P <0.003) (t test, n=3). 
 
 
 
Figure 46: Graph demonstrating chloroquine treatment inhibited HuH7 cell 
proliferation.  HuH7 cells were treated with 15 µM chloroquine for 48 hours 
and their proliferation rates were then measured by MTS assay. There was 
significant reduction of absorbance readings in the chloroquine treated 
cells compared with untreated control HuH7 cells (P <0.003). The 
experiment was conducted in triplicate. 
   
Effect of chloroquine treatment on HuH7 cell proliferarion 
Effect of CpG treatment on HuH7 cell proliferarion 
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Using MTS assay, it was found that IRS treatment for 48hours inhibited HuH7 
cell proliferation.  The inhibition of HuH7 cells proliferation with IRS treatment 
compared to the control untreated cells was significant (P <0.001) (t test, n=3).   
 
 
 
Figure 47: Graph demonstrating IRS treatment inhibited HuH7 cell 
proliferation.  HuH7 cells were incubated with 20 µg/ml of IRS for 48 hours 
and their proliferation rate was then measured by MTS assay. There was a 
significant reduction of absorbance readings in the IRS treated cells 
compared with untreated control HuH7 cells (P <0.001). The experiment 
was conducted in triplicate. 
  
d) Inhibitory effects of chloroquine & IRS on HuH7 cell proliferation are 
not due to cytotoxicity 
The inhibition of HuH7 cell proliferation associated with chloroquine and IRS 
treatment raised the question whether the effect of chloroquine and IRS 
treatments treatment was inhibitory or due to cell cytotoxicity?  To address this 
question a neutral red (NR) uptake test was performed (details in materials and 
methods section).  The principle of NR test based on the binding of cationic 
supravital dye to anionic sites in the lysosomes of viable cells; the dead and the 
injured cells did not retain the dye.   
 
 Examination of HuH7 cells by light microscopy revealed the following: 
 Treated cells with chloroquine or IRS and also untreated cells picked up and 
retained the red stain (NR) inside all the cells (Fig. 48) the red dye inside all 
HuH7 cells could be proof that all cells alive and the treatment had not a 
cytotoxic effect suggesting that chloroquine and IRS effect could be inhibitory.   
 
Effect of IRS treatment on HuH7 cell proliferarion 
Results                                                Modulation of TLR7 and TLR9 in vitro 
138 
 
 
Figure 48:  Chloroquine and IRS treatment had an inhibitory but not 
cytotoxic effect on HuH7 cell proliferation. Images shown are of HuH7 
cells treated with IMQ, CpG-ODN, chloroquine (CQ), IRS or untreated 
control cells (CTRL) stained with neutral red. Uptake of the red dye can be 
seen in all cells from the different treatments indicating that they are 
viable. However, the density of cells treated with chloroquine or IRS is 
visibly less than that of control, IMQ or CpG treated HuH7 cells. 
 
CpGCRTL IMQ
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4.4.8 pAkt expression increased with IMQ but decreased with 
chloroquine & IRS treatment of HuH7 cells 
After 48 hours of treatment, an increase in phosphorylated Akt (Ser 473) (pAkt) 
protein expression was observed with IMQ treatment but this was clearly 
reduced with chloroquine and IRS treatment compared to control (Fig.  49). 
There was no clear difference found with CpG treatment.  These data suggest 
that inhibiting TLR7 and TLR9 may reduce cell proliferation through its effect of 
Akt pathway. 
 
 
 
Figure 49: Western blot showing increased expression of pAkt protein in 
HuH7 cells after treatment with IMQ for 48 hours and decreased 
expression of pAkt protein in response to chloroquine (CQ) and IRS 
treatment.  
 
4.4.9 Expression of LC3B autophagy marker increased with chloroquine 
treatment of HuH7 cells 
The expression of LC3B protein increased with chloroquine treatment (Fig.  50) 
and this can be explained by the fact that chloroquine is known to inhibit 
autophagic degradation by preventing the fusion of lysosomes with 
autophagosomes, this lead to accumulation of LC3B protein without consuming 
and the net result is inhibition of autophagy despite the high level of LC3B 
expression.  There was no expression of LC3B in control HuH7 cells suggesting 
that there is no role for autophagy in proliferation in these cells.   
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Figure 50: Western blot showing increased expression of LC3B protein 
in HuH7 cells after 48 hours of treatment with chloroquine. There was 
no expression of LC3B in the control untreated cells or in cells treated 
with CpG. The IMQ and IRS treated HuH7 cells expressed very low 
levels of LC3B. 
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4.4.9 Discussion 
Following the immunohistochemistry data which showed up regulation of TLR7 
and TLR9 in the HCC tissue samples in Chapter 4.3, this section was 
concerned with looking at expression of these two markers in the human 
carcinoma cell line HuH7.  I was particularly interested in studying the effect of 
TLR7 and TLR9 agonists and antagonists on HuH7 proliferation and whether 
these treatments change their sub-cellular localisation. 
 
The expression of TLR7 and TLR9 was initially examined using 
immunofluorescence staining with antibodies against each TLR.  TLR7 was 
found to be expressed mainly in the nucleus whereas TLR9 expression was 
mainly cytoplasmic.  There have been no reports of TLR7 studies in human 
hepatocellular carcinoma cell lines.  A study by Tanaka and colleagues 
examined TLR9 expression in HCC cell lines, such as HuH7 and HepG2.  They 
reported that membranous and cytoplasmic TLR9 expression was detected in 
HCC cell lines and may play an important role in tumourigenesis (Tanaka et al., 
2010).   
 
The sub-cellular localisation of TLR9 within cells has been shown alter in 
response to certain stimuli.  Specifically, in dendritic cells TLR9 translocates 
from the ER to the endosomes upon stimulation with its CpG-ODN ligand.  This 
translocation results in the activation and recruitment of the dendritic cells (Latz 
et al., 2004).  As with TLR9, TLR7 is also known to localise within the 
endosomal compartments of many cells (Ewald et al., 2008) and contributes to 
signal transduction in the nucleus (Platta and Stenmark, 2011).  For this reason, 
I decided to examine the effect of certain agonists and antagonists of TLR7 and 
TLR9 in the human HCC cell line HuH7 to see if these had any effect on the 
sub-cellular localisation of these TLRs.  This was done by treating the HuH7 cell 
line with imiquimod (IMQ), TLR7 agonist, CpG (TLR9 agonist) chloroquine 
(Yasuda et al., 2008) and IRS (the latter are each inhibitors of TLR7 and TLR9) 
and comparing the sub-cellular distribution of each TLR in the treated and non-
treated control cell lines by immune-fluorescence staining and laser-scanning 
confocal microscopy. 
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The distribution of TLR7 in the treated cells remained in the vicinity of the 
nucleus despite stimulation with IMQ or inhibition with chloroquine or IRS.  The 
TLR7&TLR9 inhibitors chloroquine and IRS also had no effect on the 
cytoplasmic distribution of TLR9.  However, the sub-cellular localisation of TLR9 
was found to alter in response to CpG-ODN stimulation resulting in TLR9 
staining vesicles accumulating around the Hoechst dyed nuclei.  This change 
from a cytoplasmic to nuclear distribution of TLR9 has never been described in 
humans although it finding has been reported in equine lung (Schneberger et 
al., 2009). 
 
TLR9 was shown in previous studies to be localised in the ER in macrophages 
and dendritic cells (Latz et al., 2004) and in Hela cells prior to TLR9 stimulation 
(Leifer et al., 2004).  For my study the localisation of TLR9 within the cytoplasm 
in response to its stimulation (with CpG-ODN) with inhibition (using IRS and 
chloroquine) in HuH7 cells was examined to see if TLR9 co-localised with the 
endoplasmic reticulum marker calnexin under any of these different conditions.  
This was done by dual immunofluoresence staining using a TLR9 marker in 
addition to the endoplasmic reticulum marker calnexin.  I found no evidence of 
co-localisation between TLR9 and calnexin in HuH7 cells in any of my 
experiments.  The undetctable co-localisation between TLR9 and calnexin in 
the HuH7 cells might be explained by the fact that TLR9 can locate to different 
compartments within different cell types e.g. TLR9 is found translocate from the 
cell membranes to nuclei of equine lung tissue (Schneberger et al., 2009) 
whereas in human dendritic cells and macrophages it is found in the 
endoplasmic reticulum (Latz et al., 2004). 
 
Another possibility may be that TLR9 is already maximally stimulated and 
located outside the endoplasmic reticulum in HuH7 cells.  This is not an 
unreasonable prospect since it has previously been reported that DNA from 
damaged cells can also act as a stimulator of TLR9 (Basith et al., 2012). 
 
In addition to the endoplasmic reticululm, subcellular localisation of TLR9 has 
also previously been reported in the endo-lysosomal system.  For this reason I 
decided to look for any co-localisation of TLR9 with the lysosomal marker lamp-
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1 within HuH7 cells under the different experimental conditions.  I found limited 
co-localisation of TLR9 and lamp-1 markers regardless of stimulation or 
inhibition of TLR9 suggesting that TLR9 may reside in the lysosomes of HuH7 
cells.  The translocation of TLR9 from the ER to lysosomes in response to 
stimulation (de Jong et al., 2010) has previously been reported in human 
dendritic cells and macrophages (Latz et al., 2004).  The co-localisation of TLR9 
and lamp-1 in HuH7 cells is therefore consistent with the idea that TLR9 is 
already stimulated within these cells. 
 
The effect of TLR7 and TLR9 stimulation or inhibition on proliferation of HuH7 
cells was examined by treating these cells with IMQ, CpG-ODN, choroquinie or 
IRS over a time course of 72 hours and measuring cell proliferation at intervals 
of 24, 48 and 72  hours using the MTS assay.  Using the TLR7 agonist IMQ, a 
significant increase in cell proliferation was found at 48 hours of treatment (P 
<0.04) (Fig.  44).  In vivo studies in a mouse model of pancreatic cancer has 
previously shown that stimulation of TLR7 vigorously accelerated tumour 
progression and induced the activation of a variety of oncogenes and loss of 
number tumour suppressor genes (Ochi et al., 2012).  They concluded that 
TLR7 may be a useful target against which to develop a therapeutic treatment 
in pancreatic cancer.  This may also hold true for HCC. 
 
Treatment of HuH7 cells with the CpG-oligodeoxynucleotide (CpG-ODN), a 
TLR9 agonist did not result in a significant increase in cell proliferation at any of 
the measured time points.  This is consistent with the findings of Tanaka et al. 
who also failed to detect any significant increase in proliferation of HCC cells in 
response to CpG-ODN treatment alone (Tanaka et al., 2010).  However, they 
did find it that CpG-ODN treatment was able to reduce the cytotoxic effects of 
the anti-cancer drug Adriamycin on the HCC cells.  This effect was achieved via 
the up regulation of various apoptosis inhibitors such as Survivin, Bcl-xL, XIAP 
and cFLIP (Tanaka et al., 2010).  One possible explanation for the lack of 
increase in proliferation of HuH7 and other HCC lines in response to CpG-ODN 
stimulation of TLR9 by may be that TLR9 is already working at maximum 
capacity within these cells and is therefore unable to respond to any additional 
stimulatory signals.   
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Treatment of Huh 7 cells with the TLR7 and TLR9 inhibitors chloroquine or IRS 
resulted in a significant reduction in cell proliferation after 48 hours of treatment 
(P <0.003 and P <0.001 respectively).  The effect of IRS treatment on cell 
proliferation in cancer has not previously been reported.  However, the inhibitory 
effect of chloroquine treatment on cell proliferation has been demonstrated in 
other cancer cell lines derived from the lung and colon (Fan et al., 2006 and 
Zheng et al., 2009).  These findings along with those from our present study 
strongly support a role for TLR7 and TLR9 in the promotion of HCC 
proliferation. 
 
The process by which chloroquine and IRS bring about a reduction in HCC 
proliferation was examined more closely by conducting a viability assay using 
neutral red on HuH7 cells following 48 hours of treatment with chloroquine, or 
IRS.  The uptake of neutral red was found to be retained in the lysosomes of all 
cells treated with choroquine or IRS and it was no different from that of 
untreated HuH7 cells or those treated with CpG-ODN or IMQ.  In other words 
the inhibitory effect on proliferation of HuH7 cells following treatment with 
chloroquine or IRS was not due to cell death resulting from any cytotoxic effect 
of these drugs.  A previous study on systemic lupus reported that using IRS 954 
had no cytotoxic effect on cells (Guiducci et al., 2010).   
 
In order to decipher more accurately the mechanisms by which IMQ, CpG, 
chloroquine, IRS exert their effects on cell proliferation I decided to look for 
signaling pathways through which they may operate.  Akt has considered as 
one of the most activated proteins in many of human cancers and its activity in 
cancer cells could be explained by its ability to promote cell survival (Bhaskar 
and Hay 2007).   Furthermore, chloroquine has been shown to be an effective 
chemosensitizer when used in combination with PI3K/Akt inhibitors (Loehberg 
et al., 2012).  For this reason I decided that to examine the effects of 
chloroquine, IRS, CpG-ODN and IMQ treatment on the pAkt pathway in HuH7 
cells.  This was carried out by Western blot analysis using a pAkt antibody, 
which is the active form of Akt, on HuH7 cells from the different treatment 
groups.  pAkt expression was markedly reduced in the HuH7 cells in response 
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to treatment with chloroquine or IRS for 48 hours.  This suggests that inhibition 
of Huh 7 proliferation by chloroquine and IRS is brought about via their action 
on the Akt pathway.  In comparison with untreated HuH7 cell the levels of pAkt 
expression in the IMQ-treated cells was found to be increased.  However, no 
obvious difference was detected in the CpG-ODNs treated cells.  Our Western 
blot data would suggest that proliferation of HuH7 cells involves TLR7 and 
TLR9 and that these exert their effects by acting via the Akt pathway.  This 
concept is supported by other studies, Ochi and colleagues found markedly 
increased expression of pAkt in response to stimulation of TLR7 with ssRNA40 
in K-ras transformed mouse pancreatic cells (Ochi et al., 2012).  In a model of 
sepsis–induced cardiac dysfunction, CpG–ODN was found to significantly 
increase the level of pAkt in mouse cardiomyocytes (Gao et al., 2013).  In vitro 
studies by the same group also demonstrated that CpG-ODN promoted the 
association of TLR9 with Ras and that this resulted in phosphorylation of Akt.  In 
another study by Sester and colleagues, CpG DNA-induced survival of murine 
bone marrow-derived macrophages was shown to be completely dependent on 
TLR9.  Furthermore, this survival effect was abrogated by the inhibition of 
PI3K/Akt pathway (Sester et al., 2006). 
 
As well as being an inhibitor of TLR7 and TLR9, it is well established that 
chloroquine can act as an inhibitor of autophagy in cells.  Many cancers rely on 
the processes of autophagy to promote their growth and survival under stressful 
conditions (Pivtoraiko et al., 2009 and Janku et al., 2011).  The inhibitory effects 
of chloroquine on cell proliferation were therefore examined in relation to 
autophagy in the HuH7 cells.  Using western blot analysis the expression of 
LC3B, which is a marker of autophagy, was examined in HuH7 cells under the 
different treatment conditions.  The expression of LC3B was found to be low in 
untreated HuH7 cells and in HuH7 cells treated for with IRS, CpG-ODN or IMQ 
for 48 hours, which would suggest that these cells are not relying on autophagy 
for their proliferation.  However, the expression of LC3B was up regulated in 
HuH7 cells in response to treatment with chloroquine.  This result is not unusual 
since enhanced expression of LC3B and concomitant inhibition of autophagy 
has been reported by others (Boya et al., 2005, and Ramser et al., 2009).  Our 
western blot data would suggest that the reduction in proliferation of HuH7 cells 
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in response to treatment with chloroquine is not associated with inhibition of 
autophagy.  These results support the hypothesis that TLR7 and TLR9 play an 
important role in cell proliferation.  However, these in vitro studies need to be 
confirmed in vivo.   
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4.5 Examination of TLR7&TLR9 in animal models of HCC 
4.5.1 Introduction 
Enhanced expression of TLR7 and TLR9 and their impact on tumour 
progression has been reported in hepatocellular carcinoma (HCC) and 
pancreatic cancer in previous studies (Tanaka et al., 2010 and Ochi et al., 
2012). Inhibition of these receptors therefore can potentially retard the rate of 
growth of these tumours and delay progression. This effect has been observed 
in studies where adjunctive therapy with chloroquine, a non-specific inhibitor of 
TLR7 & 9, resulted in enhanced effect of traditional anticancer drug regime in 
the treatment of HCC (Ding et al., 2011 and Shi et al., 2011).  Along with these 
studies, the effect of chloroquine and IRS (inhibitors for TLR7 and TLR9) on 
HCC cell line, HuH7, had been investigated in the previous chapter.  We found 
that chloroquine or IRS treatment significantly reduced HuH7 cell proliferation 
after 48 hours compared to untreated cells.  These observations led to the 
present set of experiments, which were aimed at studying the effect of 
chloroquine and IRS treatment on tumour growth in vivo.  The effect of using 
TLR7- and TLR9-specific antagonists (IRS) or non-specific inhibitor 
(chloroquine) was studied in two animal models of HCC (xenograft model and 
chemical induced HCC).   
 
4.5.2 Effect of chloroquine and IRS in mouse xenograft model of HCC  
A xenograft model of HCC was used to clarify the effect of chloroquine and IRS 
treatment on tumour volume.  Two HCC cell lines were used (HuH7 and 
HepG2).   
 
a) Method  
The material and method of surgery, injection of the cells and the tumour 
formed had been described in detail in chapter one.  The animals divided into 
four groups. Each group contained 4-7 NOD-SCID mice: 
 Group one (control): Intrahepatic injection of 5x106 cells either HepG2 or 
HuH7 cells in mice with in 100μl of saline.  These mice didn’t receive any 
treatment.  Mice injected intrahepatic with HepG2 n=5 and with HuH7 n=7 
 Group two:  The same as group one but received chloroquine in the form 
of 130 mg of chloroquine dissolved in one litre water and supplied as drinking 
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water.  Mice injected intrahepatic with HepG2 n=5 for 60 days and with HuH7 
n=6 for 35 days.   
 Group three: the same as group one and injected with IRS-954 100μg (in 
100μl) IP once per week.  HepG2 n=4 for 60 days and with HuH7 n=7 for 35 
days. 
 
 Measurement of tumour volume from mouse xenografts 
The tumour masses formed from cell injections were found: 
 Inside the liver (intra-hepatic) and/or  
 Attached to the muscle of the abdominal wall overlying the liver (extra-
hepatic).   
 
As described previously, the volume of each mass was measured separately by 
multiplying it three dimensions and the total volume was calculated by 
summation of the two volumes formed intrahepatic and extra-hepatic.   
Results were presented as mean +/- SD.  To compare between groups, 
unpaired t-test was used to compare one group of treatment to untreated 
control group.     
 
b) Results from the mouse xenograft models 
I. Histopathology of liver tumours derived from HepG2 and HuH7 injected 
mice  
Histological assessment revealed that the masses formed inside and outside 
the liver formed of malignant cells with nuclear atypia, increased nucleo-
cytoplasmic ratio and atypical mitotic figures.  The microscopic features of the 
cells suggested features of malignant hepatocytes.  Inside the tumours there 
were areas of haemorrhage and necrosis. 
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II. Volume of liver tumours from HepG2 injected mice  
HepG2 injected mice developed both intra-hepatic and extra-hepatic tumours.  
The mean total tumour volume at the time of sacrifice was lower in both treated 
groups compared with the untreated group; control: 2.2±1.5; chloroquine: 
0.4±0.3 and IRS: 0.6±0.3 cm3 respectively. 
 
Table 12: Volume of HepG2 derived tumours from mouse xenograft 
models of HCC in response to different treatments. 
 
Tumour volume (Mean±SD) cm3 P value 
 Intrahepatic  Extrahepatic Total 
Control 0.99±0.6 1.2±1.1 2.2±1.5  
Chloroquine 0.2±0.3 0.3±0.35 0.4±0.3 0.03* 
IRS 0.06±0.1 0.6±0.3 0.6±0.3 0.06 
 
There was a significant reduction of total tumour volume (summation of 
intrahepatic and extrahepatic) with chloroquine treatment compared to control 
untreated mice (P <0.03) (Fig. 52). Although there was no significant reduction 
in total tumour volume between IRS treated group and control, the tumours 
formed intrahepatic in the group treated with IRS were the smallest volume 
between all the groups.  It was noticed that even the largest tumour volume in 
the groups treated with either chloroquine or IRS showed marked necrosis 
compared to control. 
 
 
 
Figure 51: Graph demonstrating total volume of HepG2 derived tumours 
(both intra- and extra-hepatic) in the mouse xenograft models of HCC. 
There is a significant reduction of total tumour volume in the chloroquine 
treated mice compared to that of untreated control group (P =0.03). 
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 Figure 52: Tumour volume decreased in response to chloroquine and IRS 
treatment in the HepG2 derived mouse xenograft model of HCC. Black 
arrows point to intra-hepatic and red arrows point to extra-hepatic 
tumours. The intra-hepatic tumour is visibly larger in the liver of the 
untreated control mouse compared to that in chloroquine and IRS treated 
mouse. The H & E stained sections to the right show the histopathological 
features of the tumours. 
 
 
Control
Chloroquine
IRS
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III. Volume of liver tumours from HuH7 injected mice  
HuH7 injected mice developed both intrahepatic and extrahepatic tumours 
(attached to the abdominal wall) in the animals with or without treatment.  The 
mean tumour volume was lower in both the treated groups compared with the 
untreated group; control 2.3±1.3 cm3, chloroquine 0.9±0.97cm3.and IRS: 0.9 ± 
0.7 cm3  
 
Table 13: Volume of HuH7 derived tumours from mouse xenograft 
models of HCC in response to different treatments. 
 
 
 
 
 
 
 
The mice treated with chloroquine developed a borderline significant smaller 
tumour compared to untreated mice (P =0.05).  However, a significant reduction 
of tumour volume was associated with IRS treated treatment (P <0.03) (Fig.  
54). There was extensive necrosis with the treated groups either with 
chloroquine or IRS more than control in tumour with the largest tumour volume. 
 
 
 
Figure 53: Graph demonstrating total volume of HuH7 derived tumours 
(both intra- and extra-hepatic) in mouse xenograft models of HCC. There 
is a significant reduction of total tumour volume in IRS treated mice 
compared to that of untreated controls group (P =0.03). 
 
 
Tumour volume (Mean±SD) cm3 P 
value 
 Intrahepatic  Extrahepatic Total 
Control 0.96±1.2 1.3±1.5 2.3±1.3  
Chloroquine 0.6±0.55 0.4±0.5 0.9±0.97 0.051 
IRS 0.6±0.6 0.3±0.2 0.85±0.7 0.026* 
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Figure 54: Tumour volume decreased in response to chloroquine and IRS 
treatment in the HuH7 derived mouse xenograft model of HCC. Black 
arrows point to intra-hepatic and red arrows point to extra-hepatic 
tumours. The intra-hepatic tumour is visibly larger in the liver of the 
untreated control mouse compared to that in chloroquine and IRS treated 
mice. The H&E stained sections on the right show the histopathological 
features of the tumours. There was necrosis in the tumour mainly the big 
one treated with chloroquine or IRS.  Orange arrow points to the necrotic 
area. 
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4.5.3 Effect of chloroquine in a chemical-induced rat model of HCC 
a) Method 
Materials and steps of developing the model has been described in details in 
chapter one. 
The animals divided into three groups of Fischer rats 
 Group one: DEN and NMOR (carcinogens) treated rats (n=15).   
 Group two:  the same as group one but received chloroquine (Sigma, 
UK) 25mg/kg once a day by gavage for 14 weeks (n=20). 
 Group three: naïve rat without treatment (n=4).    
The development of HCC was assessed with macroscopic features and 
Haematoxylin and Eosin staining on liver rat.  The assessment was performed 
on 8th, 10th and 12th and 16th weeks of treatment on selected rats from group 
one and group two. 
 
b) Results from DEN & NMOR Rat Model of HCC 
I. Histopathological assessment of rat livers 
 Macroscopic & Microscopic appearance of rat livers  
 Livers from rats treated with DEN&NMOR ± chloroquine were collected 
on 8, 10, 12 weeks after administration of DEN. After 16 weeks the rest of 
rats were culled. All rats were terminated under terminal anaesthesia.  Livers 
from all groups were examined grossly and then liver sections were 
investigated under the light microscope.  
 After 8 weeks of treatment with carcinogen (DEN&NMOR): liver section 
obtained from both groups treated with carcinogen with or without 
chloroquine did not show any evidence of HCC. However, liver sections from 
rats treated with carcinogen (n=3) had atypical cells in each liver with the 
following percentage 40%, 20% and 20%. The rats that received chloroquine 
(n=4) showed less atypical cells in 3 rats 5%, 5% and 20%. 
 After 10 weeks of carcinogen treatment: two out of three of rats treated 
with carcinogen alone developed foci of HCC on a background of atypical 
cells. One out of three rats that received chloroquine showed one focus of 
dysplastic cells and not HCC on a background of atypical cells whereas the 
other two had normal liver. 
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 After 12 weeks of carcinogen treatment: all the rats of group one 
developed multiple nodules of HCC, which were seen macroscopically with 
variable sizes. Under the microscope there were multiple foci of HCC with a 
diameter of 2mm on a background of high-grade atypia in 90% of the cells 
and inflammation in the form of inflammatory cells infiltration with areas 
showing bridging necrosis and necroinflammatory foci scattered in the 
intralobular area.  In chloroquine treated group, there was no evidence of 
malignancy.  However, there were atypical cells which varied from 5% to 
10%. 
 At the end of the experiment after 16 weeks, all of the animals in group 
one developed multiple large nodules of HCC which were macroscopically 
visible (Fig. 55).  Under the microscope there were multiple diffuse nodules 
up to 11 foci of HCC.  The background liver was dysplastic and in some 
cases there were evidence of vascular invasion (Fig. 57).  In group two, two 
out of seven animals developed small nodules of HCC (2 nodules each), the 
largest nodule did not exceed 1.4 mm. 5/7 had no evidence of HCC with 
normal hepatocytes and mild inflammation.  
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Figure 55: Livers from DEN&NMOR induced rat models of HCC 
demonstrating inhibition of tumour development in response to 
chloroquine treatment. a) The livers from DEN & NMOR only treated rats 
are pale in colour with nodules visible on the outer surface (white 
arrows) and in the cut section (black arrows). b) The livers from the 
chloroquine treated rats were brighter in colour with a smooth outer 
surface and no nodules visible in the cut section. 
 
 
Figure 56: Graph showing the differences in the percentage of 
tumours developed in the livers of rats treated with 
DEN&NMOR±chloroquine.  The percentage was calculated from the 
total size of HCC foci/ normal liver   under microscopic examination of 
the slides from different time point of treatment (ttt: treatment). 
 
b)
DEN&NMOR
DEN&NMOR +chloroquine
a)
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Table 14: Data showing the difference in tumour development in the 
livers of rats treated with DEN&NMOR±chloroquine, (ttt: treatment) 
 
 DEN&NMOR 
Mean±sd 
 
DEN&NMOR+C
Q 
Mean±sd 
 
P Value 
Percentage of tumour  
(tumour nodules sizes per 
tissue section/ size of 
tissue section *100) 
12 weeks ttt 
23.49±20.21 
 
 
14 weeks ttt:  
61.64±20.44 
  
12 weeks ttt 
0 
 
 
14 weeks ttt: 
4.540±8.1 
 
 
 
 
0.003** 
Perentage of normal 
tissue in background 
tissue.   
12 weeks ttt 
7.50±5  
 
 
14 weeks ttt 
38.00±16.4 
 
  
12 weeks ttt 
80±33.7 
 
 
14 weeks ttt: 
85.71±7.87 
0.008** 
 
 
 
0.003** 
Percentage of Atypical 
tissue in background 
tissue 
12 weeks ttt 
92.50±5  
 
14 weeks ttt 
62.00±16.4 
 
  
12 weeks ttt 
20.00±33.7 
 
14 weeks ttt: 
14.29±7.87 
0.02* 
 
 
0.003** 
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Figure 57: H&E stained liver sections from DEN&NMOR induced rat 
models of HCC at different stages of development. Foci of HCC (black 
arrows) are visible in the liver of the rat treated with DEN & NMOR for 8 
weeks. After 14 weeks of treatment vascular invasion by malignant cells is 
observed (red arrows). The liver from a rat treated with DEN & NMOR plus 
chloroquine appears normal after 8 weeks of treatment. After 14 weeks of 
treatment small foci of HCC (black arrows) are visible in the rat liver 
 
II. Assessment of liver fibrosis  
Reticulin staining was performed on liver sections obtained from rats treated 
with DEN&NMOR±chloroquine.   
 
 Reticulin staining in non-chloroquine treated rat livers 
 On 8th week of treatment: Severe inflammation in the liver, in the form of 
portal tract expansion and bridging necrosis.   
 On 12th week the inflammation progressed to fibrosis and formed 
incomplete septum. 
  After 16 weeks: Severe fibrosis and incomplete cirrhosis (Fig. 58 and 
Fig.  59) 
DEN&NMOR 8weeks DEN&NMOR 14 weeks
DEN&NMOR+CQ  
8weeks
DEN&NMOR+CQ  
14 weeks
10x
10x
20x
20x
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 Reticulin staining chloroquine-treated Rat livers 
 After 8 weeks, liver sections showed histology varying from normal to 
mild inflammation (from 0 to 1).   
  After 12 weeks of treatment, inflammation progressed to moderate 
inflammation up to 2. 
 After 16 weeks the score of fibrosis found was 3/6-4/6. 
   
  
Figure 58:  Reticulin staining showing reduction in fibrosis with 
chloroquine treatment in chemical induced HCC model.   
DEN&NMOR 14 weeks
DEN&NMOR+CQ  
14 weeks
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Table 15: The difference in the degree of liver inflammation and 
fibrosis between groups treated with DEN&NMOR±chloroquine.  
There was a significant reduction of fibrosis with chloroquine 
treatment 
 
 Weeks of 
treatment  
 DEN&NMOR  DEN&NMOR+ chloroquine 
8 The degree of inflammation 
varied portal expansion to 
portal expansion with 
bridging fibrosis from (2/6 -
4/6) 
There was no fibrosis there 
was portal expansion only in 
some cases  and it was mild 
inflammation (0/6-1/6)  
10 From bridging fibrosis portal 
to portal or portal to central 
and incomplete cirrhosis in 
one case (4/6-5/6)  
 The inflammation varied from 
no inflammation up to portal 
expansion with occasional 
bridging (0/6-3/6)  
12 Incomplete cirrhosis marked 
bridging to occasional nodule 
(5/6) 
 From no inflammation to portal 
expansion with occasional 
bridging fibrosis (0/6- 3/6) 
14 Incomplete cirrhosis (5/6)  Inflammation varied from 
portal expansion with 
occasional bridging fibrosis in 
some cases to marked 
bridging fibrosis with features 
or regressive (the bridging 
septa is incomplete) (from3/6-
4/6) 
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 Picro-Sirius Red staining in chloroquine & non-chloroquine rat livers 
Sirius red stain confirms the finding of reticulin stain.  There was reduction of 
liver fibrosis score with chloroquine treatment.  The fibrous tissue stained red in 
colour.  There was bridging fibrosis after 10 weeks of treatment with 
DEN&NMOR, which progressed to incomplete nodule (pre-cirrhosis) after 14 
weeks of treatment. 
 
 
 
Figure 59: Sirius red staining showing levels of fibrosis in the liver of rats 
treated DEN&NMOR alone or with chloroquine. Rats treated with 
DEN&NMOR alone show evidence of liver fibrosis (red stain) after 10 
weeks of treatment which progressed to pre-cirrhotic fibrosis after 14 
weeks of treatment. The liver from the chloroquine treated rat showed no 
evidence of fibrosis after 10 weeks of treatment and the level of fibrosis 
was only moderate after 14 weeks.  
 
 
DEN&NMOR 10 weeks DEN&NMOR 14 weeks
DEN&NMOR+CQ  
10 weeks
DEN&NMOR+CQ  
14 weeks
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Figure 60: Graph showing the difference in liver fibrosis score between 
rats treated with DEN&NMOR±chloroquine.  There was significant 
reduction of fibrosis with chloroquine treatment compared to the 
untreated group. 
 
4.5.4 Improvement of rat liver enzymes in response chloroquine 
treatment  
There was evidence of abnormal liver enzymes and bilirubin between the 
chloroquine treated and untreated groups. There was a significant reduction of 
alanine aminotransferase (ALT) (P <0.002), aspartate aminotransferase (AST) 
(P <0.001) and bilirubin (P <0.002) in group two that was treated with 
chloroquine compared to untreated group. 
 
Table 16: Table showing improvement of liver enzymes and bilirubin with 
chloroquine treatment compared to the untreated group in HCC model.  
Results are presented as Mean±SE.  ALT: alanine transaminase, AST: 
aspartate aminotransferase. 
 
Test Control  
 
DEN&NMOR 
 
DEN&NMOR 
+chloroquine 
 
ALT 95.63±10.51 116±7.38 80±7.31 
AST 98±5.63 109±3.47 90±2.072 
Billirubin 1.2±0.06 1.6±0.089 1.2±0.05 
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4.5.5 TLR7 & TLR9 expression in livers of chloroquine and untreated rats 
a) TLR7 expression in rat livers 
 TLR7 was found only perinucleir in malignant cells and juxtanuclear area.TLR7 
was very high in intensity and distribution (Score 2) in liver sections obtained 
from  chloroquine untreated group. With chloroquine treatment, TLR7 was found 
only in the areas with the small foci of HCC in 3 livers and with few cells (Score 
1) and the rest livers from this group showed no staining of  TLR7.  Normal rat 
liver was negative for TLR7 (Fig. 61). 
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Figure 61: Immunohistochemistry staining of TLR7 in the DEN&NMOR 
HCC model.  Liver section showing positive TLR7 in the nuclei of tumour 
areas induced with DEN and NMOR treatment (Score 2).  With chloroquine 
treatment in addition to DEN&NMOR liver section revealed scattered cells 
stained with TLR7 in the nucleus of the cells less than 1/3 of the 
hepatocytes (Score 1).  Liver section of naïve rat showing negative TLR7 
staining.  
  
DEN&NMOR
DEN&NMOR+CQ
Naive
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b) TLR9 expression in rat livers 
Hepatic localisation of TLR9 was different in each group.  In the normal rat liver, 
TLR9 expression was very faint and located around the central vein only.  With 
HCC development in the untreated group the distribution changed to surround 
the tumour nodules and was found in any zone of the liver including the portal 
area.  The intensity of TLR9 staining varied from (++ - +++) and total Score was 
2.  Then with chloroquine treatment TLR9 was found around the central vein 
and the intensity was  (++) and total Score was 1 (Fig. 62). 
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Figure 62: TLR9 expression in liver from DEN&NMOR induced rat models 
of HCC with or without chloroquine treatment and in normal untreated rat 
liver. TLR9 was highly expressed in the tumour and surrounding tissue of 
the liver from the DEN & NMOR treated rat. In the chloroquine treated rat, 
moderate expression of TLR9 was visible around the central vein only. 
Faint staining around the central vein was also be seen in the normal 
untreated rat liver. 
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4.5.6 Reduced expression of NF-кB in livers of rats treated with 
chloroquine  
The expression of NF-кB, Akt and pAkt proteins were studied using western blot 
technique on liver lysate from DEN&NMOR treated rats, DEN&NMOR 
+chloroquine and Naïve animal.  β-actin or α-tubulin was used as control for the 
loading proteins.    
 
NF-кB protein expression was increased in liver lysate obtained from DEN and 
NMOR treated rats compared to naïve untreated animals.  In liver lysates 
obtained from rats treated with chloroquine in addition to DEN and NMOR, 
NFкB expression was significantly reduced compared to DEN and NMOR only 
treated rats (P <0.05)  
 
 
 
Figure 63: Western blot showing the effect of chloroquine on reduction of 
NF-кB in DEN and NMOR induced HCC compared to the untreated group. 
 
 
 
Figure 64: Densitometry results of the NF-кB Western blot from the DEN & 
NMOR induced rat model of HCC. Results are expressed as the ratio of 
NF-кB relative to β-actin signal. The graph demonstrates a significant 
reduction of NF-кB expression in response to chloroquine treatment in the 
DEN & NMOR rat model. 
Naive
NF-κB
β- actin
NMOR+ CQNMOR
45 kDa 
65 kDa 
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4.5.7 Reduced expression of Akt in livers of rats treated with chloroquine  
Akt expression was increased with the progression of the tumour in HCC model 
as there was less in expression at 8 weeks compaired with of 14 weeks DEN 
and NMOR treatment.  The effect of chloroquine in HCC model showed 
reduction of Akt expression compared with untreated animals at the same time 
points (P <0.001).  pAkt/Akt ratio did not change between DEN and NMOR with 
or without treatment.  Although there was a reduction of pAkt this could be due 
to of a reduction of Akt expression. 
 
 
 
Figure 65: Decreased Akt expression in HCC model with chloroquine (CQ) 
treatment.  Akt increased with tumour progression.  14 weeks treatment 
with DEN and NMOR showed increase in Akt expression compared with 8 
weeks treatment. Chloroquine decreased the expression of Akt compared 
with untreated animals.  There was reduction of pAkt with chloroquine 
treatment compared to DEN and NMOR without chloroquine. 
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Figure 66: Chloroquine treatment reduced Akt and pAkt expression.  
Densitometric analysis of Akt/αtubulin  and pAkt/αtubulin expression in 
HCC model, showing increased in the expression of Akt and  pAkt in liver 
of DEN&NMOR treated rats and this high expression of Akt and pAkt 
significantly decreased with chloroquine treatment (P <0.03) and (P <0.03) 
respectively.  
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4.5.8 Discussion 
The data from the immunohistochemical analysis of the human HCC tissue 
samples and the in vitro results from the HuH7 human HCC cell line 
experiments (Chapter 4.4) suggested that TLR7 and TLR9 may have an 
important role to play in HCC proliferation.  The immunohistochemical data 
demonstrated increased expression of TLR7 and TLR9 in HCC.  In addition, 
there was a good correlation between expression of these markers and the Ki-
67 proliferation index.  The results of the HuH7 cell culture studies 
demonstrated that the inhibition of TLR7 and TLR9 leads to suppression of cell 
proliferation.  In order to confirm these findings in vivo, the effects TLR7 and 
TLR9 inhibition using chloroquine and IRS were investigated in the HCC mouse 
xenografts and chemically induced HCC rat models developed earlier in 
Chapter (4.1). 
 
The mouse xenograft models consisted of two groups of NOD-SCID mice that 
had been injected with either HuH7 or HepG2 human HCC cells in their liver.  
The mice in each group were administered with either chloroquine in their 
drinking water or injected with IRS a day following the implantation of the HuH7 
or HepG2 cells (described in Chapter 4.1).  A control group of untreated HuH7 
or HepG2 injected mice were also included in the study.  At the end of the 
treatment period (35 days for the HuH7 mice and 60 days for the HepG2 mice) 
the animals were culled and their livers examined for tumours.  Tumours were 
visible in the livers of all animals, both treated and untreated.  In some mice, 
extra-hepatic tumours, attached to the abdominal wall were also observed.  
These are believed to have arisen as a result of leakage of tumour cells at the 
site of injection or direct tumour invasion.  However, the mean tumour volume 
measured at the time of sacrifice was found to be lower in the animals 
administered either chloroquine or IRS when compared with the tumours from 
untreated mice.   
 
The reduction in tumour volume was significant in the chloroquine-treated 
HepG2 injected mice (P =0.03) but only reached borderline significance in the 
HuH7 derived tumours (P =0.05).  In the IRS treated mice the reduction in 
tumour volume was significant in the HuH7 derived tumours (P =0.02) but not 
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significant in the HepG2 derived tumours (P =0.06).  However, the number of 
animals in the latter group was very small (only 4 mice) due to the fact that 
some of the mice in this group died during the course of the study.  The results 
from these in vitro experiments are consistent with the TLR7 and TLR9 data 
from the human HCC immunohistochemistry and HuH7 cell culture studies and 
provide additional support to the hypothesis that TLR7 and TLR9 play an 
important role in HCC proliferation.  The inhibitory effect of chloroquine on HCC 
development has previously been demonstrated both in vitro and in vivo by 
Ding et al. and Shi et al.  Specifically, the combined use of chloroquine with 
either oxaloplatin or sorafanib resulted in an enhancement of cell death in 
human HCC cultures and a more pronounced tumour suppression of HCC 
xenografts (Ding et al., 2011, Shi et al., 2011 and Shimizu et al., 2012).   
 
Tumour xenograft models are a useful for examining human cancer behaviour 
in vivo.  However, the need to establish them in immune-compromised animals 
means that any modulatory effect the immune system might have on tumour 
development is not accurately represented.  Chemical-induced cancers in 
animal models provide an alternative means of studying tumour development 
within the environment of a fully functioning immune system.  For this reason, 
the Fischer rat HCC model developed earlier, using DEN and NMOR, was also 
used to examine the effects of chloroquine on HCC development.  DEN & 
NMOR rats were gavaged with chloroquine on a daily basis over a 14 week 
period then sacrificed at different time points (8, 10, 12, and 16 weeks) to 
examine their livers.  A similar group of DEN & NMOR rats, which were not 
administered chloroquine, was also included in the study.  Blood was taken 
from the animals prior to sacrifice to assess liver injury by measurement of the 
AST, ALT and bilirubin levels. 
 
At 8 weeks from the start of the experiment no tumours were detected either 
macroscopically or histologically in any of the rat livers.  In the chloroquine 
treated group 2 out of 4 rat livers were histologically normal but the other 2 
showed signs of atypia involving 5 - 20% of hepatocytes.  Mild inflammation of 
the liver was also seen in 2 cases.  The liver inflammation was more severe and 
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the atypia more widespread involving 20 - 40% of hepatocytes in all 3 cases 
from the untreated group.   
 
At 10 weeks multiple tumours were macroscopically visible in 2 of 3 livers from 
the untreated rats.  Liver inflammation was severe and atypia more extensive 
involving 90-100% of rat hepatocytes in all 3 cases.  However, no tumours were 
detected in any of the rat livers, either macroscopically or microscopically from 
the chloroquine treated group although some atypia and mild to moderate 
inflammation was visible in 3 of 4 cases.  One liver was completely normal on 
examination.   
 
At 12 and 16 weeks multiple tumours were macroscopically visible in all livers 
from the untreated rats and the cellular atypia was even more pronounced 
involving 50-90% of the background liver in all cases.  This was accompanied 
by incomplete cirrhosis (5/6 according to the Ishak criteria) in all livers.   
In the chloroquine treated group no tumours were visible at 12 weeks but atypia 
involving 5-10% of hepatocytes was seen in all 4 cases.  At 16 weeks 2 of the 7 
chloroquine treated rat livers developed tumours (2 nodules each) on a 
background cellular atypia involving 20-30% of hepatocytes. 
The results from the rat HCC model above demonstrates that chloroquine 
treatment has a significant inhibitory effect on the development of inflammation 
or fibrosis (P <0.0001) and HCC (P <0.0001).  The HCC in vivo data from the 
chemically induced rat model are similar to those from our mouse xenograft 
model and demonstrate that the inhibition of TLR7 and TLR9 leads to 
suppression of tumour growth regardless of an effective immune system.  
Furthermore, administration of chloroquine had a significantly beneficial effect 
on liver enzymes and bilirubin levels (all decreased to nearly normal levels) in 
the carcinogen treated rats suggesting that inhibition of TLR7 and TLR9 not 
only suppresses tumour growth (both frequency and size of tumours) but also 
has a protective effect on the liver from damage induced by carcinogens.   
Overall the results from both the mouse xenograft and chemical-induced rat 
models of HCC further reinforce the concept that TLR7 and TLR9 play an 
important role in HCC growth.  Furthermore, the data are a strong indicator that 
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the pathways to liver inflammation, fibrosis and hepatocarcinogenesis are 
closely linked to TLR7 and TLR9.   
I demonstrated in previous section a significant effect of IRS 954 on inhibiting 
cell proliferation of HuH7 cells and this effect was translated into inhibitory effect 
on tumour masses in mice. 
 
The effect of chloroquine on reducing liver fibrosis is demonstrated for the first 
time in this study.  However, a previous study had shown that administration of 
chloroquine to chronic active hepatitis B patients returned AST and ALT values 
to normal levels (Kouroumalis and Koskinas et al., 1986).  Another study in SLE 
patient diagnosed with autoimmune liver disease, chloroquine treatment was 
found to be effective in treatment of inflammatory conditions through its 
inhibitory effect on TLRs expressed on the dendritic cells (Efe et al., 2011) .     
Several lines of investigation indicate that TLR9 is also up regulated in chronic 
liver diseases and promotes the development of non-alcoholic steatohepatitis 
and hepatic fibrosis (Gäbele et al., 2008, Stadlbauer et al., 2009 and Henao-
Mejia et al., 2012).  Increased circulating bacterial DNA is a hallmark of cirrhosis 
and the unmethylated CpG containing DNA serves as a potential ligand of TLR9 
(Seki et al., 2012).  Therefore, the inhibitory effect of chloroquine on fibrosis can 
be due to its inhibitory effect on TLR9.   
 
In order to determine whether the action of chloroquine on the livers of the 
DEN&NMOR rat models of HCC was brought about through inhibition of TLR7 
and TLR9 I also looked at the expression of these molecules by 
immmunohistochemisty.  In normal naïve rats the expression of TLR9 was 
found to be extremely weak and confined to the central veins.  However, in the 
DEN&NMOR treated rats expression of TLR9 was high (Score 2) and not 
confined to any particular region of the liver.  In the rat livers which developed 
HCC, TLR9 was weakly detected within the tumours but its expression was high 
and heterogeneous in the surrounding liver tissue (Score 2).  In the chloroquine 
treated rats, TLR9 staining was found to be weak (Score 1) but slightly higher 
than in the livers of normal naïve rats.  It was also confined to the central veins.  
In the two chloroquine treated rats, which developed HCC, TLR9 was weakly 
present within the tumours but its expression was high in the immediate vicinity 
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of the tumour and in the hepatocytes around the central veins.  Overall, it would 
appear that chloroquine treatment inhibits liver inflammation, fibrosis and 
tumourigenesis by inhibiting the expression of TLR9.  However, its lack of 
expression within the rat tumours would suggest that TLR9 is not necessary for 
tumour growth.  The results appear to contradict the data from the human HCCs 
and cell culture studies (Chapter 4.4) in which TLR9 is more highly expressed.  
One possible explanation for this discrepancy could be that TLR9 plays an 
important role during liver inflammation and initial stages of liver carcinogenesis 
in this rat model but its expression may not be necessary for tumour 
proliferation later on.  Other TLRs or pathways could possibly take on more 
important roles during the later stages of tumour development and progression 
in these animals.   
 
The expression of TLR7 was found to be completely absent in the livers of 
naïve rats.  In the DEN & NMOR treated rats the expression of TLR7 in the 
early weeks was weak and involved less than one third of the hepatocyte nuclei 
(Score 1).  However, TLR7 expression was higher in the tumours, which 
developed in later weeks (more than two thirds of malignant hepatocyte nuclei 
were positive for TLR7) (Score 2), although it remained low in the surrounding 
liver.   
In the chloroquine treated group of rat livers, the expression of TLR7 was also 
absent in the early weeks of the experiment.  As the weeks progressed, the 
expression of TLR7 increased slightly but still involved no more than one third of 
the hepatocyte nuclei (Score 1).  In the livers and tumours, which developed in 
later weeks, the expression of TLR7 remained low (Score 1). 
 
The TLR7 data in the carcinogen-induced rat model of HCC is more consistent 
than the TLR9 data with our findings in human HCC tissues and cell lines and 
provides further evidence that the inhibitory action of chloroquine on liver 
inflammation and tumour development is brought about through its inhibition of 
TLR7.  Recent work that supports our findings comes from a study of pancreatic 
cancer in which TLR7 was shown to be highly expressed in the transformed 
epithelial cells as well as peritumoural inflammatory cells (Ochi et al., 2012).  
TLR7 expression was reported to be absent from the normal pancreas in 
Discussion                                   Effect of TLR7 and TLR9 inhibition in vivo 
174 
 
human and murine systems and furthermore, inhibition of TLR7 was shown to 
protect against development of pancreatic cancer.  The authors concluded that 
TLR7 could be a potential target for treatment of pancreatic cancer in humans 
(Ochi et al., 2012).  However, in contrast to the above, TLR7 activation has also 
been demonstrated to have antitumour properties and TLR7 agonists have 
been used as effective treatments for basal cell carcinoma (Tandon and Brodell, 
2012)  as well as melanoma (Adams et al., 2008).  In order to explain these 
seemingly contradictory roles of TLR7, Ochi et al. proposed that in malignancies 
which are not associated with an inflammatory component TLR7 stimulation 
may elicit antitumour immune responses.  However, malignancies that arise on 
a background of inflammation such as pancreatic cancer associated with 
chronic pancreatitis, TLR7 activation may have a pro-tumourigenic effect.  
Furthermore, TLR7 activation was found to stimulate tumour development in 
colon cancer and lung cancer by promoting inflammation as well as tumour cell 
survival (Grimm et al., 2010 and Cherfils-Vicini et al., 2010).  The latter process 
seems also to apply to TLR7 and HCC.   
 
The links between TLR9 and HCC have been discussed previously in Chapter 
4.3 in light of Tanaka‘s study which reported that CpG-ODN promotes HCC 
proliferation and survival (Tanaka et al., 2010).  In other cancer studies TLR9 
activation was linked to promotion of cancer invasion in the prostate (Ilvesaro et 
al., 2007), breast (Merrell et al., 2006) in lung cancer cells, stimulation of the 
TLR9 pathway using CpG was recently shown to enhance tumour growth 
(Wang et al., 2012).   
 
The mechanism of how TLR7 and TLR9 produce HCC is not completely 
clarified in this thesis.  It is possible that the initial insults leading to liver 
inflammation leads to partial breakdown of the liver tissue which in turn leads to 
the release of ssRNA and unmethylated CpG DNA which act as stimulators of 
TLR7 and TLR9 respectively (Barrat et al., 2005).  This in turn leads to the 
release of other pro-inflammatory cytokines and/or chemokines, which 
exacerbate the liver inflammation and increase the risk of developing of HCC.  
The inhibitory action of chloroquine on TLR7 and TLR9 may therefore help to 
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break this vicious circle by reducing the liver inflammation and thereby reduce 
the chances of developing HCC.   
 
The expression of NF-kB protein in The DEN&NMOR rat model of liver 
inflammation and HCC was examined at the end of the experimental period, i.e. 
16 weeks, in regions of liver tissue which were macroscopically free of tumour.  
Using Western blot analysis the expression of NF-kB in the liver of the DEN & 
NMOR only treated rats was seen to be higher than in the livers of naïve rats.  
However, this up regulated expression of NF-kB was diminished in the livers of 
the chloroquine treated rats.  These findings are another confirmation that the 
reduced liver inflammation in response to chloroquine treatment occurs via a 
decrease in TLR7 and TLR9 stimulation leading to inactivation of the 
downstream NF-kB pathway.  These results are consistent with the known 
action of TLRs in inflammatory pathways, which all culminate in the activation of 
NF-kB protein.  The inhibition of TLR7 and TLR9 stimulation by chloroquine has 
previously been shown to significantly reduce the downstream activation of NF-
kB in a human embryonic kidney cell line (HEK293) and human B cell line cell 
(Ramos) (lee et al., 2003).  Furthermore, chloroquine has been shown to inhibit 
CpG-DNA–driven activation of NF-κB activation by acting as a TLR9 antagonist.  
Specifically, chloroquine inhibited binding of CpG to the TLR9 ectodomain 
(Kuznik et al., 2011).  Our in vivo findings in the rat model of liver inflammation 
and HCC are consistent with the previous in vitro studies in the human cell lines 
and support the idea that NF-kB may act as a central link between hepatic 
injury, fibrosis and HCC as proposed by Luedde and Schwabe (2011). 
 
One of the most frequently observed alterations in human cancer is the 
activation of the protein kinase Akt.  This protein regulates a variety of cellular 
processes involved in cell survival and metabolism.  The inhibition of Akt kinase 
previously has been shown to induce apoptosis and suppress the growth of 
human ovarian cancer cells in vivo and in vitro (Choi et al., 2008).  In addition, 
chloroquine has been shown to reduce cell proliferation in a mouse colon 
carcinoma cell line and this effect was shown to be associated with a decreased 
level of pAkt (Zheng et al., 2009).  Moreover, PI3k/Akt pathway inhibitors in 
combination with chloroquine have been shown to promote γ-irradiation-induced 
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cell death in primary stem-like glioma cells (Firat et al., 2011).  Furthermore, 
CpG-ODN was shown to induce a protection against myocardial 
ischemic/reperfusion injury through activation of PI3K/Akt (Cao et al., 2013).   
 
A link between Akt and TLR9 was demonstrated in the study by Guiducci et al., 
(2008) in which Akt phosphorylation was observed in human plasmacytoid 
predendritic cells following TLR9 stimulation with CpG.  In light of the above 
information an investigation of Akt expression levels in our rat model was clearly 
warranted.  The data from our study demonstrated a significant reduction in the 
levels of total Akt (P =0.03) and pAkt (P =0.03) in the livers of chloroquine 
treated rats when compared with the untreated rats.  It is difficult to determine 
from our results whether the reduction in pAkt is just a reflection of the 
decreased total Akt levels or whether it is due to a direct reduction in Akt protein 
phosphorylation.  Whichever the case, the findings are in keeping with the 
hypothesis that TLR7 and TLR9 up regulation play an important role in HCC by 
induction of Akt phosphorylation.  Furthermore, the inhibition of these pathways 
could provide a novel approach to the treatment of HCC. 
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4.6 TLR expression in cholangiocarcinoma 
4.6.1 Introduction 
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are primary liver 
cancers; CC is a malignant tumour that derives from cholangiocytes of either 
small intrahepatic bile ducts or ductules (intrahepatic cholangiocarcinoma; ICC), 
or of large extrahepatic bile ducts (extrahepatic cholangiocarcinoma; ECC).  
ICC and ECC differ in morphology, pathogenesis, risk factors, treatment and 
prognosis. However, some of the risk factors for ICC and HCC are the similar 
such as cirrhosis, chronic hepatitis B and C, alcohol use, diabetes, and obesity 
are major risk factors for ICC (Charbel and Al-Kawas, 2011).  Moreover, there 
were recorded cases of mixed HCC and CC (Yano et al., 2003 and Chantajitr et 
al., 2006). This phenotypic overlap between HCC and CC is histopathologically 
an intermediate form between HCC and CC.  In addition, there is a novel 
subtype of HCC was identified as cholangiocarcinoma like-HCC, which is 
believed to be derived from biliary lineage cells (Woo et al., 2010). These data 
suggest a common pathogenesis of primary intrahepatic epithelial cancers 
(HCC and ICC) (Palmer and Patel, 2012). I have shown previously that 
inhibition of TLR4 reduced liver fibrosis, which is one of the risk factors for 
developing HCC and ICC; also, I have shown that inhibition of TLR7 and TLR9 
reduced the incidence and growth of HCC in animal models and in vitro. 
Unfortunately, there is not enough data supporting the role of toll-like receptors 
in CC development except in few studies on cholangiocarcinoma. These studies 
demonstrated that the carcinogenic effect of liver fluke Opisthorchis viverrini 
could be through chronic inflammation and stimulation of TLR2 or TLR4 (Pinlaor 
et al., 2005 and Ninlawan et al., 2010). Our aims in this chapter were to 
determine whether a) TLR4, TLR7 and TLR9 are up regulated in human CC. b) 
whether inhibition of the up regulated TLR signaling in CC reduced cell 
proliferation in vitro and tumour growth in vivo. 
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4.6.2 Results from human cholangiocarcinoma tissues 
a) Results from tissue microarrays  
By using immunohistochemistry technique and tissue microarray platform, ten 
cases of CC were compared with bile ducts in normal liver caes as control. 
 
I. Decreased expression of TLR4 in cholangiocarcinoma 
The normal bile duct epithelium was strongly positive (Score 2) for TLR4 in 80% 
and was moderately positive (Score 1) in 20% of cases. In CC, reduced TLR4 
staining was observed compared to normal controls; 60% were negative and 
10%-30% of cases stained for TLR4 (Score 2) (Score 1) respectively. 
 
 
Figure 67: TLR4 expression analysis in normal liver and 
cholangiocarcinoma (CC). a) Normal liver section from the tissue 
microarray showing high expression of TLR4 in the bile duct epithelium 
but no expression in the hepatocytes. b) The area within the zooming box 
of image (a) is seen at higher (40x) magnification and shows more clearly 
the TLR4 expression in the bile ducts. c) CC section from the tissue 
microarray showing no expression of TLR4 in the malignant cells. d)At 
higher (40 x) magnification of the CC section, TLR4 expression is clearly 
visible in the inflammatory cells scattered within the tumour background. 
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Figure 68: Graph showing the expression of TLR4 in normal bile duct and 
CC.  There is up regulation of TLR4 in normal bile duct epithelium and 
down regulation in CC.  
 
II. Increased expression of TLR7 in cholangiocarcinoma 
All the normal bile duct epithelium were negative for TLR7 expression among 
the CC cases; 20% cases showed no staining of TLR7 while 30% cases had 
positive perinuclear staining of TLR7 in less than 1/3 of the tumour nuclei 
(Score 1) and 50% cases showed positive TLR7 in more than 2/3 of the CC 
nuclei (Score 2).  
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Figure 69: TLR7 expression in CC and normal bile duct epithelium: a) 10x 
core of tissue microarray of normal liver, showing negative TLR7 in bile 
duct epithelium, c) 10x of core of tissue microarray of CC, showing 
strongly positive TLR7 in nearly all acini.  d) 40x of CC showing strongly 
positive of TLR7 in nuclear membrane of CC in 90% the malignant cells. 
 
 
 
Figure 70: Distribution of TLR7 expression in normal bile duct and CC 
cases. There is significant up regulation of TLR7 in CC. Only 20% of cases 
were negative TLR7 staining. More than 50% of cases of CC had (Score 2) 
TLR7 and 30% of cases showed (Score 1). Normal bile duct epithelium 
was negative in all cases. 
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III. Increased expression of TLR9 in cholangiocarcinoma 
The normal bile duct epithelium was mainly negative for TLR9 staining only 
one case (10%) stained with TLR9 (Score1), however, CC samples showed 
cytoplasmic TLR9 expression only 20% cases were negative, 30% were 
scored as Score 1 depending on the intensity and distribution of TLR9 
staining. and 50% were scored as Score 2.   
 
 
 
Figure 71: TLR9 expression in CC and normal bile duct epithelium: a) 10x 
core of tissue microarray of normal liver, showing negative TLR9 in bile 
duct epithelium, c) 10x core of tissue microarray of CC, showing strongly 
positive TLR9 in nearly all acini.  d) 40x of CC showing strongly positive of 
TLR9 in the cytoplasm (Score 2) of CC in nearly all the malignant cells. 
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Figure 72:  TLR9 expression in normal bile duct and CC samples. There is 
up regulation of TLR9 in CC. 
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4.6.3 TLR7 & TLR9 expression studies in the human HuCCT1 
cholangiocarcinoma cell line  
The observed overexpression of TLR7 and TLR9 in CC specimens led me to 
investigate their expression also in cholangiocarcinoma (HuCCT1 cell line).  
Similarly to what was found in the tissue sample by immunohistochemistry, 
confocal microscopy analysis in HuCCT1 showed a nuclear TLR7.  On the other 
hand TLR9 was shown to be expressed in the plasma membrane, in the 
cytoplasm and in the nucleus (Fig. 73). 
 
  
 
Figure 73: TLR7 and TLR9 were expressed in HuCCT1 cells.  
Immunofluorecense staining of TLR7 and TLR9 in methanol fixed 
HuCCT1.  TLR7 was mainly expressed in the nucleus of HuCCT1 with 
residual expression in the cytoplasm. Merge of the staining of TLR7 
(white) and nuclear staining Hoechst 33342  (blue).  TLR9 (white) colour 
expressed in the plasma membrane, cytoplasm and nucleus.  Merge 
channel of the TLR9 (white) and nuclear staining Hoechst 33342 (blue) 
(scale bar =10μm). 
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4.6.4 Subcellular localisation of TLR7 unchanged in response to IMQ, 
chloroquine or IRS treatment of HuCCT1 cells 
HuCCT1 cells stained for TLR7 mainly in the nucleus and to some extent in the 
cytoplasm.  No clear change in TLR7 localisation was observed with IMQ 
treatment (TLR7 stimulant), chloroquine or IRS treatment (TLR7 inhibitors) (Fig.  
74). 
 
 
 
Figure 74: TLR7 expressed in HuCCT1 mainly in the nucleus with residual 
expression in the cytoplasm. Immunofluorescence staining of methanol 
fixed HuCCT1 showed that TLR7 distribution and localisation did not 
change with IMQ, chloroquine or IRS treatment TLR7 (white colour) and 
nuclear staining Hoechst 33342 (blue) (scale bar =10μm). 
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4.6.5 TLR9 expression shifts towards the nucleus in HuCCT1 treated with 
CpG or chloroquine  
HuCCT1 cells stained with TLR9 showed diffuse localisation in the cell 
membrane, cytoplasm and the nucleus.  CpG-ODN treatment resulted in TLR9 
crowding around and inside the nucleus.  The perinuclear accumulation was 
observed also with chloroquine treatment.  IRS treatment did not induce any 
change TLR9 localisation compared to control (Fig. 75).   
 
 
 
Figure 75: Immunofluorescence staining of TLR9 in HuCCT1 showing 
the localisation difference upon stimulation and inhibition.  In control 
untreated cells, TLR9 was found in the cell membrane, cytoplasm and 
nucleus.  With CpG stimulation there was more nuclear TLR9. With 
chloroquine, TLR9 was perinuclear while with IRS the staining was the 
same as the control TLR9 (white) and nuclear staining Hoechst 33342 
(blue) (scale bar =10μm). 
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4.6.6 Increased co-localisation of TLR9 with the endoplasmic reticulum 
marker calnexin in response to chloroquine & IRS treatment  
 The subcellular distribution TLR9 was changed with CpG and with chloroquine 
treatment.  Co-staining of HuCCT1 cells with TLR9 and cell organelle markers 
was performed using immunofluorescence staining. Confocal microscopy 
analysis revealed that there were limited co-localisation between TLR9 and 
endoplasmic reticulum marker calnexin in untreated HuCCT1. With CpG-ODN 
treatment, this limited co-localisation was not detected. However with 
chloroquine and IRS treatment this localisation was clearly detected (Fig. 76).   
 
 
 
Figure 76: Co-localisation between TLR9 and calnexin with chloroquine 
and IRS treatment. Co-immunofluoresence staining of endoplasmic 
reticulum marker calnexin and TLR9 in methanol fixed HuCCT1.  There 
was focal co-localisation between TLR9 and calnexin in untreated 
HuCCT1. With CpG treatment no co-localisation was observed. With 
chloroquine and IRS treatment, co-localisation was detected. The merge 
channel showing the calnexin (green color), TLR9 (red color) and Hoechst 
33342 (blue). Zooming box showing the individual green and red granules. 
No yellow staining detected with CpG treatment. With chloroquine and IRS 
treatment there were yellow granules showing the co-localisation between 
TLR9 and calnexin. 
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4.6.7 Swelling of lysosomes in response to chloroquine treatment of 
HuCCT1 cells 
With CpG-ODN and IMQ treatment of HuCCT1 there was no change in the 
morphology of lysosome labeled with lamp-1 compared to the untreated cells.  
Alongwith what was previously demonstrated in HuH7 cells, chloroquine 
treatment was associated with lysosomal swelling detected with lysosomal 
marker lamp-1 (Fig. 77). 
 
 
Figure 77: Immunofluorescence staining of the lysosomal marker lamp-1 
in HuCCT1 cells demonstrates increased lysosomal swelling in response 
to chloroquine treatment. The Hoechst 33342 stained nuclei appear blue 
and the lamp-1 stained lysosomes appear as white granules surrounding 
the nuclei. No change in lysosomes was seen with CpG, IMQ or IRS 
treatment of the HuCCT1 cells (scale bar =10μm). 
 
4.6.8 LC3B expression increased with chloroquine and CpG treatment of 
HuCCT1 cells but disappeared in response to IRS 
The autophagic marker LC3B protein was detected in the cytoplasm of 
untreated cells or HuCCT1 cells treated with CpG-ODN as a scattered punctae 
mainly around the nucleus.  However, LC3B protein was not detected using the 
same settings with IRS treatment. However, with chloroquine treatment there 
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were larger size granule accumulation in the juxtanulear area. This disappeared 
from the cytoplasm (Fig. 78). 
 
 
 
Figure 78: Immunofluorescence analysis of the autophagy marker LC3B in 
HuCCT1 cells. The cell nuclei are stained blue with Hoechst 33342. A 
slight increase in the white LC3B stained granules can be seen in 
response to CpG treatment of HuCCT1 cells.  With chloroquine treatment 
there is an accumulation of LC3B around the cell nuclei and with IRS 
treatment the expression of LC3B disappeared completely (scale bar 
=10μm). 
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4.6.7 TLR7 & TLR9 stimulation and inhibition affect HuCCT1 cell 
proliferation  
Cell proliferation was assessed by seeding 10,000 cells /well (96-well plate) in 
triplicate for each condition.  Cell viability was measured by adding MTS reagent 
(Promega), 24h, 48h and 72h after treatment.  Details for treatment and 
dosages are reported in materials and methods (Chapter 3). 
 
a) IMQ treatment increased proliferation of HuCCT1 cells 
Treatment of HuCCT1 cell with IMQ (TLR7 stimulant) resulted in a significant 
increase in cell proliferation compared to untreated controls after 48h (P <0.03).   
 
 
Figure 79: Increased proliferation of HuCCT1 cells in response to 
treatment with IMQ.  HuCCT1 cells were treated with 5μg/ml of IMQ for 48 
hours and their proliferation rate was then measured using the MTS 
assay. A significantly higher rate of cell proliferation was observed in the 
IMQ treated cells when compared with that of untreated HuCCT1 cells (P 
<0.03) 
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b) CpG-ODN treatment increased proliferation of HuCCT1 cells 
After 48 hour stimulation of TLR9 using CpG-ODN treatment resulted in 
significant increase in HuCCT1 cell proliferation when compared to untreated 
controls (P <0.002). 
 
 
Figure 80: Increased proliferation of HuCCT1 cells in response to 
treatment with CpG-ODN. HuCCT1 cells were treated with 5μM of CpG-
ODN for 48 hours and their proliferation rate was then measured using the 
MTS assay. A significantly higher rate of cell proliferation was observed in 
the CpG-ODN treated cells when compared with that of untreated HuCCT1 
cells (P < 0.002). 
 
c) Proliferation of HuCCT1 cells increased in response to treatment 
with chloroquine but not IRS  
Chloroquine treatment of HuCCT1 cells for 48 hours had no effect   on HuCCT1 
cell proliferation.  However, 72 hours of chloroquine treatment resulted in 
significant inhibition of HuCCT1 cell proliferation P<0.02 (t test, n=2). 
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Figure 81: Inhibition of HuCCT1 cell proliferation in response to 
chloroquine treatment.  Cells were treated with 15μM chloroquine for 72 
hours and their proliferation rate was then measured using the MTS 
assay.  A significant reduction of cell proliferation rate was observed in 
the chloroquine treated cells compared with that of untreated HuCCT1 
cells (P <0.02). 
 
IRS (TLR7 and TLR9 antagonist) treatment for 48 or 72 hours did not inhibit 
HuCCT1 cell proliferation (n=2) 
 
 
Figure 82: IRS treatment does not inhibit HuCCT1 cell proliferation.  Cells 
were treated with 20μg/ml of IRS for 72 hours and their proliferation rates 
were then measured using the MTS assay.  No difference in cell 
proliferation rate was observed between IRS treated and untreated 
HuCCT1 cells. 
 
4.6.8 Effect of TLR7&TLR9 inhibition in a xenograft model of 
cholangiocarcinoma 
 A xenograft model of cholangiocarcinoma was established with injection of 
5x106 HuCCT1 cells into NOD-SCID mice livers details about the procedure and 
the tumour formation were reported in Chapter 4.1.  The mice were divided into 
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groups and administered with either chloroquine in their drinking water 
(130mg/L) or injected with IRS-954 100μg (in 100μl) IP once per week a day 
following the implantation (control (untreated) n=7, chloroquine treated group 
n=4 and IRS treated group n=5).   
 
Sixty days later after the intra-hepatic sub-capsular injection of HuCCT1 cells, 
tumour masses were formed.  The masses were firm in consistency white in 
colour.  The tumours were found outside the liver, and attached to the muscle of 
the abdominal wall.  Tumour volume was calculated by measuring the three 
dimensions and they were multiplied.  There were reduction in the tumour 
volume found in mice treated chloroquine and IRS.  The mean tumour volume 
formed in control was (1.4±0.01) cm3 whereas with chloroquine and IRS 
treatment this was reduced significantly to (0.5±0.03) and (0.6±0.1) cm3 (P 
<0.01) and (P <0.003) respectively. 
 
 
Figure 83: Chloroquine and IRS treatment reduced tumour growth in a 
xenograft model of cholangiocarcinoma.  Tumours were measured 60 days 
after intra-hepatic injection of HuCCT1 cells into NOD-SCID mice. The liver 
tumour volume from the chloroquine and IRS treated mice was significantly 
smaller than from the non-treated control mice. 
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4.6.8 Discussion  
I have previously shown in chapters 4.3, 4.4 and 4.5 that expression of TLR7 
and TLR9 is up regulated in HCC and that inhibition of this expression can 
reduce cancer cell proliferation and growth. However, TLR4 expression was 
shown to be high in normal bile duct epithelium and inflammatory cells 
surrounding HCC but not in the malignant hepatocytes. These findings 
encouraged us to test whether a similar effect occurred with CC. The same 
experimental approach used in these studies have been now been applied 
examine expression of these TLRs in a small panel of cholangiocarcinoma 
tissue and cholangiocarcinoma cell line. The tissue microarray data revealed 
high expression of TLR4 (Score 2) in liver bile duct epithelium in the majority 
(80%) of normal liver tissue samples whilst its expression was (Score 1) in the 
bile ducts of the remaining cases. In contrast, TLR4 was absent from the 
majority (60%) of CC cases and only mildly or moderately expressed in the 
remainder (40%). Our results would suggest that the loss of TLR4 expression in 
cholangiocytes may promote tumour progression but our sample size is too 
small to reach any precise conclusion.  
 
Only two studies of TLR4 in human cholangiocytes have been reported in the 
literature. Using RT-PCR and immunohistochemistry demonstrated TLR4 
mRNA expression in 2 human intrahepatic cholangiocarcinoma (CC) cell lines, 
CCKSl and HuCCT1 lines and a murine biliary epithelial cell line. They 
speculated that TLR4 in biliary epithelial cells may play a role in the 
immunopathology of the intrahepatic biliary tree in vivo (Harada et al., 2003). 
Another study showed that increased TLR4 mRNA expression and activation of 
NF-kB could be induced in the immortalised human cholangiocyte cell line (H69 
cell line) in response to stimulation by excretory/secretory products of the liver 
fluke O. viverrini.  They proposed that TLR4 recognition of O. viverrini products 
could contribute to the severe inflammation associated with 
cholangiocarcinogenesis (Ninlawan et al., 2010). 
 
The expression of TLR7 was found to be negative in the normal bile ducts of all 
normal livers examined by immunohistochemistry. TLR9 expression was also 
absent in the majority of cases; only one of 10 normal livers in the tissue array 
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demonstrated weak expression of TLR9 in the bile duct epithelial cells.  In 
contrast, however, TLR7 or TLR9 were expressed in the majority (80%) of CC 
and moreover the expression of TLR7 or TLR9 was high in 50% of cases. The 
pattern of expression was predominantly perinuclear for TLR7 and confined to 
the cytoplasm in the case of TLR9, as was previously found in the HCC tissues 
(Chapter 4.3). A similar pattern of TLR7 and TLR9 expression was 
demonstrated in the HuCCT1 cholangiocarcinoma cell line i.e. peri-nuclear 
expression of TLR7 and cytoplasmic expression of TLR9. In addition expression 
of TLR9 was also seen in the membranes of HuCCT1 cells. Altogether these 
findings would suggest that TLR7 and TLR9 might play important roles in the 
progression of CC as was observed with HCC.  
 
The intracellular distribution of TLR7 in the HuCCT1 line was not found to alter 
in response to treatment with IMQ (TLR7 agonist), chloroquine or IRS (both 
antagonists of TLR7 and TLR9). However, a shift in TLR9 distribution from the 
cytoplasm towards the nucleus was observed in response to chloroquine and 
CpG-ODN (TLR9 agonist) treatment. This same observation was previously 
made in the HuH7 hepatocellular carcinoma cell line in response to CpG-ODN. 
The findings would suggest that relationship between TLR9 activity and 
subcellular location is not a simple one. 
In order to throw more light on the subcellular distribution localisation of TLR9, 
co-localisation experiments using markers of endoplasmic reticulum, lysosomes 
and TLR9 were conducted on the HuCCT1 cell line using immunofluorescence 
staining. Analysis of these markers by confocal microscopy revealed a limited 
co-localisation between TLR9 and the endoplasmic reticulum marker calnexin in 
the untreated cell line suggesting that some of the TLR9 is located within the 
ER. The co-localisation of TLR9 with calnexin was more obvious in the 
presence of the TLR9 inhibitors chloroquine or IRS but completely undetected 
in the presence of the TLR9 agonist CpG. These findings would suggest that 
the inactive form of TLR9 is located within the ER and its active form is outside 
of the ER.  These findings are similar to those previously observed in dendritic 
cells and macrophages where TLR9 was reportedly located in the endoplasmic 
reticulum under resting condition and translocated to endolysosomal system 
upon stimulation (Latz et al., 2004 and Leifer et al., 2004). 
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The effects of stimulating or inhibiting TLR7 and TLR9 expression in the 
HuCCT1 cells were examined in order to assess any role these TLRs might 
play in cholangiocarcinogenesis. A significant increase in HuCCT1 proliferation 
was found after 48 hours of treatment with either IMQ (P <0.03) or CpG-ODN (P 
<0.002); TLR7 and TLR9 agonists respectively.  Treatment of the cell line with 
chloroquine for 72 hours resulted in a highly significant reduction in cell 
proliferation. However, no change in the level of cell proliferation was detected 
with IRS treatment after 72 hours treatment. This pattern of expression is similar 
to what was previously seen in the HCC cell line HuH7 and would suggest that 
expression of TLR7 and TLR9 play an important role in the proliferation of CC 
as well as HCC. Autophagic pathway is important in tumourigenesis and LC3B 
protein was highly expressed in CC cell line (Huang and Hezel, 2012). 
Therefore, I studied LC3B expression using immunofluorescence staining; I 
found that in chloroquine treated HuCCT1 cells, LC3B protein was accumulated 
in one pole of the nuclei, whereas with IRS treatment there was no LC3B 
detection. Increased LC3B expression with chloroquine treatment was 
previously reported and it was associated with lysosomal swelling. This was 
confirmed (Yoon et al., 2010).  Increased TLR7 and TLR9 expression in CC and 
undetectable LC3B in IRS (TLR7 and TLR9 inhibitor) treated HuCCT1 or arrest 
of autophagy with chloroquine treatment suggests that TLR7 and TLR9 might 
have role in CC carcinogensis through autophagy. Previous study reported that 
TLR9 is required for autophagy and CpG stimulation induced autophagy in 
cancer (Bertin and Pierrefite-Carle 2008).  The effect of chloroquine on 
inhibition of lung and colon cancer was mentioned (Fan et al., 2006 and Zheng 
et al., 2009).  Another recent study suggested that pancreatic carcinogenesis is 
regulated by TLR7 and its inhibition is protective against tumour progression 
(Ochi et al., 2012).  
 
In order to determine whether the inhibition of TLR7 and TLR9 had the same 
effects on CC proliferation in vivo as well as in vitro, the mouse CC xenograft 
model developed in Chapter 1 was treated for 60 days with either IRS or 
chloroquine.  A significant reduction in tumour volume was found with both 
chloroquine (P <0.01) and IRS (P <0.05) thus giving additional support to the 
idea that TLR7 and TLR9 signaling plays a role in the development of CC. 
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Our data suggest that TLR7 and TLR9 might have a pivotal role in cellular 
proliferation in HuCCT1 cells. Furthermore, chloroquine or IRS treatment 
reduced CC tumour volume in our xenograft model.  These findings merit 
further studies to explore the possibility of exploiting it as a potential target for 
future therapy in CC patients 
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5. General discussion 
HCC is one of the commonest cancers worldwide and one which has a very low 
five year survival rate.  Understanding the mechanisms by which this cancer 
arises are vital if more effective treatment strategies are to be developed.   
The major risk factor for HCC is chronic liver damage caused by viral infection, 
excessive alcohol intake, aflatoxicosis, diabetes or metabolic syndrome.  These 
conditions often result in liver inflammation and cirrhosis, which can persist for 
many years prior to development of HCC or CC.  Chronic liver inflammation is 
therefore considered to be the main predisposing factor for initiation of 
hepatocarcinogenesis.   
 
Disturbances in the gut micro flora are common feature in patients with chronic 
liver disease.  The overgrowth of gut bacteria and increased translocation of 
bacteria from the intestinal lumen to the systemic circulation is believed to 
exacerbate the inflammatory state in patients with chronic liver disease 
(Weistand Garcia 2005 and Almeida et al., 2006).  This has been demonstrated 
in animal models of chronic liver injury in which bacterial translocation has been 
shown to promote liver fibrosis (Seki et al., 2007).  In addition, bacterial 
translocation has been shown to increase with progression of liver fibrosis and 
cirrhosis (Fukui et al., 1991, Lin et al., 1995).  The mechanism of bacterial 
translocation is not entirely clear and probably multifactorial including gut barrier 
dysfunction, bacterial overgrowth and loss of systemic and local immune 
surveillance.   
 
TLRs are known to play a crucial role in the induction of innate immunity against 
microbial pathogens. TLR4, in particular, is activated by the LPS contained 
within the walls of gram negative bacteria which are often elevated in the blood 
of patients with chronic liver disease.  Much evidence has accumulated in 
recent years of an important role for TLR4 signaling in the pathogenesis of 
chronic liver disease.  Mice with mutations in TLR4, for example, are found to 
develop less inflammation and fibrosis in their livers compared to wild type mice 
(Seki et al., 2007 and Aoyama et al., 2010). 
 
General discussion   
199 
 
A number of studies on the effects of gut bacterial translocation and TLR4 
signaling on liver inflammation and cirrhosis have been reported in the literature 
but their effects on pathogenesis of liver cancer have not previously been 
examined.  I therefore set out to study the effects of gut decontamination on 
TLR4 signaling and hepatocarcinogenesis in vivo using a rat model of HCC on 
a background of liver inflammation.  The model was developed by administering 
rats with the carcinogens DEN&NMOR and then examining the effects of 
selective gut decontamination using Norfloxacin on liver inflammation, fibrosis 
and tumourigenesis.  I found Norfloxacin treatment led to a reduction in the level 
of blood endotoxins and a decrease in the expression of hepatic TLR4.  A 
concurrent reduction in liver inflammation and fibrosis was also observed.  
However, the Norfloxacin treatment had no visible effect on the size or 
frequency of tumours developing in the rat livers.  Closer examination of the rat 
livers by immunohistochemistry revealed the malignant hepatocytes do not 
express TLR4 whereas it was expressed in the surrounding inflammatory cells 
and fibroblasts.  A similar pattern of expression was found in the human HCC 
tissues; TLR4 was not expressed in the malignant hepatocytes but it was 
expressed in the inflammatory cells within or surrounding the malignant tumour.  
These findings suggest that TLR4 expression has some role to play in liver 
inflammation and fibrosis but its expression within HCCs does not appear to be 
necessary for their progression.  However, this is does not rule out the 
possibility that TLR4 expression within hepatocytes could have a protective 
effect against malignancy, perhaps, by activating vital tumour suppressor 
pathways or by not allowing the malignant cells to escape immune surveillance.   
 
Following the above findings with TLR4 I examined the possibility that other 
TLRs could be involved in HCC pathogenesis.  A variety of TLRs have been 
implicated in human cancers but few studies have examined the role of TLRs in 
HCC.  I decided to focus our attention on the expression of TLR7 and TLR9 in 
HCC since these have been implicated in a variety of chronic liver diseases and 
liver fibrosis (Gäbele et al., 2008, Stadlbauer et al., 2008, Stärkel et al., 2010, 
Henao-Mejia et al., 2012 and Tarantino et al., 2013).  In addition, TLR7 and 
TLR9 have also been reported to be up regulated in a wide variety of human 
cancers including pancreatic cancer (Ochi et al., 2012), oesophageal cancer 
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(SHeyhidin et al., 2011), prostate cancer and (González-Reyes et al., 2011).  
Our immunohistochemistry data demonstrated a very strong association 
between high expression of TLR7 and TLR9, and HCC where it was shown to 
be expressed in the vast majority of tumours.  Very little expression of these 
markers was found in normal, cirrhotic or hepatitis human liver.  I also 
demonstrated a significant correlation between high Ki-67 proliferation index 
and high expression of TLR7 and TLR9.  Overall the immunohistochemistry 
data suggested that the expression of TLR7 and TLR9 in HCCs may play a role 
in enhancing HCC proliferation and growth.   
 
Having established a strong link between high expression of TLR7 and TLR9 
and HCC in human liver tissues, in vitro studies were carried out on the HuH7 
human HCC cell line in order to determine whether stimulation or inhibition of 
TLR7 or TLR9 activity has any effect on cell proliferation or whether it can 
influence the activity of other pathways that are known to be involved in HCC 
pathogenesis.  I found that stimulation of TLR7 with IMQ resulted in a significant 
increase in HuH7 cell proliferation but this effect was not seen when the cells 
were treated with the TLR9 agonist CpG-ODN.  The inhibition of TLR7 and 
TLR9 with IRS and chloroquine, respectively, however, resulted in a significant 
reduction in the proliferation of HuH7 cells.  In addition, the data showed that 
the decrease in levels of proliferation were not due to cell death resulting from 
any cytotoxic effect of the drugs. 
 
Our next step was to determine whether the actions of TLR7 and TLR9 on cell 
proliferation were being exerted via activation of the Akt pathway, which is one 
of the most commonly activated pathways human cancer (Chen et al., 2011, 
Zhou et al., 2011 and Xu et al., 2013).  The expression of pAkt protein, which is 
the active form of Akt, was found to disappear almost completely in HuH7 cells 
in response to treatment with the TLR7 and TLR9 inhibitors chloroquine and 
IRS, respectively.  In addition, a slight increase in pAkt protein expression was 
detected in response the TLR7 agonist IMQ.  The inferences I drew from these 
findings was that the proliferation of human HCC cells were under the control of 
TLR7 and TLR9 and that these may be exerting their actions by influencing the 
Akt pathway.   
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As well as acting as an inhibitor of TLR7 and TLR9 chloroquine is also known to 
interfere with the autophagic pathway which is often used by cancer cells as a 
cyto-protective mechanism at times of stress.  I therefore examined the HuH7 
cells for expression of LC3B which is a marker of autophagy but found no 
evidence that this pathway was activated in this cell line.  Furthermore, it could 
not be induced in response to activation of TLR7 or TLR9 by IMQ and CpG-
ODN, respectively.  These findings were further evidence that proliferation of 
HuH7 cells was under the control of TLR7 and TLR9 and was not being 
influenced by the autophagic pathway.   
 
Following the in vitro work on TLR7 and TLR9 in the human liver tissues and 
HuH7 cell line I wanted to see if the results obtained from these studies could 
be confirmed in vivo using a mouse xenograft model of human HCC and a DEN 
& NMOR-induced rat model of human HCC with cirrhosis.  The administration of 
TLR7 and TLR9 inhibitors led to a significant reduction in liver tumour growth in 
both models of HCC.  In addition, chloroquine treatment was found to have a 
significantly beneficial effect on liver inflammation and fibrosis as well as a 
beneficial effect on liver function in the rat model.  Furthermore, the expression 
of TLR7, TLR9 and NF-kB, Akt and pAkt were found to be reduced in response 
to chloroquine treatment in the livers of the rat HCC model.  These findings 
were concordant with the in vitro data and provided further support for a role for 
TLR7 and TLR9 in HCC pathogenesis.   
 
My studies in CC revealed a similar pattern of TLR expression to the one found 
in the HCCs.  TLR4 was not expressed in the majority of CC but highly 
expressed in the bile duct epithelial cells.  TLR7 and TLR9 were also found to 
be expressed in the majority of cholangiocarcinoma.  Stimulation of TLR7 and 
TLR9 with IMQ or CpG, respectively, resulted in increased proliferation of the 
HuCCT1 cells and inhibition of these TLRs with chloroquine led to a reduction in 
cell proliferation.  Furthermore, inhibition of TLR7 or TLR9 with chloroquine and 
IRS, inhibited tumour growth in a mouse xenograft model of CC.  However, 
unlike the HCC HuH7 cells, the autophagy pathway was also found to be 
activated in the HuCCT1 cell line and treatment of these cultures with the TLR9 
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agonist CpG resulted in elevated expression of the autophagy marker LC3B in 
addition to increasing cell proliferation.   
 
In summary, TLR7 and TLR9 are highly up regulated in human HCC tissues 
and cultures as well as animal models of HCC but their expression is low in 
normal, cirrhotic or hepatitis human livers.  Inhibition of TLR7 and TLR9 is 
associated with a marked reduction in proliferation of human HCC cell cultures 
and xenograft models of human HCC.  It was also associated with a reduction 
in liver inflammation, fibrosis and tumour growth, as well as decreased 
expression of Akt and NF-кB in the animal models of HCC.  Stimulation of TLR7 
resulted in increased proliferation of human HCC cultures.  TLR4 is not 
expressed in human HCC or animal models of HCC.  However, gut 
decontamination led to a decrease of TLR4 and NF-кB expression and a 
reduction in liver inflammation and fibrosis in the animal models.  The pattern of 
TLR4, TLR7 and TLR9 expression and the effects of up regulating or down 
regulating TLR7 or TLR9 in the cholangiocarcinoma were also similar those in 
the HCCs. 
 
Our findings would suggest that the inhibition of TLR7 and TLR9 using 
chloroquine or other antagonists of these TLRs may serve as novel approaches 
for the treatment of HCC and CC.  However, before translation into the clinical 
arena, a more thorough investigation of the precise role(s) played by these 
TLRs in HCC and CC pathogenesis is essential since any therapeutic 
intervention involving the immune system can sometimes lead to unpredictable 
and harmful consequences.  Also, since a large proportion of HCCs and CCs 
arise as within the context of HBV or HCV infection in humans, the effects of 
TLR7 or TLR9 inhibition on viral propagation is another important factor that 
needs to be taken into consideration in any future therapies that may target  
these TLRs. 
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Future research  
The focus of any future studies should include an examination of the following: 
 
 The pattern of TLR4, TLR7 and TLR9 expression in a much larger group 
of human HCCs and CCs from a variety of aetiologies in order to identify more 
precisely the liver cells involved and examine any correlation between tumour 
grade, stage or metastasis and expression of these TLRs.  
 Studies to understand the ligands for TLR7 and TLR9 that may drive 
their stimulation in chronic hepatic inflammation.  
 The effects of TLR4, TLR7 and TLR9 stimulation or inhibition in a much 
larger group of animals and over a longer period of time to look for any 
unforeseeable side effects. 
 The optimum dose of chloroquine which can give a maximum therapeutic 
result without any harmful side effects in animal models. 
 HCC and CC development within TLR4, TLR7 and TLR9 knockout 
animals in order to understand the relationship between the tumour and its 
environment with respect to expression of these TLRs.  
 The links between TLR7 and TLR9 expression and the PIk3/Akt/mTOR 
pathway in order identify the exact targets within these pathways that can elicit 
tumour inhibition 
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Conclusion 
The results presented in this thesis suggest that modulation of TLR7 and TLR9 
may provide a safe and effective approach to the treatment of HCC and CC. 
Appropriate clinical trials should be planned after consideration of the pending 
issues. 
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7. Appendix 
1. Reticulin stain reagents  
- Acidified potassium permanganate 5% potassium permanganate 5ml, 
2% hydrochloric acid 3ml, Distilled water 42 ml.   
- 1%aqueous oxalic. 
- 2.5% ferric ammonium sulphate. 
- Ammonical silver nitrate: in fume hood 10% silver nitrate 5ml then 
concentrate cold ammonium hydroxide was added drop by drop until the formed 
precipitate just redissolve (clear colour).  3%aqueous sodium hydroxide 5ml 
then added to the sliver and ammonium hydroxide and a dark precipitate was 
formed.  Redissolve the precipitate by adding ammonium hydroxide but stop 
adding the ammonium hydroxide with few precipitate granules remaining.  
Dilute to 50 ml with distilled water. 
-  10% formalin in tap water. 
 
2. Picro-Sirius Red staining reagents 
To prepare Sirius red stain: 1% aqueous Sirius RedF3B 10ml was added to 
aqueous picric acid (90ml).  The two solutions were mixed together and allowed 
to stand for 24 hours before use.  The collagen and reticulin were stained red 
with this stain. 
 
3. Endotoxin kinetic LAL assay measurement reagents and material 
 Endotoxin free tips were used for this experiment,  
 LAL Reagent Water, Lyofilized Limulus Amebocyte Lysate LAL reagent 
 Standard Endotoxin (Endosafe Endochrome-K ).   
 Flat bottomed 96 well plate. 
 Endotoxin free basin. 
 
4. Tissue Lysis Buffer 
 0.3gm of Trizma base in 45ml deionised H2O  PH:7.4 
 2.1 ml of 1 molar HCL      
 1 mM EDTA (Sigma) = 19 mg 
 20 µl/ml Protease Inhibitor Cocktail (Sigma)* Added just before use. 
 100 mM Phenylmethanesulfonyl fluoride (PMSF)   
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(10µl / ml stock solution prepared by dissolving 0.172 in 10 ml Ethanol). 
 
5. Preparation of Biuret solution reagents 
 0.75gm of Copper (II) sulfate (CuSO4),  
 3gm of NaK tartarate,  
 25gm of NaOH and  
 500ml deionised water 
 Copper II sulphate (CuSO4) and potassium sodium tartarate (NaK 
tartarate) were added together in 400ml of de-ionised water in a flask and 
placed on hot plate.  Then sodium hydroxide (NaOH) was added slowly with 
constant stirring.  When this was dissolved de-ionised water was added to make 
up 500ml of solution. 
 
6.  Tris-Buffered Saline and Tween 20 (TBST) buffer 
 20 ml of 1M Tris-HCl  pH 7.5      
 29g of  NaCl   
 1 ml of Tween 20  
 De-ionised H2O to 1 litre  
 
7. TNF- α ELISA reagents 
1- Coating Buffer: 0.1M Sodium Carbonate = 7.13g NaHCO3, 3.56g 
Na2CO3 in 1L of deionised H2O pH 9.5 
2-  Phosphate Buffer Solution (PBS) :  8g NaCl, 0.2g KCl, 1.15g Na2HPO4, 
0.2g KH2PO4 (for 10x) in 1L of dioniesed H2O then 1X was prepared by dilution 
1:10 H2O PH 7.4 
3- Wash Buffer: 0.05% Tween 20 in PBS, pH 7.4.   
4- Assay Diluent: 1% Bovine serum albumin (BSA) in PBS, pH 7.2 – 7.4 
(1g/100ml) 
5- Substrate Solution : O-Phenylenediamine dihydrochloride.  (Dissolve 1 
tablet in 0.05M phosphate citrate buffer, add 1 tablet, at final moment add 40uL 
of 30% hydrogen peroxide)(1 tablet dissolved phosphate citrate buffer dissolved 
in 100ml of distilled water). 
6- Stop Solution: 1M H2SO4 (2ml H2SO4 added to 34ml water ). 
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8. Immunohistochemistry antibodies 
Human tissue antibodies 
Rabbit polyclonal anti TLR4 (1:100) was purchased from Lifespam, UK.  Rabbit 
polyclonal anti TLR7 (1:100), mouse monoclonal anti TLR9 (1:200), rabbit 
polyclonal anti ki-67 (1:100) and rabbit polyclonal anti VEGF (1:100) were 
purchased from Abcam, UK. 
Animal tissue antibodies 
Antibody for animal tissue; Rabbit polyclonal anti TLR4 Lifespam, UK, TLR7, 
TLR9 and smooth muscle actin (SMA) (1:100) (Abcam, UK). 
 
9. Micro BCA Kit Reagents (Pierce, thermoscientific, UK) 
Reagent A 
 NaOH solution.  containing: 
 Na carbonate  
 Na bicarbonate 
 BCA 
 Na tartrate 
Reagent B 
4% cupric sulphate 
 
